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 Horses suffer from chronic skin wounds such as exuberant granulation tissue (EGT), also 
called “proud flesh”, and allergic dermatitis (AD) in part because there are no adequate 
treatments for these pathologies. Equine mesenchymal stromal cells (MSC) are adult multipotent 
progenitor cells that can be isolated from a variety of horse tissues and expanded in culture. 
These cells have been used for decades by clinicians as a biologic treatment for orthopedic 
injuries of horses, but the mechanisms by which MSC improve healing in vivo have not been 
well-defined. Based on work carried out in other species, we hypothesized that equine MSC can 
be used as a therapy to promote the healing of horse cutaneous wounds because factors secreted 
by MSC, collectively called the MSC secretome, act on the wound environment, in ways that 
stimulate healing. We carried out a series of in vitro studies to (i) characterize the secretome of 
MSC isolated from horse peripheral blood and (ii) determine if the MSC secretome acts on target 
cell types found in the skin, in ways that suggest it will promote wound healing in vivo.  
 First, I present a description of MSC and a history of equine MSC research and therapy, 
to provide a context for our experimental work. Then, I review the utility of the horse as a model 
for cutaneous wound healing, which provides additional justification for our studies. We used 
various experimental methods to evaluate the composition of the MSC secretome and performed 
series of in vitro assays to determine that specific factors secreted by MSC stimulate equine 
dermal fibroblast (DF) migration, a necessary aspect of skin wound healing. We carried out an 
additional set of experiments showing that MSC secreted factors act on dysregulated equine DF, 
pushing them toward a more normal phenotype that may be better suited to contribute to wound 
closure. Finally, we demonstrated that the MSC secretome inhibits the growth of bacterial 
species found as contaminants in chronic horse skin wounds. 
 These results show that factors secreted by equine MSC do act on cell types found in 
horse skin wounds in ways that may lead to improved wound healing in vivo and warrant future 
studies to test the efficacy of the MSC secretome as a treatment for horse skin wound in vivo.
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CHAPTER ONE: AN INTRODUCTION TO MESENCHYMAL STROMAL CELLS AND 
REVIEW OF EQUINE MESCHYMAL STROMAL CELL THERAPY  
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1.1. Introduction 
 Our lab studies the potential of the equine of the mesenchymal stromal cell (MSC) 
secretome, comprised of all factors secreted by MSC, to be used as a biologic therapy for horse 
cutaneous wounds. The goal of this dissertation is to use in vitro assays to determine if MSC 
secreted factors act on cell types found in the skin in ways that suggest they may be a useful 
therapy for cutaneous wounds of horses. The long-terms goals of this project are to (i) validate 
equine MSC-secreted factors in vivo as a safe and effective therapy for horse skin wounds, (ii) 
provide equine clinicians with protocols to offer MSC-secreted factors as a therapy to their 
patients, and (iii) use what is learned while evaluating this therapy for horses, to improve 
treatments for humans. 
 This chapter starts with a definition of MSC and a broad review of the isolation, culture 
and therapeutic use of MSC from other species, primarily humans. It then provides a 
comprehensive review of the history of equine MSC research and the current therapeutic 
applications of MSC in equine medicine. The chapter ends with citing specific work supporting 
the use of MSC-secreted factors as a therapy for skin wounds. This information, along with the 
review of horse cutaneous wound healing in Chapter Two, sets the stage for both the studies 
presented in this dissertation and our long-term goals for the project.  
1.2. The history of MSC culture and MSC as a stem cell therapy 
1.2.1. History of MSC culture  
 MSC are adult, non-hematopoietic, multipotent progenitors derived from the mesodermal 
germ layer. These cells can self-renew as well as differentiate into the various cells of the 
skeletal system including osteocytes, chondrocytes and adipocytes [1]. MSC were first described 
as fibroblast-like cells isolated from human bone marrow [2], but the term MSC was not coined 
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until 1991 [3]. Since the original MSC isolation, these cells have been collected from a range of 
species including mouse, rat, horse, cow, pig, dog and cat. In addition, MSC have been isolated 
from a variety of adult tissues including bone marrow, adipose tissue, placental tissues, and 
umbilical cord blood [4]. They are typically isolated from a heterogeneous mixture of cells and 
purified through culture. In the case of bone marrow-derived MSC (BM-MSC), for example, 
diluted bone marrow is plated in a tissue culture vessel in appropriate medium. Cultures are 
maintained over several weeks, with the medium being removed and replaced every few days. 
Early in the culture period, non-adherent lymphoid cells are washed away, while adherent cells 
of lymphoid origin eventually die and are removed. The remaining adherent cells, representing 
the MSC, grow as small, dense colonies with a fibroblast-like morphology. Although individual 
primary MSC look like fibroblasts, they do not behave as fibroblasts do in primary culture. 
Primary fibroblasts will spread and cover the surface of a culture vessel, whereas MSC form 
discrete colonies which need to be dispersed and passaged in order to form a monolayer. Once 
MSC cultures are established, they proliferate rapidly, allowing for tremendous expansion of 
MSC lines.  
 As MSC are derived from heterogeneous populations of cells collected from different 
tissues and a variety of species, and many laboratory groups isolate MSC using slightly different 
techniques, there has been debate between researchers about what features define MSC. To set a 
universal standard for the definition of MSC, the International Society of Cellular Therapy 
(ISCT) published minimal criteria for characterizing cells as MSC in 2006, based on  the 
following 3 in vitro characteristics; (i) MSC must be plastic-adherent when maintained under 
standard culture conditions, (ii) MSC must express the surface proteins CD105, CD73 and 
CD90, and lack the expression of CD45, CD34, CD14 or CD11b, CD79 or CD19 and HLA-
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DR, and (iii) MSC must have the potential to differentiate into osteoblasts, adipocytes and 
chondroblasts in vitro [5] (Table 1.1). 
 
 
 
 
 
 
 
  
 
  
 
 Since the majority of what is known about MSC comes from in vitro studies, there is an 
ongoing debate in the field as to whether or not MSC exist as we know them in vivo or if they are 
a by-product of cell culture. It has been proposed that in vivo, MSC reside in close association 
with the vasculature and home to sites of injury in response to cytokine and chemokine signals 
from wounded tissues.  At their homing sites, MSC are thought to differentiate into cells to 
replace those that were damaged or lost due to injury, and more importantly, to stimulate healing 
by secreting factors that act on the wound environment. There is evidence that human and equine 
MSC are indeed perivascular in origin, and may even represent pericytes [6,7]; contractile cells 
that wrap around blood vessels and serve to regulate both capillary blood flow and the 
Table 1.1. Defining features of mesenchymal stromal cells 
Feature Requirement 
morphology plastic-adherent 
surface marker expression CD105 positive 
 CD73 positive 
 CD 90 positive 
 CD45 negative 
 CD34 negative 
 CD14 negative 
 CD11b negative 
 CD79 or CD19 negative 
 HLA-DR negative 
differentiation potential osteoblasts 
 adipocytes 
 chondroblasts 
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differentiation of endothelial cells [8], but the proposed natural actions and functions of MSC in 
vivo are largely speculative.  
1.2.2. MSC as a means for stem cell therapy  
 Irrespective of the precise origin of MSC, it is understandable that stem cell biologists 
have investigated their value as a therapy. Embryonic stem cells (ESC) that exhibit prolonged 
undifferentiated proliferation potential and are capable of forming cells of all three embryonic 
germ layers were first derived from mouse embryos nearly 40 years ago [9, 10]. Authors of an 
early paper describing human ESC lines recognized the therapeutic value of these cells [11], but 
also realized that although ESC have tremendous potential as regenerative therapies, there are 
ethical issues associated with collecting cells from embryos. Since then, legal obstructions have 
limited work that can be done with ESC. In response to the difficulties of obtaining ESC, 
researchers have developed methods of reprogramming adult human cells to induce them into a 
pluripotent state [12, 13, 14]. These induced pluripotent stem cells (iPSC) are not plagued with 
the restrictions placed on ESC, but they have proven to be difficult to generate and depending on 
the reprogramming methods used may not be appropriate for therapeutic use. The idea that MSC, 
a naturally-occurring cell type that can be collected non-invasively from adults, may be used as a 
regenerative therapy makes them an attractive alternative to ESC and iPSC.  
1.3. A review of equine MSC research and therapy 
 The isolation of equine MSC, and the use of these cells as a therapy for orthopedic 
injuries, was first described in 2003 [15]. In this study, 500,000 autologous BM-MSC were 
injected into a lesion in the superficial digital flexor tendon of one horse. No observable swelling 
was noted immediately after the procedure, and at 10 days and 6 weeks post-procedure, the 
animal showed no signs of lameness and there was no increased thickening of tendon as 
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determined by ultrasonography. The technique was determined “rational and feasible”, but no 
conclusions could be made based on a study consisting of one animal and one treatment, with no 
controls. Larger and more complete studies carried out in the past 15 years have established that 
autologous MSC therapy is not detrimental to horses [16, 17], and the clinical use of autologous 
MSC to treat orthopedic injuries is now routine. However, fundamental research has not kept 
pace with practice [18], so there are many gaps in our knowledge of basic equine MSC biology. 
The following sections highlight past and active areas of equine MSC research, in addition to the 
current knowledge on equine MSC and what questions remain to be addressed. 
1.3.1. Isolation, culture and storage of equine MSC 
 In the 15 years since equine MSC were first isolated from bone marrow aspirates and 
expanded in culture [15], numerous publications have described protocols for the isolation of 
these cells from different tissue sources, methods to culture these cells, and optimal conditions 
for long-term MSC storage. In addition to bone marrow, equine MSC have been isolated from 
adipose tissue [19], whole blood [20], synovial fluid [21], uterine endometrium [22], umbilical 
cord blood and tissues [23, 24] amnion and amniotic fluid [25, 26], dental pulp [27] gingiva and 
the periodontal ligament [28]. As described above, MSC cultures typically start from a 
heterogenous population of cells, which over time become essentially “pure” populations of 
MSC. Steps to enrich for MSC before culture such as applying cells to a density gradient, 
selectively digesting tissue with enzymes, or taking advantage of cell migration from tissue 
explants have been reported, depending on the tissue source of origin [29, 30, 31] (Figure 1.1).   
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Figure 1.1. Tissue sources of equine mesenchymal stromal cells (MSC). Equine MSC from 
each of the tissue sources indicated above have been reported on.  
 
 Standard culture conditions for equine MSC exist, regardless of tissue source of origin. 
Equine MSC are typically maintained in culture medium containing fetal bovine serum (FBS). 
This is opposed to human MSC, which are often grown in commercially available serum-free 
medium, with the goal of standardizing cell products and preventing contamination by pathogens 
[32]. Studies evaluating the suitability of commercially available serum-free culture medium for 
equine bone marrow and adipose tissue (AD)-MSC determined that although the equine MSC 
could be isolated and expanded in serum-free medium, cell morphology, proliferation rate and 
surface immunophenotype were variable as compared to control equine MSC cultured in 
medium containing FBS [33, 34]. The authors concluded that serum-free culture conditions are 
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species-specific, and although currently available serum-free culture products are suitable for 
human MSC, optimization of serum-free culture conditions are needed if equine MSC are to be 
grown in the absence of FBS.   
 Similar to human MSC, researchers recommend passing equine MSC before cell 
monolayers reach confluency and maintaining the cells in culture for a limited time to avoid 
unwanted MSC differentiation, which is particularly important for cultures that are being 
expanded for therapeutic use.  
 Any cell type that will be used therapeutically is more useful if it can be successfully 
stored for long periods of time for “off-the-shelf” use. Cryopreservation of MSC is currently the 
standard method of maintaining cells for future applications. Several groups have compared the 
viability, proliferation rate, cell morphology, and immunophenotype and differentiation 
potential, of MSC before and after different methods of cryopreservation [35, 36, 37, 38]. The 
consensus of these studies is that MSC cryopreserved in medium containing FBS and 
dimethlysulfoxide maintain their integrity and minimal stem cell qualities after thawing (Figure 
1.2) 
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Figure 1.2. Isolation, culture and storage of equine peripheral blood-derived mesenchymal 
stromal cells (MSC).  Equine MSC can be isolated from peripheral blood (as well as from other 
tissues), and then purified and expanded in culture. MSC and/or MSC-secreted factors can either 
be delivered immediately to recipients, or the cells can be cryopreserved for revival, expansion 
and use when needed.  
 
1.3.2. Characterization of equine MSC 
 The bulk of equine MSC scientific literature describes studies designed to compare the 
characteristics of MSC cultures isolated from different tissue sources or animal origins. As 
described above, equine MSC have been isolated from multiple different tissue sources. In 
addition, they have been collected from the same tissue source at various body sites, for 
example; from adipose tissue biopsies collected from the tail head, inguinal region and 
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mesentery or bone marrow aspirates from the ilium and sternum [39, 40]. In addition, MSC have 
been isolated from horses suffering from a particular disease [41, 42], as well as from cadavers 
[43, 44]. The two most common features that have been analyzed for these comparative studies 
are the surface protein immunoprofile of MSC, and their potential for trilineage differentiation in 
vitro [45, 46, 47, 48, 49]. The majority of equine MSC cultures tested express the surface 
proteins proposed by the ISCT to be MSC markers and can differentiate into osteoblasts, 
adipocytes and chondroblasts, but the degree of protein expression and efficiency of 
differentiation often are variable between cultures obtained from different sources.  
 Other features of MSC cultures have been examined, depending on the interests of the 
particular research group, as well as the desired application for MSC. Specifically, susceptibility 
to senescence [50], proliferation rates [51], migration rates [52], immunomodulatory properties 
[53, 54], and gene expression patterns [55, 56] have been compared across MSC cultures. 
Overall, the results from these studies, combined with unpublished observations, are that equine 
MSC populations are not identical. Differences may be attributed to the tissue source from which 
the MSC were isolated, age, health and hormonal status of the donor animal and potentially the 
length of time MSC were in culture prior to characterization. A reasonable conclusion when 
considering MSC for therapeutic purposes is that different MSC cultures may be more or less 
appropriate to use as treatments for specific ailments. Before using MSC as therapy, the specific 
culture should be screened to determine if it expresses and fulfills the desired characteristics.  
 Despite differences across equine MSC cultures, inherent characteristics are preserved 
across most, if not all MSC lines. All equine MSC are spindle-shaped cells that grow in  
monolayers, even if they exhibit slightly variable morphologies. For example, these cells may be 
very long and slender, or appear more cuboidal with short cytoplasmic extensions [23]. All 
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equine MSC divide rapidly in culture and are viable for multiple passages in culture without 
major changes in surface protein expression or differentiation potential. Moreover, they can be 
cryopreserved and revived, without compromising original surface marker expression or 
differentiation potential [57].   
1.3.3. Treatment of tissue injuries with equine MSC  
 As noted above, the clinical use of autologous equine MSC to treat orthopedic injuries is 
now a routine practice. Surprisingly, few scientific reports that document the efficacy of MSC 
therapy for damaged tissues, have been published since the original study by Smith in 2003. The 
effects of MSC on ligament and tendon injuries have been the most commonly described; about 
20 peer-reviewed manuscripts have been published on this topic [58, 59, 60, 61, 62,17]. Other 
publications describing the use of MSC in vivo as a therapy report on torn menisci [63], damaged 
peripheral nerves, inflamed laminae [64, 65], and inflamed uterine endometria [66].  
 Although some of these studies have yielded promising data, for example the 
significantly increased vascularization at the site of injury upon MSC administration in an 
induced tendon injury model when compared to control injuries [62], the majority of them led to 
variable and inconclusive outcomes. Multiple factors contribute to the difficulty researchers face 
when carrying out experiments designed to test the efficacy of MSC therapy in horses. The 
evaluation of clinical cases can be useful for obtaining preliminary data, but case reports 
typically do not compare treatments to controls and often do not describe the treatment of 
multiple animals that are in comparable situations. Another hurdle is the expense incurred when 
enrolling large animals in long-term experiments. It is costly to maintain enough animals to 
include treatment and control conditions and reach statistical significance when analyzing 
results. An additional challenging aspect of working with veterinary species is that the diversity 
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between individuals may influence study results in ways that do not impact experiments 
performed using inbred laboratory species such as mice, rats and rabbits. Careful and creative 
ways of thinking about experimental set-ups, as well as increased funding are needed to obtain 
more conclusive results about the efficacy of equine MSC to treat equine tissue injuries.  
1.3.4. Safety of allogeneic versus autologous equine MSC therapy 
 The wide spread clinical use of autologous equine MSC to treat joint and tendon injuries 
has led clinicians and clients to trust that MSC therapies are safe. In addition, experimental 
studies specifically designed to test the safety of MSC administered to horses have determined 
that the risks of treating horses with autologous MSC are minimal. However, an ideal treatment 
for any aliment is an off-the-shelf, ready-to-use product and as autologous MSC may not be 
readily available, researchers have explored the potential of using allogeneic equine MSC 
therapeutically. In theory, allogeneic MSC can be isolated, expanded in culture, and 
cryopreserved from donor horses for use in any patient, making them more versatile than 
autologous MSC.  
 A recent study designed to test the level of inflammation induced by intramuscular 
injection of allogeneic equine MSC, showed that the introduction of these cells did not promote 
significantly more inflammation or tissue damage, as assessed by ultrasound, hematological 
evaluation and histology compared to a saline injection [67]. A more sophisticated study, 
evaluating the clinical response of the synovial joint to intra-articular injection of autologous 
versus allogeneic MSC, found no differences in the examined clinical parameters following the 
first injection. After the second injection, however, there was a significant adverse clinical 
response of the joint to allogeneic MSC as compared to autologous MSC, leading the authors to 
conclude that there is immune recognition of allogeneic MSC upon second exposure [68]. 
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Elegant work by another group showed that major histocompatibility complex (MHC)-
incompatible equine MSC induced cytotoxic antibodies to donor MHC antigens in recipient 
horses after intradermal injection [69]. This led the authors to conclude that this type of response 
may limit the effectiveness of repeated allogeneic MSC use in a single horse and could lead to 
undesirable inflammatory responses in recipients. Another study determined that multiple 
injections of allogeneic MSC do not induce a systemic inflammatory response but do alter 
lymphocyte subsets in healthy horses [70].  
 The overall conclusion based on these, and other, studies is that recipient animals do 
recognize allogeneic MSC, but the type and severity of reaction is variable and may depend on 
the source of donor MSC, how many times donor MSC are administered, and how donor MSC 
are delivered.  
1.3.5. Mechanisms of action of equine MSC 
 Elucidating the mechanisms by which MSC act on target tissues is not only important 
from a basic scientific perspective but has practical implications as well. If we know how 
exogenous MSC contribute to healing, we can fine tune MSC therapy to maximize benefits and 
minimize unwanted side effects [71]. 
 1.3.5.1 Integration of equine MSC at sites of injury 
 Some clues to the mechanisms of action of therapeutically-administered MSC have been 
gathered from studies in which MSC have been tracked in vivo after injection. One such study 
tracked labeled autologous MSC injected at the sites of induced superficial digital flexor tendon 
(SDFT) lesions for 24 weeks post-injection [72].  The authors reported that the numbers of 
labeled cells within the tendon lesions decreased over time, and that some of the remaining cells 
were viable and integrated into the local tissue. In addition, small numbers of labeled cells were 
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identified in the peripheral blood within 24 hours of injection and could be detected 24 weeks 
later in contralateral control tendon lesions that had not been injected with cells. The authors, 
however, did not report on improvement in SDFT lesions during the course of the study. Another 
group tracked allogeneic MSC injected at the sites of naturally occurring SDFT disease for 8 
weeks post-injection. This study detected sporadic labeled cells at the site of injury in 5 out of 7 
cases after 8 weeks and found that the MSC injection was tolerated with no side effects in most 
animals. No untreated control animals were included in the study, so clinical improvement as a 
result of treatment could not be assessed [60].  Additional studies have also indicated that MSC 
injected at the site of tendon lesions do sporadically persist at the wound site [61, 73], but none 
of this work provides evidence that the MSC actually differentiate into the cells needed to 
rebuild and replace tissues damaged or lost by injury. Evidence from in vivo experiments in 
horses, combined with data collected from other species, suggests that if equine MSC 
administered therapeutically do indeed contribute to tissue repair, their primary mechanism of 
action is most likely through secreted factors (as a whole called the secretome, see section 1.4.1), 
that act on the wound environment to promote healing.  
 1.3.5.2. Immunomodulatory action of equine MSC  
 Based on work carried out in humans and mice, which established an immunomodulatory 
role for MSC, equine researchers have designed experiments based on hypotheses that equine 
MSC can affect immune cell function, and as a result alter the course of disease progression or 
tissue healing. Results from in vivo studies in horses, designed to examine the 
immunomodulatory properties have largely been inconclusive. This is in part because many 
studies used inadequate numbers of animals, and in part because protocols were not optimized 
[58, 74]. Select studies however, have convincingly shown that MSC influence the inflammatory 
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response in vivo. When 1.5 x 107 MSC were injected into the uterine lumen, the inflammatory 
response to uterine infusion was diminished as compared to the vehicle control, as assessed by 
histology [75]. Another study used histologic analysis as well as antibody-binding to determine 
that inflammation was increased in joints after intra-articular injection of 1.5 x 107 MSC as 
compared to joints receiving the vehicle control [76]. Studies such as these have provided useful 
information about the dose of MSC needed to generate a response and have proved that MSC can 
indeed elicit a response in vivo, but they were not designed to uncover the mechanistic details of 
how MSC interact with immune cells. 
 Work in simpler culture systems has shed light on some of the specific 
immunomodulatory actions of equine MSC. Umbilical cord blood-derived MSC (CB-MSC) 
were shown to suppress in vitro lymphocyte proliferation [77]. Microvesicles from equine 
amniotic MSC (AM-MSC) down regulate pro-inflammatory gene expression and decrease the 
secretion of pro-inflammatory cytokines by endometrial cells and tendon cells [78, 74], and 
microvesicles as well as conditioned medium from AM-MSC modulate the release of pro-
inflammatory cytokines by equine alveolar macrophages [79].  Studies evaluating the 
immunomodulatory properties of BM-MSC found that these cells can mildly activate 
lymphocytes in vitro, and stimulate them to secrete inflammatory cytokines [80, 81]. BM-MSC 
can also suppress pre-activated lymphocytes in a prostaglandin E2 (PGE2)-dependent manner 
[80]. Likewise, a more recent in vitro study with BM-MSC that was designed to determine how 
the inflammatory stimuli toll-like receptor (TLR) ligands and inflammatory macrophages affect 
the phenotype and function of MSC, found that exposure of MSC to TLR ligands or 
inflammatory macrophages enhances the ability of MSC to suppress lymphocyte proliferation 
[82]. The authors speculate that consistent with the inflammatory licensing theory, the idea that 
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the inflammatory state of the environment directs cells to respond in ways that will temper 
inflammation, exposure to inflammatory signals activates the immunomodulatory capabilities of 
MSC.  
 Collectively, these studies show that equine MSC exert direct immunomodulatory 
properties on target cells, primarily via paracrine secretion, and that secretion can be manipulated 
by altering the environment in which MSC reside. 
1.3.6. Delivery of equine MSC therapy 
 An intriguing aspect of therapeutic development is to determine the most optimal 
delivery methods for a given therapy. A thorough review of published literature yielded only one 
manuscript describing the administration of MSC or MSC-secreted factors to horses in any way 
other than introducing the cells themselves to recipient animals [74]. However, in vitro 
experiments designed to explore MSC delivery methods have recently been performed, with a 
primary focus on supporting MSC in biomaterials with the goal of maximizing their efficacy in 
cartilage repair.  
 1.3.6.1 Scaffold-supported equine MSC for cartilage repair 
 For the purpose of cartilage repair, culturing MSC in supportive matrices can provide 
several benefits. The supportive material provides MSC with three-dimensional contacts that 
mimic the in vivo environment, which may efficiently stimulate the differentiation of MSC into 
the large numbers of cells with an elastic cartilage phenotype needed for successful transplant.  
The supportive material may also be rendered bioactive, supplying MSC with chemical signals 
that promote appropriate differentiation in addition to providing physical support. In either 
situation, the supportive material may be populated with MSC in vitro, and then transplanted into 
injured joints to serve as an anchor to keep MSC localized to the site of injury in vivo. Matrices 
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that have been tested include gelatin meth acryloyl-based hydrogels [83], decellularized 
cartilage-derived ECM [83, 84, 85], hyaluronic acid-infused hydrogels [87], collagen-infused 
hydrogels [88], bacterial cellulose hydrogels [89], as well as combinations of these materials 
[90]. Bioactive factors of significance have been successfully incorporated in hydrogels along 
with MSC, with the primary goal of directing MSC to differentiate into functional cartilage. 
These factors include TGF-β1, bone morphogenic protein-2 (BMP-2) [91], and acid ceramidase 
[92]. In these studies, various read-outs were used to quantify the differentiation of MSC into 
functional, elastic, cartilage cells. The authors detected a level of success when compared to 
controls but proposed future experiments to fine-tune their protocols. This incorporation of 
bioengineering techniques into the field of equine MSC therapy is a relatively new, but active, 
area of study that is particularly suited to improve the success of MSC as a treatment for joint 
injuries.   
 1.3.6.2 Equine MSC secretome delivery 
 To date, there have been few published studies describing the reactions of recipient 
horses to secreted factors obtained from (i) allogeneic MSC and no reports of (ii) allogeneic 
MSC encapsulated in biomaterials. The purpose of the latter is to prevent direct cell-cell contact 
with the recipient in order to avert recognition of foreign material and unwanted inflammatory 
responses by the recipient, while providing factors secreted by MSC that promote regenerative 
effects. Our group has carried out experiments to evaluate the efficacy of MSC-secreted factors 
as well as of microencapsulated MSC in vitro, and the results are outlined in the research 
chapters of this dissertation.  
1.4. The MSC secretome as a therapy for cutaneous wounds 
1.4.1. The MSC secretome 
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 The MSC secretome, consisting of all factors secreted by MSC, has been implicated as 
the most important mechanism through which MSC contribute to tissue repair in various species 
[93]. MSC-secreted factors include secreted vesicles, such as exosomes, microvesicles and 
apoptotic bodies [94, 95, 96], as well as free peptides, proteins, and small molecules [97, 98]. 
Select evidence of the functional impacts of these secreted factors exists in vivo. For example, it 
has been determined that treatment with the human BM-MSC secretome reduces pain and 
subchondral bone alterations in a mouse model of osteoarthritis [99]. In another mouse study, 
researchers found that topically administered BM-MSC attenuates clinical symptoms in an 
allergic conjunctivitis model through multiple cyclooxygenase 2-dependendent anti-allergic 
mechanisms [100]. Finally, a human clinical study showed that exogenously delivered AD-
MSC-derived secretome inhibits inflammatory responses of microglia [101]. Collectively, results 
from these, and many other studies that have been previously compiled in published review 
articles [102, 93, 103], support the use of MSC-secreted factors as a therapy for various disease 
conditions.  
 MSC have been shown to respond to environmental signals by altering their secretion 
patterns in ways reminiscent of the adaptive and innate immune system responses [104, 105], 
which further increases the attractiveness of MSC as a biologic therapy since exogenously 
delivered MSC may react to the recipient environment by secreting factors that promote 
homeostasis in whatever tissue they home to [106, 1067 108]. Finally, several studies found that 
MSC can also be “pre” primed in vitro to secrete specific products, before their use in vivo for 
therapeutic purposes [109, 110, 111].  
 Studies to define the functional effects of equine MSC-secreted factors on target cells or 
tissues have only been initiated over the past 5 years, mainly by our research group. For 
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example, we and others have shown that equine MSC promote angiogenesis in an in vitro model 
system [112, 113] through the paracrine stimulation of endothelial cells, which causes them to 
secrete higher levels of vascular endothelial growth factor (VEGF-A) [112]. Another group 
determined that secreted factors from equine MSC stimulate the migration of corneal fibroblasts 
in culture, and that one of the factors likely responsible for this effect was transforming growth 
factor beta-1 (TGF-β1) [114]. We have evaluated the effects of the equine MSC secretome on 
fibroblasts, as well as bacteria commonly found in horse skin wounds. These results are 
described in the research chapters presented in this thesis.  
1.4.2. MSC as a therapy for cutaneous wounds 
 Multiple characteristics of MSC, as outlined above, make them an attractive biologic 
treatment for skin wounds, and their therapeutic potential to heal skin has been intensively 
explored in human medicine, including in rodent animal models of wound healing and small-
scale human clinical trials. In contrast, the potential of equine MSC to aid in equine wound 
management has been far less explored and is the basis for this dissertation. 
 Cutaneous wound healing in humans and horses consists of an overlapping series of 
highly coordinated cellular responses to injury that serve to (i) stop bleeding, (ii) remove and 
replace damaged tissues, and (iii) restore epithelial barrier function. Even under the best of 
circumstances, the repair of adult skin is imperfect, and complications often lead to delayed 
healing and scarring. As reviewed in Chapter 2, current therapies for cutaneous wound healing 
are inadequate, so novel alternate and adjunctive treatments are needed. 
 As mentioned above, the efficacy of MSC and MSC-secreted factors as biologic therapies 
for human skin wounds has been explored, and evidence suggests that these cells can be useful 
as a complete, or supplemental treatment for a variety of wound types. The majority of this 
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research was done with human BM-MSC administered to induced wounds in rodent animal 
models. For example, a recent study demonstrated that MSC conditioned medium administered 
to full-thickness skin wounds of rats led to enhanced epithelialization and angiogenesis [115]. 
Another group used BM-MSC acellular derivatives (which primarily consisted of secreted 
vesicles) to treat wounds in a diabetic mouse model. Wounds treated with acellular derivatives 
showed higher degrees of closure at select times post-wounding than wounds treated with a 
vehicle control. Treated wounds also exhibited a less pronounced inflammatory response, more 
granulation tissue formation and a higher density of collagen fibers [116]. In addition to small 
rodent models, pigs have been used to test the efficacy of MSC as a therapy for skin wounds. In 
one study, porcine BM-MSC were injected into the skin of pigs intradermally just prior to the 
infliction of full-thickness incisional wounds. After 28 days, the wounds exposed to MSC scored 
better than the controls and fibroblasts in wounds exposed to MSC were larger than those in 
control wounds [117]. 
 In addition to studies carried out in these animal models, a number of experiments with 
human subjects have also provided evidence that MSC can improve skin wound healing. In a 
small study consisting of 3 patients with chronic wounds, treatment of wounds with bone 
marrow aspirate, followed by sequential treatments of BM-MSC, led to a decrease in wound size 
and increase in dermal vascularity and thickness [118]. In another case study, BM-MSC that 
were applied topically to acute surgical wounds and chronic lower-extremity wounds, were 
shown to accelerate the healing of acute wounds and decrease the size of chronic wounds at the 
time of examination, 20 weeks post-treatment [119]. In a relatively large study, 20 chronic, non-
healing wounds were treated with BM-MSC seeded in a collagen sponge, ninety percent of the 
wounds healed completely at the end of the study [120]. 
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 The results of these investigations suggest that there is potential for MSC to be 
administered as a therapy to treat human cutaneous wounds, but larger clinical studies with 
longer follow-up periods as well as randomized controlled trials are necessary before MSC 
therapy can be accepted as a clinical practice [121].  Currently, patients are being actively 
recruited for trials designed to examine the long-term effects of MSC therapy on chronic wounds 
[ClinicalTrials.gov], which is a step towards bringing this promising treatment to those suffering 
from non-healing wounds.  
1.5. Concluding remarks 
 The work referenced in this chapter (i) describes the history of MSC culture in species 
other than horses, (ii) provides a broad history of equine MSC research and therapy, and (iii) 
briefly describes the use of MSC-secreted factors as a therapy for human skin wounds, providing 
the rationale for evaluating the potential of MSC-secreted factors to treat horse cutaneous 
wounds. As outlined in the following research chapters, we designed in vitro experiments to 
assess the effects of the equine MSC secretome on cell types found in the skin. The research 
described in this dissertation was carried out to support our long-term goals of (i) validating 
equine MSC-secreted factors in vivo as a safe and effective therapy for horse skin wounds, (ii) 
providing equine clinicians with protocols to offer MSC-secreted factors as a therapy to their 
patients, and (iii) using what is learned while developing this therapy for horses, to improve 
treatments for humans. 
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2.1. Introduction  
 
 The skin is the largest organ of the mammalian body. Skin serves as a protective barrier to 
foreign pathogens and chemical compounds, regulates body temperature, prevents dehydration, 
and allows for sensing the environment [1]. As uncompromised skin is necessary for good health 
and well-being, treatment of skin wounds is of high priority in medicine.   
 At its 2012 annual meeting, The Wound Healing Society sponsored a symposium on 
preclinical models of wound healing. This meeting led to the drafting of a consensus statement 
that “strongly encourages all wound researchers to involve human wound tissue validation 
studies to make their animal and cell biology studies more translationally and clinically 
significant” [2]. Indeed, the practice of generating hypotheses based on what is known about 
wound healing in humans can guide researchers as they design experiments using relevant 
models to appropriately answer the questions at hand. The horse is an underused, yet 
physiologically relevant model animal that is well-suited to address questions about the 
mechanistic details of normal and impaired cutaneous wound healing in humans. Horses share 
anatomical features with humans and naturally suffer from several types of chronic wounds that 
are reminiscent of human conditions, making them an ideal model for the study of particular skin 
pathologies. In addition, as caretakers of veterinary species, we are obligated to understand the 
conditions horses suffer from and attempt to relieve them.  With this in mind, horses do not only 
serve as models for humans, but what is learned from cutaneous wound research in horses will 
improve veterinary medicine as well. The goals of this review are to (i) describe the common 
limitations of current wound therapies for humans and horses, that are in part a result of our lack 
of understanding of wound healing processes, (ii) compare skin physiology and normal wound 
healing in humans and horses, (iii) propose the horse as a model for two types of chronic wounds 
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experienced by humans, and (iv) offer evidence that the horse is an appropriate model in which 
to test novel therapeutics for cutaneous wound management. Based on the information provided 
in this review, we put the horse forward as a relevant model for wound healing studies, which 
will benefit both human and veterinary health. 
2.1.1 Relevance of cutaneous wounds in humans and horses  
 More than 11 million people in the United States are negatively affected by acute wounds, 
inflicted by accidents or surgical procedures yearly [3]. In addition, the prevalence rate of chronic, 
non-healing wounds in developed countries is estimated to be an approximate 2% of the population 
[4]. In the United States alone, 6.5 million patients are affected by chronic wounds annually, with 
an estimated health care cost of $25 billion [5, 6, 7]. Unfortunately, these numbers are on the rise, 
corresponding with increasing rates of diabetes and obesity, as well as aging populations, all of 
which predispose people to suffer from chronic wounds. Indirect costs of cutaneous wounds are 
associated with skin scarring, with $12 billion spent annually in the United States to reduce or 
remove scars [8], as well as with disabilities and lost wages caused by chronic non-healing wounds. 
In addition to placing an economic burden on individuals and health care systems, skin wounds 
take an unquantifiable physical and emotional toll on affected patients. 
  The economic cost of wounds in horses is not as well documented, but skin wounds are 
among the most common ailments treated by equine practitioners [9]. Moreover, a 2006 USDA 
report states that ~19-24% of equine euthanasia cases are carried out as a way to humanely deal 
with non-healing skin wounds or traumatic injury to the skin [10].  
2.1.2 Current therapies for wound management in humans and horses 
 The complexity of the cutaneous wound healing process contributes to difficulties in executing 
successful treatment protocols when natural wound healing is not adequate. Indeed, it is well-
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established that healing of full-thickness skin wounds is far more intricate than implied by the 
conventional description of the 4 phases of wound healing. It is clear that each of the “phases” 
(hemostasis, inflammation, proliferation, and remodeling) is made up of interdependent events 
executed by resident skin cells, migrating immune cells and extracellular matrix (ECM) 
components, in addition to growth factors, cytokines, and chemokines, released by cells and the 
surrounding environment [11]. The events required for successful wound healing consist of a 
cascade that is initiated by wounding and continues until long after wound closure is achieved 
[12]. Conventional treatments for cutaneous wounds of humans and horses broadly aim to improve 
the wound bed by keeping it moist, free of pathogens, and adding or removing pressure, depending 
on the type of wound [13, 14]. These methods have remained largely unchanged over the past 
decades. 
 In parallel with our increasing knowledge of wound healing processes in humans, there has 
been an effort to incorporate increasingly sophisticated treatment strategies based on specific 
cellular responses to injury. Various recombinant growth factors, such as platelet-derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF), 
have been used to treat wounds in experimental settings. However, malignancy risks and other 
problems associated with adding recombinant proteins to cutaneous wounds have been recognized, 
and these therapies have not yet been fine-tuned for clinical use [15]. Hyperbaric oxygen therapy, 
which consists of breathing pure oxygen while in a total body chamber where pressure is 
controlled, is also used as a method to positively influence cells involved in wound healing by 
altering clotting, cell proliferation, angiogenesis and tissue repair [16]. Although there are few 
negative side effects to this type of therapy, it is currently not widely used due to the extensive 
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equipment and technical expertise needed to execute it, and long-term positive results are not well 
documented [16, 17]. 
 Likewise, equine practitioners have made efforts to refine treatments for cutaneous wounds, 
based on the growing knowledge of the cellular mechanisms that drive wound repair. The choice 
of treatment for cutaneous wounds in equine patients depends on the body location of the wound. 
Wounds on the lower neck and trunk of horses tend to heal by the contraction of muscle below the 
skin, which draws the edges of the wound together. In contrast, wounds on the upper neck, face 
and legs close primarily by epithelialization, consisting of the migration of keratinocytes over 
granulation tissue. Similar to studies for the treatment of human skin wounds, active research is 
focused on determining the effects of specific proteins, such as VEGF-E and interleukin-10 (IL-
10), or oxygen therapy, on the healing of horse wounds [18, 19, 20, 21], but as in human medicine, 
these treatments are not yet available to equine patients.  
 Collectively, the expenses associated with cutaneous wounds, as well as the lack of adequate 
treatment options for both humans and horses, creates the need for (i) basic scientific research 
designed to understand the mechanisms that drive normal and delayed wound healing, and (ii) the 
development and testing of targeted adjunctive and novel therapies in both human and veterinary 
medicine. 
 
2.2. Skin physiology and normal wound healing in humans and horses 
2.2.1. Skin physiology  
 The skin of humans and horses is comprised of two primary layers which protect internal 
organs from mechanical damage and invasion by pathogens. The outer epidermis, derived from 
the embryonic ectoderm, is a thin, cellular layer that provides a waterproof barrier to the 
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environment. The dermis lies beneath the epidermis and is made up of two regions, the papillary 
dermis and the reticular dermis. This layer contains fibroblast cells which produce and remodel 
the dense, collagenous connective tissue that makes up the bulk of the dermal layer. The dermis 
is also rich with blood vessels, lymphatic vessels, and glands such as sweat and sebaceous 
glands. Hair follicles originate in this layer as well.  Epidermal extensions, referred to as rete 
ridges or pegs, extend into the dermal layers. Resident and infiltrating immune cells can be found 
in both layers of the skin. The hypodermis, or superficial facia, is located below the dermis and 
primarily consists of fat and connective tissue, but also contains blood vessels. This layer is not 
considered part of the skin, but rather serves as an insulating layer and helps attach the skin to 
underlying structures.  
 The human epidermis is comprised of 4-5 stratified layers of epithelial cells [22], while 
the horse epidermis is described as being made up of 5 stratified squamous cell layers [23, 24]. 
Human and horse skin both have a thick dermal layer, which in the human contains sparse hair 
follicles while the hair follicles in the horse are densely distributed [22, 25] (Figure 2.1A). 
Human skin thickness is relatively uniform from site-to-site on the body [26], while the thickness 
of horse skin is variable according to body site [14]. Humans are considered “tight-skinned”, 
meaning that the skin is firmly attached to the underlying subcutaneous connective tissue [22].  
Horses are often also described as “tight-skinned” [27], but since the qualities of horse skin vary 
across the body, some parts of the horse such as the trunk, may be considered to have “loose-
skin”, which is more typical to that of laboratory rodents. Humans and horses each have a 
disrupted panniculus carnosus; a layer of striated muscle below the hypodermis. In humans, 
remnants of this muscle are found in the face, hands, chest and scrotum [28], whereas it stretches 
from the knees to the base of the neck in horses [29] Figure 2.1B). 
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Figure 2.1. Human and horse skin physiology. A. Schematic cross sections of human (left) and 
horse (right) skin. One primary difference between the species is the density of hair follicles. B. 
Distribution of the panniculus carnosus muscle in humans (left) and horses (right).  
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2.2.2. Normal wound healing 
 Similar to most mammals, successful skin wound healing in humans and horses involves 
a network of synchronized biological processes that restores the integrity of the skin after injury. 
The process of wound healing after full-thickness injury is often divided into four phases (Figure 
2.2).  
 
Figure 2.2. Stages of normal wound healing in human and horse. Normal wound healing in 
humans and horses is comprised of a similar overlapping series of events. Immediately after 
injury, bleeding is stopped by hemostasis. An intense inflammatory response follows, which 
serves to clear pathogens and induce proliferation of cells needed to fill the wound space. The 
remodeling phase continues long after wound closure. In this phase stromal cells coordinate the 
turnover of extracellular molecules in the wound bed, leading to increasing tissue strength.   
 
 During hemostasis, the immediate response to injury, vasoconstriction and coagulation 
serve to stop blood loss and to concentrate the growth factors that contribute to wound healing. 
The subsequent inflammatory or debridement phase, lasting for 3 to 7 days post injury, is 
characterized by infiltration of immune cells which control contamination, and secrete cytokines 
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and growth factors that induce the proliferative phase [30]. The proliferative phase continues for 
at least 2 weeks post injury, during which time epithelial cells migrate from the wound margins 
to close the wound, and a population of dermal fibroblasts (DF) are activated by tumor necrosis 
factor alpha (TNF), PDGF, transforming growth factor beta 1 (TGF-1) and mechanical stress  
in the wound bed [31]. Activated DF secrete collagen and other ECM proteins and may 
differentiate into myofibroblasts, which contribute to wound contraction. Finally, the remodeling 
phase can proceed for up to a year after initial injury. During this phase, ECM proteins are 
alternately laid down and degraded, creating an increasingly organized tissue environment [30]. 
In many cases, however, complete tissue regeneration is not achieved, leading to chronic non-
healing wounds or abnormal scar formation. As the details of wound healing have been 
elucidated, it has become apparent that the four phases of healing are not distinct, rather the 
events required for successful wound healing are a continuous cascade that is initiated by 
wounding and continues until long after wound closure is achieved [12].   
 Due to similarities in skin architecture, aspects of normal cutaneous wound healing in 
humans and horses are very much alike (Table 2.1). 
 
Table 2.1. Features of normal wound healing in human and horse 
Feature Human Horse 
primary surface closure 27,32 epithelialization epithelialization (limb), muscular 
contraction (trunk) 
dermal healing 27 stromal granulation, 
myofibroblast activity 
stromal granulation, 
myofibroblast activity (limb) 
neutrophil:lymphocyte ratio 26 60:40 60:40 
blood oxygen capacity 38 high low 
ambulatory species 38 yes no 
platelet composition 39 high low 
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 Humans have skin that is firmly attached to the underlying connective tissue and as a 
result, rely on epithelialization for the primary surface closure of skin wounds, followed by 
dermal healing via stromal granulation and myofibroblast migration and contraction. This is very 
similar to how skin healing progresses on horse distal limbs [27]. In contrast, the mechanism of 
primary wound closure on the horse trunk is more similar to that seen in rodents, which involves 
contraction of the panniculus carnosus [32]. Another concordance between humans and horses 
that may contribute to similarities in skin wound healing is the ratio of neutrophils to 
lymphocytes (NLR) in peripheral blood. Human and horse blood each have a ratio of about 60% 
neutrophils to 40% lymphocytes, whereas the NLR is much lower in mouse blood [26]. In 
human medicine, the NLR in blood as well as in tissues is emerging as a measure of subclinical 
inflammation [33, 34, 35, 36, 37]. Since inflammation is a critical aspect of cutaneous wound 
healing in mammalian species (Figure 2.2), similar basal NLR may contribute to similarities in 
this stage of wound healing.  
 In addition to parallels, there are basic physiological differences between humans and 
horses that may contribute to variable mechanisms of skin wound healing between these species 
(Table 2.1). Humans can be classified as stalking predators, whereas horses are flight animals, 
with hearts capable of going from resting to 300 beats per minute almost instantly. This extreme 
flight response results in a contraction of the spleen, which releases a reserve of red blood cells 
into the circulation, increasing the oxygen carrying capacity of blood to levels far higher than are 
possible in humans [38]. As successful skin wound repair depends on a steady supply of well-
oxygenated blood, it stands to reason that the different patterns of blood oxygen availability in 
humans and horses may result in alternative mechanisms for healing between the species. 
Another notable difference between humans and horses is that while humans can be immobilized 
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for months to years with proper nursing care, horses are an ambulatory species that must stand 
and walk to survive. If horses are recumbent for longer than 72-96 hours, life-threatening 
complications begin to develop [38]. A subtler difference between the species is the platelet 
composition of the blood; human blood has a much higher concentration of platelets compared to 
horse blood [39], which may affect the rate of coagulation and alter the initial inflammatory 
response to wounding. There are no published reports describing how these basic physiological 
differences between humans and horses lead to differences in skin wound healing between the 
species, but an awareness of them may help researchers determine which human skin conditions 
can be accurately recapitulated in the horse model.  
 
2.3.  The horse as a model for cutaneous wound healing research 
 Researchers have been studying the mechanisms of cutaneous wound healing in humans 
and horses for decades. For an overview of the models used for human wound healing research, 
we would like to refer to other reviews [40, 41, 42, 43, 44, 45]. In this review, we will focus on 
the models, both in vitro and in vivo, used to study the (patho)physiology of wound healing in 
horses.  
2.3.1. Naturally-occurring chronic skin wounds similar in humans and horses 
 Several types of naturally-occurring skin wounds of horses are uniquely similar to 
conditions experienced by humans, making the horse an ideal animal model in which to study 
these pathologies. Two such naturally occurring wound types, namely fibroproliferative wounds 
and wounds resulting from allergic responses, are particularly relevant because the development 
of these wounds is not well understood and treatment options for both species are inadequate. 
 2.3.1.1. Fibroproliferative disorders 
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 The formation of normal granulation tissue is an essential process in successful cutaneous 
wound healing in both human and horse [46, 47, 27]. Granulation tissue is created by fibroblasts 
and is primarily composed of type-III collagen. It fills the wound space, forming a barrier 
between the body and external contaminants, and provides epithelial cells a surface over which 
to migrate. Granulation tissue also serves as support for the cells that contribute to wound repair. 
Endothelial cells in the granulation tissue form new capillaries, needed to bring oxygen and 
immune cells to the wound bed. Fibroblasts secrete ECM molecules, and the enzymes required to 
break them down during the rounds of ECM remodeling that occur during the course of tissue 
repair [48]. Fibroproliferative disorders, characterized by the deposition of excessive ECM or 
granulation tissue, are associated with chronic low-grade inflammation, cellular proliferation and 
lack of wound closure. Fibroproliferative tissue occurs uniquely in humans, as hypertrophic scars 
and keloids, and on the distal limbs of horses where it is called proud flesh, or exuberant 
granulation tissue (EGT). Table 2.2 gives an overview of the key features that are either similar 
or different between human keloids and equine EGT. 
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 Keloids are defined as scars that grow continuously and invasively beyond the margins of 
the original wound, which can range from pea-sized to as large as a football [49]. The quality of 
life of patients suffering from keloid disease can be reduced due to both physical complications, 
including severe itching, pain, loss of mobility and infection, as well as psychological 
impairments, such as embarrassment, lack of self-confidence and depression [50]. There is no 
single, effective treatment regime, and although many therapies are available, most are 
associated with extreme high rates of recurrence [51]. Keloid development involves alterations in 
complex pathways, but the mechanisms of the initiation and regulation of these pathways in the 
Table 2.2. Key features of human keloids and equine exuberant granulation tissue (EGT) 
Feature Keloids EGT 
protrudes beyond wound margins 49,14 yes yes 
ulceration 54 yes yes 
epithelial cell coverage 54 often complete usually absent 
disorganized collagen 54 yes yes 
tissue macrophages 54 minimal minimal 
tissue mast cell 54 minimal minimal 
dermal fibrosis 54 moderate-severe moderate-severe 
fibroblast proliferation 54 excessive excessive 
elastic fibers 54 no no 
granulation tissue 54 no yes 
dermal vascularity 54 moderate-severe minimal 
keloidal collagen 54 yes no 
myofibroblast 54 yes no 
inflammation 52 55,56,57,58,59 low-level, sustained low-level, sustained 
microvascular occlusion 54,68  yes yes 
apoptotic balance 66,67,68 skewed skewed 
hypoxia 56,69,70 yes yes 
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context of keloid scarring are unknown [52]. Although chronic inflammation has been shown to 
contribute to keloid formation, details of keloid pathogenesis in the early stages remain poorly 
understood. In response to trauma, 15-20% of people of Asian, African and Hispanic origins 
develop keloids [51]. There is evidence of genetic susceptibility to keloid, but again, the 
underlying pathogenesis is not well-defined.  
 As described above, horse skin wounds heal by distinct mechanisms based on the body 
site on which they occur. Wounds on the distal limbs that heal by epithelialization usually close 
slowly and can develop EGT. EGT is visually irregular with a pebbled, moist surface that 
protrudes beyond the margins of the wound. This phenotype is a result of residual fibrin deposits, 
disorganized fibroblasts and vasculature, and a lack of epithelial cell coverage [14].  As this 
tissue is exposed to the environment, it is susceptible to abrasion, secondary infection, and re-
injury. Removal of EGT by surgical excision is currently considered the best treatment option, 
even though the procedure often needs to be performed multiple times before successful wound 
closure occurs [53]. Interestingly, ponies, which are the same species as horses, but are 
distinguished from horses based on size (ponies are <1.48 m in height at the withers, while 
horses are taller) rarely develop EGT in association with limb wounds. The intriguing differences 
in wound healing between (i) body site in horses and (ii) horses versus ponies, have been the 
focus of many in vivo studies that led to what is known about EGT, and are described in more 
detail in section 2.3.3.  
 A comparative histological study of keloids and EGT determined that both tissues are 
characterized by ulceration, although keloids tend to exhibit substantial epithelial cell coverage, 
while EGT usually is lacking epithelial cells. Both keloids and EGT also have disorganized, 
thickened collagen fibers, minimal numbers of tissue macrophages and mast cells, moderate to 
  54 
severe dermal fibrosis, and excessive numbers of proliferative fibroblasts. Elastic fibers were not 
observed in either tissue type. Granulation tissue was absent in keloid tissue, but present in EGT. 
Dermal vascularity was moderate to severe in keloids, and minimal in EGT. Keloidal collagen 
and myofibroblasts were observed in keloids but not in EGT [54].  
 Gene and protein expression has been well studied in keloids and EGT, as well as 
individual cell types isolated from these tissues. Analysis  of mRNA and protein from keloids 
has shown that the expression of TGF-1, matrix metalloproteinase-1 (MMP1), PDGF, and FGF, 
are increased in this tissue as compared to normal skin [55, 56]. These cytokines and growth 
factors directly and indirectly contribute to a prolonged low-level inflammatory phase of wound 
healing and delay the healing response [52]. Early work measuring growth factor concentrations 
in homogenates made from horse limb and thoracic wounds demonstrated that TGF-1 is more 
highly expressed in limb versus thoracic wounds post-injury, while transforming growth factor 
3 (TGF-3) and FGF expression patterns are similar irrespective of wound site [57].  Analysis 
of the inflammatory mediators in the TGF- family in horse and pony wounds showed that while 
wounds on ponies express higher levels of active TGF- post-wounding regardless of wound 
location (trunk or limb), wounds on horse limbs that are prone to develop EGT exhibit a 
sustained low-level expression of this family of growth factors [58].  Building on this work, a 
study was performed to analyze the function of polymorphonuclear leukocytes (PMN) as well as 
the local cytokine profiles in horse and pony limb and neck wounds [59]. The results of this 
study indicated that pony PMN produce higher levels of reactive oxygen species compared to 
horse PMN, and that TNF, interleukin-1 (IL-1), and chemoattractants, are produced at higher 
concentrations in pony wounds than in horse wounds. Collectively, these suggest that an intense, 
yet temporally limited inflammatory response, supports efficient wound closure, while a 
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sustained low-level inflammatory response promotes excessive fibrosis in both humans and 
horses (Figure 2.3). 
 
Figure 2.3. Illustration of the inflammatory response in normal wound healing as 
compared to keloid or exuberant granulation tissue (EGT) development. Normal wound 
healing is characterized by an intense and short-lived inflammatory response immediately after 
wounding. During the development of human keloids or EGT in horses, the inflammatory 
response is delayed, sub-optimal and does not fully resolve.  
 
 Suppression subtractive hybridization was used to identify genes differentially expressed 
in the margins of normally healing wounds as compared to intact skin in horses [60]. This work 
resulted in a list of 226 genes expressed 7 days post wounding. The authors used this data to 
compare gene expression patterns in biopsies taken from normally healing wounds on horse 
trunks as opposed to biopsies collected from EGT wounds on horse limbs. Annexin A2 
(ANXA2) and MMP1 mRNA was found to be upregulated in trunk but not limb wounds, 
corresponding to the rapid tissue turnover required for normal wound healing [61]. Another 
study by the same group examined the expression, both on mRNA and protein levels, of laminin 
receptor 1 (RPSA) in healing wounds on the bodies and legs of horses [62]. This work showed 
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upregulation of RPSA in thoracic wounds at 4 and 6 weeks post-wounding, when 
epithelialization was occurring, while expression in limb wounds was downregulated at post-
wounding times. Data on the expression patterns of RPSA, a receptor that binds multiple ligands 
including a variety of ECM molecules, may help tease out events that favor normal wound 
healing over the development of excessive fibrotic tissue and chronic wounds. Follow up work 
showed that OB-cadherin, a protein positively associated with contractile fibroblasts, was higher 
in thorax than limb wounds [63]. Additionally,  osteopontin (OPN), which is essential for proper 
ECM organization in normal wound healing was also differentially expressed in horse wounds 
depending on wound site, which the authors suggest may reflect the delayed and low-level 
inflammatory response characteristic of EGT [64]. 
 Microvascular occlusion, the excessive proliferation of fibroblasts, and a skewed 
apoptotic balance are all characteristics of keloids and hypertrophic scars in humans and EGT in 
horses that may contribute to the excessive deposition of ECM [65, 66, 67, 68]. Tissue hypoxia 
has been implicated as a contributing factor to fibroproliferative diseases in humans, although the 
underlying mechanisms are not fully understood. Studies in horses indicate that microvascular 
occlusion leads to a relative state of hypoxia in limb wounds, which may promote the weak, but 
prolonged inflammatory response characteristic of chronic, fibrotic wounds [69, 70].  
  Based on the similarities between the two diseases, and the benefits provided by studying 
cutaneous pathologies in a large animal species (discussed in section 2.3.3), EGT in horses has 
been proposed as a model for keloids in humans [27].  
 2.3.1.2. Atopic dermatitis 
 Another chronic inflammatory skin disease experienced by both humans and horses is 
atopic dermatitis (AD). Intense itch and recurrent eczematous lesions, triggered by exposure to 
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harmless environmental allergens, characterize this increasingly common condition. Clinical 
signs of AD in humans often develop during childhood and include pruritic lesions, hives, 
lichenified skin, and staphylococcal colonization [71, 72, 73]. AD is frequently accompanied by 
asthma and allergic rhinitis in humans [74, 75, 76], and food allergies are another associated 
condition [77, 78]. As the tendency to have an allergic condition is associated with susceptibility 
to additional allergic conditions, symptoms often appear in sequence with age, supporting the 
concept of an ‘atopic march’ [71]. AD in humans is also associated with non-atopic comorbid 
conditions including other autoimmune-mediated diseases as well as depression and anxiety [79, 
80, 81]. 
 Patients with AD often present with ultrastructural abnormalities of the stratum corneum, 
characterized by dry skin and compromised barrier function. These abnormalities have been 
linked to mutations in the filaggrin (FLG) gene, that lead to a lack of this protein in the outer 
layer of the skin [82, 83]. 
 AD in humans has historically been considered IgE-mediated, supported by an 
exaggerated T helper 2 (Th2) response, [84, 85], but this view is expanding into one in which 
epidermal barrier disruption, the responses of various T cell subsets, and dysbiosis of the 
commensal skin microbiota all contribute to the pathology [71]. Although it is proposed that 
molecules secreted upon damage of the epidermis and products of the immune cells that respond 
to them are increased in AD lesions, cytokine profiles in skin affected with AD have not been 
accurately defined. It has been shown, however, that epithelial cells from AD patients express 
high levels of thymic stromal lymphopoietin (TSLP), a mediator that indirectly stimulates T cells 
to produce T helper (Th)2 cytokines in other pathologic situations [86]. Increased mRNA levels 
of the Th2 interleukins IL-4, IL-10, and IL-13, and the Th22-associated cytokine interleukin-22 
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(IL-22), have all been detected in acute atopic dermatitis lesions when compared to healthy skin 
[87]. CD4+ T cells from AD lesions produce IL-4, IL-13, and IL-22, whereas CD8+ T cells from 
AD lesions are a source of IL-13, IL-22, IL-17 and interferon-gamma (IFN) [88], and type 2 
innate lymphoid cells (ILC-2) in AD lesions express IL-4 [89]. 
 AD in horses presents both as a skin and a respiratory disease, but evidence of a 
progressive atopic march is only anecdotal in horses [90]. Clinical signs of AD in horses include 
hives and pruritus, and similar to human AD, staphylococcal colonization is commonly found 
[90]. Food allergies can lead to AD in horses, although other conditions, such as hypersensitivity 
to proteins in the saliva of biting midges in the genus Culicoides, are more commonly associated 
with equine AD [91]. Ultrastructural abnormalities in lipid lamella and disorganization of the 
stratum corneum, which resembles skin lesions in human AD, have been reported in horses [92]. 
The antibody and cytokine profiles in the skin and/or serum of horses that are sensitive to AD 
have not been described thoroughly, but equine AD has been shown to be an IgE-mediated 
disease that presents with an increased expression of IL-4 [91, 93, 94]. The horse is currently not 
actively used as an animal model for human AD, but efforts to increase our knowledge of equine 
AD and to better define similarities and differences, will provide better insights into the 
suitability of the horse as a model for AD in humans. Some of the key features, both similar and 
different, that have been studied in both species are shown in Table 2.3.  
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2.3.2. Equine in vitro skin wound models 
 In vitro cell culture models have been used extensively to study the characteristics of 
cells involved in equine cutaneous wound healing, such as resident skin cells and migrating 
immune cells, as well as their responses to potential treatments.   
 2.3.2.1. Two-dimensional (2D) cell culture 
 Because of their simplicity, 2D cell models are heavily used to define basal 
characteristics of skin cell populations such as cell morphology, population doubling time, gene 
and protein expression patterns, and cell motility. They are also useful to detect changes in target 
cells in response to an insult, treatment, or change in culture conditions.  
 For example, the inherent growth characteristics of DF isolated from the trunk and distal 
limbs of horses and ponies have been evaluated in a 2D culture system [95]. Results from this 
study showed that DF isolated from horse limbs grow more slowly than DF isolated from the 
horse trunk, as well as from pony limb and trunk, and led the authors to conclude that differences 
Table 2.3. Key features of human and horse atopic dermatitis (AD) 
Feature Human Horse 
recurring lesions 71,90 yes yes 
hives 71,90 yes yes 
lichenified skin 71,90 yes yes 
Staphylococcal colonization 72,73,90 yes yes 
co morbidities 74,75,76,90 asthma, allergic rhinitis respiratory disease 
allergen triggers 77,78,91 food, environmental allergens Culicoides salivary proteins 
atopic march 71,90 yes anecdotal evidence 
abnormalities of stratum corneum 82,83,92 yes, associated with FLG mutation yes, cause unknown 
IgE-mediated 84,85,91 yes yes 
Th2 cytokine expression 86,87,93,94 yes, well defined yes, not well explored 
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in DF growth may contribute to the development of EGT. Consequently, influencing DF growth 
could be a potential way to control the development of EGT [95]. Another study from our group 
compared basic characteristics of DF isolated from healthy horse skin and horse EGT in a 2D 
monoculture model [96]. This work showed that cultured DF from EGT display a more cuboidal 
morphology in culture compared to DF cultured from healthy skin, and that DF isolated from 
EGT have a longer population doubling time, migrate more slowly, and have gene expression 
profiles that are distinct from those observed in DF isolated from healthy skin. Moreover, EGT-
derived DF were found to be more susceptible to busulfan-induced senescence than DF derived 
from healthy skin [96]. These observations could provide some clues as to why EGT persists in 
vivo. In addition to DF, primary equine keratinocyte cultures [97] and equine digital vein 
endothelial and smooth muscle cell cultures [98] have been established in 2D culture systems. As 
these cell types are all involved in skin wound healing in vivo, they can be used in future 
experiments to learn more about the cell-cell and cell-ECM interactions that occur during normal 
and impaired wound closure.  
 Migrating immune cells can also be isolated from horse blood, characterized in culture, 
and then used in various 2D and 3D (see below) co-culture models used to observe cell-cell 
interactions relevant to wound healing processes. For example, CD4+ T cells, were purified from 
horse and pony peripheral blood mononuclear cell preparations and cultured, which allowed for 
the identification of a subpopulation of FOXP3+ cells analogous to regulatory T cells in other 
species [99, 100]. As these cells are known to be dysregulated in human AD and 
fibroproliferative tissue, they may prove to be a useful tool for in vitro wound healing studies 
with equine cells. Polymorphonuclear cells (PMN) isolated from horses and ponies, and 
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maintained in culture, showed that (i) reactive oxygen species production of pony PMN is higher 
than that of horse PMN and (ii) in vitro chemotaxis of PMN differs between those isolated from  
ponies and horses, providing the basis that these cells can contribute to differences observed in 
horse and pony skin wound healing [101]. Equine monocyte-derived macrophages [102] and 
mesenchymal stromal cells (MSC) [103, 104] are additional examples of migratory cells that 
have been characterized using 2D cell culture systems and contribute to skin wound healing.  
 2.3.2.2. Three-dimensional (3D) cell culture 
 A variety of 3D cell culture systems have been developed for the study of equine 
cutaneous wound healing (Figure 2.4). These models are often considered more anatomically 
significant than 2D cell culture, as they incorporate both a cellular support system or matrix 
and/or multiple cell types, which allow for the establishment of cell-matrix and cell-cell contacts 
that mimic the in vivo wound microenvironment [105]. 
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Figure 2.4. Three-dimensional (3D) equine in vitro cell culture models. Collagen gels are 
used to determine the contractile capacity of cells, which can be quantified. Tissue explants, 
which maintain in vivo architecture, are useful to observe responses to treatments and monitor 
cell-cell interactions, but their lifespan in vitro is limited. Uniform dermal equivalents are used in 
automated wound healing studies. Organoids, which have a long lifespan in culture and exhibit a 
high degree of cellular organization are used to observe responses to treatments, monitor cell-cell 
interactions and study disease progression.  
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 The contractile capacity of equine DF isolated from the distal limb and buttocks of horses 
and ponies was determined by taking advantage of relatively simple 3D cell culture models; 
growing equine DF in both floating and anchored collage gels [59]. From these studies it was 
concluded that in vivo differences in contraction between wounds on the limbs versus buttocks, 
and between horses versus ponies, is not caused by the inherent contraction capacity of DF at 
wound sites, suggesting that the activity of these cells in vivo is determined by the wound 
environment.  
 Tissue explants are 3D culture models that are perhaps the most directly reminiscent of 
the in vivo environment. For these cultures, biopsies are collected and maintained in culture 
medium, with or without physical support, for several weeks [106]. These explants are primarily 
used to compare the responses of tissue to treatments [107, 108], test the toxicity of compounds 
[109], and monitor cell migration and reepithelization after wounding [110]. While explants (i) 
contain a greater diversity of cell types than can be incorporated in an engineered 3D model and 
(ii) maintain the complex architecture of the skin, they have a limited life span in culture. Equine 
dermal explants have been used as a source of hair follicle-derived stem cells [111], as well as 
primary keratinocytes [112], and our lab is currently optimizing an equine skin explant model in 
which to study bacterial biofilm growth in skin wounds (Van de Walle, personal 
communication).  
 Dermal equivalent models are another type of 3D cell culture model, often comprised of 
DF, embedded in a solid ECM, seeded with an “epidermis” of keratinocytes. Additionally, a 
hypodermis of adipose tissue can be incorporated [113]. Over several weeks in culture, the 
keratinocytes will form several layers, including the stratum corneum. These models are 
typically less complex than tissue explants, but since it is possible to generate many uniform 
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dermal equivalents that may be maintained for a relatively long time in culture, they are 
considered ideal for automated wound healing studies and toxicity testing [114, 115]. Recently, 
an equine dermal equivalent model has been developed that consists of “normal” horse DF and 
keratinocytes, supported by a collagen matrix and resembles equine skin morphologically and 
structurally [116]. Although not currently available, construction of similar models using cells 
isolated from EGT or from animals suffering from AD, with or without the addition of immune 
cells, could prove to be a productive and physiologically relevant way to study pathological 
wound healing processes in vitro.  
 Finally, organoids are defined as ex vivo multicellular fragments containing the major cell 
types of a particular organ that approximate in vivo organization. One strategy for developing 
organoids is to culture multipotent or pluripotent stem cells in a 3D matrix under conditions that 
promote self-organization of the cells. As these models achieve a level of cellular organization 
not possible with dermal equivalents, and they can be maintained in culture longer than tissue 
explants, they are useful models for the study of pathologies, cell-cell interactions, and drug 
discovery [117, 118, 119]. Murine and human organoids have been developed from retinal 
tissue, kidney, liver, intestines, stomach, lung and brain [117], and very recently, from skin 
[120]. Equine intestinal organoids are currently the only organoid type published [121], although 
we anticipate that equine organoids from additional tissues, including skin, will be established in 
coming years.  
2.3.3. Equine in vivo skin wound models 
 In vivo studies in horses have provided researchers with a well-controlled environment in 
which to study conventional therapies such as bandaging and ointments [122, 123, 124], and they 
have been used to evaluate the efficacy of full-thickness grafts [125], to understand 
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complications of sores associated with casting [126, 127], and to elucidate the mechanisms 
responsible for AD [128, 91]. However, the majority of experimentally-induced and controlled 
horse wound studies have been carried out with the goal of increasing our understanding of the 
development of cutaneous fibroproliferative disorders.  
 As described above, horse skin wounds on the distal limbs heal primarily by 
epithelialization, similar to human wounds. Since horse body wounds tend to heal by contraction, 
the horse provides a model in which wound healing by different mechanisms can be studied 
within the same animal, eliminating individual-to-individual variation. Moreover, the size of 
horses also provides the following experimental benefits: (i) multiple experimentally-induced 
wounds can be generated at one site on an animal, allowing for controls and treatments to be 
performed on the same individual and (ii) multiple biopsies of horse wounds can be collected 
over time, to evaluate healing processes in a way that cannot be performed in humans or small 
model species.  
 The horse model for experimentally-induced EGT was developed and validated in 2001 
and has since been adopted by many equine researchers [57, 129, 68, 21, 130]. In this model, 
multiple full thickness 6.25 cm2 wounds are created on the lower limbs using a scalpel. Wounds 
can be as close as 1.5 cm apart and are typically arranged in a vertical column. Postoperative 
bandaging reliably induces the formation of EGT (Figure 2.5A). Full thickness wounds of the 
same size, inflicted on the thorax or neck, and which do not develop EGT, can serve as controls 
(Figure 2.5B).  This model has allowed for the study of the effects of wound oxygenation and 
temperature on EGT development [69,70], and the evaluation of gene and protein expression 
patterns in EGT compared to wounds that heal quickly [61, 62, 63, 64, 131, 132].  
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Figure 2.5. Experimentally inflicted horse skin wounds. A. Exuberant granulation tissue 
(EGT) induced by bandaging experimentally inflicted wounds on the lower leg of a horse [14]. 
B. Experimentally inflicted wounds on the torso do not develop EGT [129]. Images from the 
referenced published work.  
 
2.4. The horse as a model to explore novel therapeutics for wound management 
  As a large animal, with physiological concordance to humans, the horse may serve not only 
as a model for the biological processes involved in wound healing, but also as a translational 
species in which to study novel therapies. Benefits of using an animal the size of a horse to test 
new wound management therapies include (i) the ability to experimentally inflict well-controlled 
skin injuries instead of having to rely on human patients enrolled in clinical trials with different 
stages of chronic wounds and/or additional underlying diseases, and (ii) testing alternate 
therapies for skin wounds in horses allows for earlier invention then is possible in humans, where 
unconventional treatments are usually only administered as ‘a last resort’. Finally, progress in the 
development of novel therapies in an equine model will not only benefit humans, but equine 
patients as well. The therapies described in this section are currently being developed for both 
humans and horses.  
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2.4.1. Stem cell therapies 
 Stem cells, or their products, are a type of cell-based therapy that may be used to augment 
the natural events required for successful wound healing, while avoiding the side effects 
associated with administering recombinant factors and the limits associated with a technology-
heavy procedure [7]. Stem cells are defined as undifferentiated cells that can (i) self-renew, 
maintaining the stem cell pool, and (ii) differentiate into mature cell types. Stem cells are 
classified based on their potency, with totipotent stem cells, present during the zygote stage, that 
can differentiate into all cell types of the body. Pluripotent stem cells, such as embryonic stem 
cells (ESC) and induced pluripotent stem cells (iPSC), can give rise to almost all of the cells that 
comprise an organism with exception of placental tissues. Multipotent stem cells are found after 
birth, and these adult tissue-specific stem cells exhibit the ability to differentiate into any of the 
cell types that arise from their germ layer of origin (Figure 2.6). 
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Figure 2.6. Stem cell hierarchy. The totipotent cells of the zygote can differentiate into all cell 
types of the body. The embryonic stem cells (ESC) of the blastocyst are pluripotent stem cells 
that can give rise to most of the cells making up an organism. Mesenchymal stromal cells (MSC) 
are considered to be multipotent tissue-specific stem cells, able to differentiate into the cell types 
making up their specific tissue-of-origin. Terminally differentiated cells can be re-programmed 
into induced pluripotent stem cells (iPSC), with a potential analogous to that of ESC.    
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2.4.1.1. Embryonic stem cells (ESC) 
 Human ESC, with a limitless capacity to self-renew and the ability to differentiation into 
almost any cell type could be therapeutically valuable, but ethical issues associated with 
collecting cells from embryos have largely hindered their evaluation for this purpose. Ethical 
concerns are not as much of a concern when studying ESC isolated from veterinary species, but 
these cells are currently not actively being used in equine medicine. Putative equine ESC have 
been described and validated as ECS based on marker expression and differentiation potential, 
but they did not form teratomas when injected into immunocompromised mice, which is the gold 
standard for human and murine ESC verification [133]. After this first description, additional 
studies with equine ESC have been carried out in relation to their potential for treatment of 
tendon injuries [134, 135, 136, 137], but these cells, to our knowledge, have never been explored 
as a therapy for cutaneous wounds.  
 2.4.1.2. Induced pluripotent stem cells (iPSC) 
 iPSC are adult cells, often skin fibroblasts, that have been re-programmed from a 
differentiated state into a less-differentiated state, typically by the introduction of transcription 
factors specific to pluripotent cells [138]. Human iPSC were first derived from adult human DF 
in 2007 [139]. Since then, they have been differentiated successfully into cardiomyocytes, cells 
of the skeletal system, hepatocyte-like cells, and cells of the skin, with the goal of generating 
cells and tissues that can be used for transplantation [140, 141, 142, 143]. In human medicine, 
the skin has been recognized as an ideal organ for iPSC-based applications. Skin equivalents can 
be generated from iPSC derived from patients with inherited genetic skin conditions, allowing 
for the study of these diseases in vitro [143]. In addition, disease-causing mutations can be 
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corrected in iPSC, allowing for the generation of gene-corrected replacement skin for patients 
suffering from genodermatoses [144].  
 Equine iPSC have been generated from fetal fibroblasts and keratinocytes. iPSC derived 
from horse fibroblasts expressed endogenous markers associated with pluripotency, displayed a 
stable karyotype over long-term culture, and formed teratomas containing all three embryonic 
germ layers when grafted into mice [145, 146]. Keratinocyte-derived iPSC have been reported to 
express endogenous pluripotent stem cell markers and to form derivatives of the three germ 
layers when injected into mice. With the appropriate in vitro conditions, they were found to 
resemble cholinergic motor neurons that were functionally active, based on the ability to 
generate action potentials. Importantly, these cells could be expanded without the support of 
feeder cells, a desirable quality if these cells are to be used for biomedical applications [147]. 
 2.4.1.3. Mesenchymal stromal cells (MSC) 
 MSC are a type of adult, multipotent progenitor cell that can be readily expanded in 
culture [148]. These cells actively secrete a rich composite of bioactive factors that may prove to 
be a safe, easy-to-deliver therapy to improve tissue repair [149]. Human MSC have been actively 
studied as a therapy for the healing of burn wounds, incisional wounds made by a scalpel during 
surgery, and excisional wounds generated by the removal of a portion of skin [150, 151, 
152,153]. On the NIH Clinical Trials website, there are currently several trials listed to test the 
efficacy of MSC to promote the healing of diabetic foot wounds as well as burn wounds. 
Although human MSC therapy for wound, and other, injuries and diseases has been studied for 
years, it still is not accepted as a clinical practice. This is in contrast to equine medicine, where 
MSC are clinically used as a therapy for orthopedic injuries. As a standard practice, equine 
clinicians isolate MSC from the patient’s bone marrow, expand the cells in culture, and then 
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cryopreserve the cultured cells in the event the patient suffers from a tendon or ligament injury 
later in life. If and when this happens, these autologous MSC are revived and injected at the site 
of injury. This general acceptance of MSC therapy by equine practitioners and clients, makes 
veterinary medicine an ideal setting in which to explore the therapeutic value of MSC for 
additional types of injuries and disorders.   
 We have used in vitro systems to study the potential of equine MSC derived from 
peripheral blood, a less invasive source than bone marrow, for wound management. We have 
shown that these cells secrete factors that stimulate angiogenesis, secrete proteins that promote 
DF migration, and produce antimicrobial compounds that inhibit the growth of bacteria 
commonly found in skin wounds [154, 155, 156]. We also found that when exposed to MSC-
derived secreted factors, the expression of genes associated with a contractile cell phenotype is 
altered in EGT-derived DF, but not DF isolated from normal skin, and that these factors do not 
stimulate the migration of EGT-derived DF as they do for DF derived from normal skin [96]. 
Finally, we have begun to explore methods of cell encapsulation that may facilitate the delivery 
of equine MSC secreted factors to skin wounds [103]. Collectively, these in vitro studies suggest 
that secreted factors from equine MSC could promote wound healing in vivo and may be used as 
a treatment option to prevent or reduce proud flesh formation on the lower limbs of horses.  
 A recent in vivo study from the group of Borjensson showed that injection of allogeneic 
MSC into experimentally-induced distal limb wounds altered gene expression at the wound site 
and enhanced early healing [130]. The promising results of this preliminary in vivo study 
provides a strong basis for additional in vivo studies designed to further evaluate the effects of 
MSC therapy on skin wounds of the horse. 
2.4.2. Platelet concentrates 
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 A fine-tuned balance of growth factors and cytokines is critical to successful wound 
healing. As these signaling proteins are responsible for stimulating and directing the dynamic 
cell-cell and cell-ECM interactions that occur during healing, the composition and concentration 
of growth factors and cytokines varies both across the wound bed and temporally during the 
healing process. Since growth factors such as PDGF, VEGF, and EGF, and cytokines such as 
interleukins, IFNs, lymphokines and TNFs are necessary for cutaneous wound healing, their 
therapeutic potential has been studied. Applying individual growth factors or cytokines to 
wounds, however, has not proven to be successful. This is not surprising as the wound bed 
contains a changing array of proteases, enzymes that may immediately destroy specific 
exogenous proteins, that can inhibit the action of these growth, and other, factors. Conversely, 
the application of individual growth factors or cytokines to wounds might flood the wound bed 
with overwhelming signals, which could disable resident cells and prevent them from 
participating in the healing process [14]. The administration of platelet concentrates, also called 
platelet-rich plasma or PRP, has been explored as an alternative to treating wounds with 
individual factors in both human and equine medicine. Platelet concentrates are usually 
generated by centrifuging the patient’s own blood, in order to collect the platelet-rich fraction as 
well as blood cells that secrete an array of growth factors and cytokines. Human platelet 
concentrates of various compositions have been classified and characterized based on leukocyte 
and fibrin content in an attempt to identify features that add therapeutic value [157]. A recent 
review on PRP adjunct therapy in humans described that PRP (i) improved the healing of acute 
wounds, (ii) had mild (or no) positive effects on wounds resulting from laser therapy, and (iii) 
has not been studied in the context of burn wounds extensively enough to draw any conclusions 
for the treatment of this type of wounds [158]. In horses, several studies suggest that PRP has 
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beneficial effects on the healing of surgical as well as burn wounds [159, 160], while it has been 
reported by other studies that topical application of PRP does not accelerate the repair of small 
granulating wounds on the distal limbs of horses [161]. Clearly, more work is needed to 
determine what types of platelet concentrates are the most appropriate for the treatment of which 
types of cutaneous wounds.  
2.4.3. Maggot debridement therapy 
 For centuries, fly larvae have been purposefully used to debride necrotic tissue from 
human cutaneous wounds, but the efficacy and complete benefits of larval therapy have not been 
adequately assessed or optimized [162]. The most commonly used flies belong to the family 
Calliphoridae, with Lucilia sericata, the greenbottle blowfly, being the most widely accepted 
species. Newly emerged, germ-free larvae can be purchased from FDA-approved vendors with a 
prescription for both human and veterinary use [14]. Historically, it has been accepted that 
maggots debride wounds, which prepares the wound bed for healing. More recent evidence 
suggests that larvae may contribute to wound healing in additional ways. In vitro studies have 
shown that maggot secretions can reduce biofilms [163, 164] and digest components of necrotic 
human tissue [165], implying that they may serve to disinfect wounds. A retrospective analysis 
designed to describe and assess the results of maggot debridement therapy in horses concluded 
that, “maggot debridement therapy can be recommended in equids for debridement and enhanced 
healing and its potent antibacterial action” [166]. Similarly, a survey of veterinarians who used 
maggot debridement therapy on horse hoof and leg wounds concluded that maggot therapy can 
serve as a useful treatment [167]. This therapy, especially until fully optimized and proven 
effective, may be rejected by people as it is considered to be aesthetically unappealing by many. 
The horse is a reasonable model in which to refine maggot debridement therapy, to elucidate the 
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mechanisms by which it improves wound healing, and to provide the evidence that it can be a 
safe and effective therapy for both humans and horses.  
2.4.4. Negative pressure therapy 
 In human medicine, negative-pressure wound therapy (NPWT) is used as an adjunct to 
traditional methods for treating a variety of cutaneous wound types. There are several types of 
NPWT systems, but all are similar in that they involve dressing the wound to create a sealed area 
that is then subjected to a vacuum. Drainage tubing is also incorporated to allow for the removal 
of fluids moved to the surface by the vacuum [168]. NPWT promotes second intention healing, 
by reducing the wound size, removing excess fluid, and improving the wound environment in 
ways that are not fully understood, but are thought to contribute by modulating cytokine 
expression in the wound bed towards a profile that favors angiogenesis, ECM remodeling, and 
deposition of granulation tissue [169, 170]. A recent and comprehensive review of NPWT 
concluded that it can be used to manage chronic, complex and infected wounds, but that results 
from randomized control trials are variable [168]. Therefore, additional research focused on 
understanding the mechanisms of action of NPWT is needed in order to fully take advantage of 
this promising adjunctive therapy. Several case studies in horses have also concluded that NPWT 
facilitated second-intention healing and shortened the time to healing [171, 172, 173]. However, 
and in line with human studies, the mechanisms through which NPWT acts in horses have not 
been defined. Clinical trials in horses could shed light on how NPWT alters the wound 
microenvironment, leading to more effective treatments for both humans and horses.  
2.4.5. Engineered skin tissue substitutes 
 Skin substitutes, grown ex vivo, are commercially available for human use. They are used 
when patients do not have adequate skin available for autografting, and to reduce the risks of 
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rejection and disease transmission that are associated with allografted skin. Engineered skin 
substitutes may be used to replace the dermal or epidermal layers and are comprised of various 
combinations of skin cells and ECM molecules. A recent review of human skin substitutes 
determined that these products have revolutionized the management of wounds, but that more 
robust trials are needed to identify optimal skin substitutes for specific types of wounds, as well 
as to determine what features can be added to improve the intrinsic quality of currently available 
substitutes [174]. Equine researchers have developed cell culture systems to support the 
proliferation and differentiation of keratinocytes and to produce skin-equivalents that consist of 
fibroblasts and an epidermal layer of differentiated keratinocytes [116, 112], but engineered skin 
substitutes are not currently used in equine medicine.  
 A major limitation of skin substitutes for both species is that they don’t include, glands, 
blood vessels and nerves. An ideal skin substitute would include a population of stem cells, 
which could divide and, differentiate under the appropriate environmental conditions into the 
various cell types found in skin. As mentioned above, equine iPSC have been differentiated 
successfully into functional neurons [147], suggesting an equine skin substitute could be seeded 
with these cells in order to form complete structures necessary for full skin regeneration. 
 
2.5. Concluding remarks 
 Healthy, uncompromised skin is required for both humans and horses to experience a 
high quality of life. Due to a lack of understanding of the mechanisms that contribute to normal 
and impaired cutaneous wound healing, current therapies are inadequate for both species. This 
poses a large burden to the human and veterinary health care systems not only economically, but 
physically, as a result of the pain and suffering experienced by human and equine patients with 
  76 
non-healing wounds.  The horse is a physiologically relevant large animal species that may serve 
as a model to answer questions about mechanisms involved in wound healing that effect humans 
and equids, and to test therapies for both species. We believe that an increase in basic scientific 
research and clinical studies focusing on skin wound healing in horses will produce data that will 
benefit both human and veterinary health.  
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3.1. Summary 
 The prevalence of impaired cutaneous wound healing is high, and treatment is difficult 
and often ineffective, leading to negative social and economic impacts for our society. 
Innovative treatments to improve cutaneous wound healing by promoting complete tissue 
regeneration are therefore urgently needed. Mesenchymal stromal cells (MSC) have been 
reported to provide paracrine signals that promote wound healing, but (i) how they exert their 
effects on target cells is unclear and (ii) a suitable delivery system to supply these MSC-derived 
secreted factors in a controlled and safe way is unavailable. The present study was designed to 
provide answers to these questions using the horse as a translational model. Specifically, we 
aimed to (i) evaluate the in vitro effects of equine MSC-derived conditioned medium (CM), 
containing all factors secreted by MSC, on equine dermal fibroblasts, a cell type critical for 
successful wound healing, and (ii) explore the potential of microencapsulated equine MSC to 
deliver CM to wounded cells in vitro.  
 Mesenchymal stem cells (MSC) were isolated from the peripheral blood of healthy 
horses. Equine dermal fibroblasts from the NBL-6 line were wounded in vitro, and cell migration 
and expression levels of genes involved in wound healing were evaluated after treatment with 
MSC-CM or NBL6-CM. These assays were then repeated using the CM collected from MSC 
encapsulated in core-shell hydrogel microcapsules. 
 Our salient findings were that equine MSC-derived CM stimulated the migration of 
equine dermal fibroblasts and increased their expression level of genes that positively contribute 
to wound healing. In addition, we found that equine MSC packaged in core-shell hydrogel 
microcapsules had similar effects on equine dermal fibroblast migration and gene expression, 
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indicating that microencapsulation of MSC does not interfere with the release of bioactive 
factors.  
 Our results demonstrate that the use of CM from MSC might be a promising new therapy 
for impaired cutaneous wounds and that encapsulation may be a suitable way to effectively 
deliver CM to wounded cells in vivo. 
3.2. Introduction 
 Cutaneous wound healing is comprised of a network of biological processes, collectively 
restoring the integrity of the skin after injury. Unfortunately, the ideal outcome of cutaneous 
wound healing, which encompasses complete tissue regeneration, is often sacrificed in favor of 
quickly closing a wound with formation of fibrotic scar tissue [1]. Fibrotic scar formation is an 
undesirable result of cutaneous wound healing, not only for cosmetic reasons, but because scar 
tissue has compromised mechanical strength and is more sensitive to pain than healthy skin [2]. 
Treating cutaneous skin wounds and reducing scar tissue causes a financial burden worldwide, 
with annual expenditures on products designed to minimize scarring exceeding $5 billion [3]. 
 In order to understand the processes involved in cutaneous wound healing and/or treat 
fibrotic scar tissue, researchers commonly use laboratory rodents as models. Although relevant 
information has been obtained from studies using rodents, wound healing in these species does 
not accurately mimic human tissue regeneration [4-7]. For example, mice primarily heal by 
contraction due to the presence of the panniculus carnosus in their subcutaneous tissues, whereas 
humans lack this muscle and instead rely on epithelialization to close cutaneous wounds [7]. Due 
to these differences, there is a critical need for an animal wound model that closely mimics the 
natural processes of healing and scar formation in humans. Horses may prove to be an ideal 
species in which to study cutaneous wound healing, since they also depend on epithelial cell 
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activity to heal skin wounds. In addition, horses and humans both suffer from hypergranulation 
formation, a pathological process defined as an excess of granulation tissue beyond the amount 
required to replace the tissue deficit. Hypergranulation tissue is referred to as proud flesh in 
horses and keloid in humans [8]. These common features make the horse an attractive 
translational model in which to study the underlying pathogenesis of excessive cutaneous wound 
healing as well as to evaluate the potential of novel treatments. 
 Mesenchymal stromal cells (MSCs) are multipotent stromal progenitor cells with 
regenerative properties that are present in a variety of tissues and organs [9]. MSC actively 
contribute to regenerative processes, as they are involved in the inflammatory [10], proliferative 
[11] and remodeling [12] phases of tissue regeneration. Although MSC were originally reported 
to contribute to tissue repair by trans-differentiating into the specific cell types needed to restore 
injured tissue, recent data indicate paracrine signaling as the primary mechanism for the 
regenerative effects of MSC [13,14]. Indeed, we recently identified angiogenic stimulating 
factors in the conditioned medium (CM) of equine MSC and showed that these factors could 
induce proliferation and vessel formation of equine endothelial cells in vitro [15]. Practically, 
this implies that the CM obtained from MSC cultures, which contains all factors secreted by 
MSC, may be used as a “stem cell-free” therapy in regenerative medicine. This type of therapy 
offers several advantages over cellular MSC cell remedies, including the absence of inherent 
toxicity, no risk for tumor formation of engrafted cells, and no concerns about allograft-
associated immune rejection [16,17]. Previous reports have demonstrated that CM obtained from 
human MSC cultures can improve cutaneous wound healing, although the underlying 
mechanisms remain unclear [18,19]. The potential of CM obtained from equine MSC cultures to 
contribute to wound healing has not been studied to date but is essential in order to take 
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advantage of the horse as a physiologically relevant translational model in which to study 
cutaneous wound healing. 
 An important aspect to take into consideration when proposing the use of MSC-derived 
CM in regenerative medicine is the development of a suitable delivery system for these secreted 
products. Indeed, optimal spatial distribution and continuous release of factors at the site of 
injury are two key components of MSC treatment that may significantly improve clinical 
outcome. Cell microencapsulation, which involves immobilization of the cells within a 
polymeric semi-permeable membrane, provides a supportive microenvironment for the cells in 
which they can proliferate and release bioactive factors while being shielded from the external 
environment [20,21]. These microcapsules can be injected at the transplantation bed localizing 
the release of therapeutic factors in a controlled way. A recent study by Xu et al. describes the 
potential use of human MSC encapsulated in biomaterials for the treatment of cutaneous wounds 
and their initial findings were that cells ‘packaged’ in a gelatin/poly(ethylene glycol) biomatrix 
mediated the early resolution of inflammatory events and facilitated the proliferative phases in 
wound healing [22]. To the best of our knowledge, however, the use of microencapsulated 
equine MSC in equine regenerative medicine has not been explored to date. 
 Therefore, the aims of the present study were (i) to evaluate the in vitro effects of equine 
MSC-derived CM on equine dermal fibroblasts, a cell type critical for successful wound healing, 
and (ii) to explore the potential of microencapsulated equine MSC to deliver the critical 
components of CM to wounded cells in vitro. Our salient findings were that equine MSC-derived 
CM stimulated the migration of equine dermal fibroblasts and increased the expression levels of 
genes that positively contribute to wound healing in these cells. In addition, we found that equine 
MSC packaged in core-shell hydrogel microcapsules have similar effects on equine dermal 
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fibroblast migration and gene expression, suggesting MSC encapsulation may be a suitable way 
to effectively deliver products secreted by MSC to wounded cells in vivo. 
3.3. Methods 
Cells 
 Equine mesenchymal stromal cells (MSC) were isolated from the peripheral blood of 3 
healthy warmblood mares between 8 and 12 years old, exactly as described previously [15,23]. 
The blood collection was approved by the Cornell Institutional Animal Care and Use Committee 
(IACUC # 2014–0038). Briefly, blood was collected from the v. jugularis of healthy donor 
horses, peripheral blood mononuclear cells (PBMC) were isolated using density gradient 
centrifugation on 1.080 g/mL Percoll (GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
and subsequently seeded at a density of 16 × 104cells/cm2 in a T75 flask in culture medium, 
consisting of low glucose (LG) Dulbecco’s modified Eagle medium (DMEM) (Invitrogen), 
supplemented with 30% fetal bovine serum (FBS) (Atlanta Biological, Flowery Branch, GA), 
10−7 M low dexamethasone (Sigma Aldrich, St. Louis, MO), 50 μg /mL gentamycin, 1x 
penicillin-streptomycin, and 2 mM L-glutamine (all from Life Technologies, Grand Island, NY). 
Cultures were maintained at 37°C with 5% CO2. At 70% confluency, cells were removed from 
flasks using 0.25% trypsin–EDTA and further cultured in expansion medium, which is identical 
to the culture medium but without dexamethasone. Equine MSC were characterized by 
immunophenotypical protein profiling using flow cytometry and their potential for trilineage 
differentiation, exactly as described previously [15]. In essence, equine MSC were confirmed to 
be positive for CD29, CD44, CD90 and CD105, and negative for CD45, CD79α, MHC II and a 
monocyte/macrophage marker. The successful trilineage differentiation of MSC toward 
osteoblasts, chondroblasts and adipocytes was confirmed using a range of histochemical stains. 
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 The equine dermal fibroblast cell line NBL6 (ATCC, Manassas, VA) was cultured in 
standard medium, consisting of minimal essential medium (MEM, Corning) supplemented with 
10% FBS (Atlanta Biochemicals) and 1% penicillin/streptomycin (Invitrogen). Cells were 
maintained at 37°C with 5% CO2. 
Generation of conditioned media and pre-treatments 
 Conditioned medium (CM) was collected from MSC after 2 days of culture, when cells 
were 70% confluent. To this end, 6 × 105 MSC were seeded in a T75 flask in 8 ml expansion 
medium. After 48 hours (h), medium was collected, centrifuged twice for 7 minutes at 300 × g to 
remove any cellular debris, and used for further experiments. CM from NBL-6 cells was used as 
a control and was collected after 2 days of culture, exactly as described for MSC-derived CM. 
For pre-treatment experiments, MSC were seeded in expansion medium supplemented with 10 
ng/ml tumor necrosis factor alpha (TNFα; R&D, Minneapolis, MN), 20 ng/ml interferon gamma 
(IFNγ; R&D) or 150 μM cobalt chloride (CoCl2, Sigma). After 24 h of culture, cells were 
washed twice with phosphate buffered saline (PBS) and fed with 8 ml fresh expansion medium. 
CM was collected 24 h later, as described above. 
Microencapsulated MSC 
 For experiments using encapsulated MSC, 6 × 105 MSC were seeded per T75 flask in 8 
mL expansion medium, and in parallel the same number of cells were encapsulated in double 
layer microparticles using a multi-fluidic electrostatic cell micropackaging technique [24]. 
Briefly, type I collagen neutralized by 1 N sodium hydroxide was mixed with MSC in expansion 
medium for a final concentration of 0.45 mg/mL. Cells supported by collagen were encapsulated 
in 0.9% (w/v) alginate hydrogel (FMC Biopolymers, Philadelpha, PA) at a concentration of 
about 37 cells per capsule. Microencapsulated MSC were incubated in a crosslinking bath with 
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100 mM calcium chloride and 5 mM barium chloride under electrical field strength of 7 kV. 
Microencapsulated MSC were resuspended in 8 mL expansion medium and maintained at 37°C 
with 5% CO2. Empty core-shell hydrogel microcapsules, containing no cells, were included as 
negative control. After 48 h, supernatants were collected, centrifuged twice for 7 minutes at 300 
× g to remove cellular debris, and used as CM in experiments. 
In vitro scratch assays 
 NBL-6 cells were seeded in 6-well plates at a density of 6 × 104 cells/cm2. Upon 90% 
confluency (~ after 24 h), cells were washed twice with PBS and serum-starved overnight. A 
linear defect was then inflicted on the monolayer using a 200 μl pipette tip. Culture medium was 
immediately removed (along with any dislodged cells) and replaced with freshly collected CM, 
diluted 1:1 in expansion medium. Similar scratch assays were repeated in the presence of 2 
μg/mL mitomycin C, which was added at the time of scratch infliction. Reference marks were 
made across the bottoms of the wells with an ultrafine marker. Images of scratches were captured 
using a Nikon Diaphot-TMD inverted light microscope with an attached Cohu CCD camera 
(Nikon, Melville, NY) leaving the reference marks outside the capture image field but within the 
eye-piece field of view for repeatable orientation of scratches. Photographs of scratches were 
taken at 0, 24 and 48 h post scratching, and migration distances of cells were calculated in a 
blinded-manner using ImageJ [25]. Widths of scratches were taken in two places in each of 3 
wells scratched per treatment, for a total of 6 measurements per treatment. Scratch width was 
subtracted from the time 0 scratch widths at the same location to determine cell migration 
distance. Migration distances within treatments were then averaged to determine overall 
migration. 
Electric cell-substrate impedance sensing 
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 Cell migration was measured by Electric Cell-substrate Impedance Sensing (ECIS) using 
the ECIS Model Z instrument with 96 W array station (ECIS, Applied BioPhysics Inc., Troy, 
NY). Dermal fibroblasts were seeded at a density of 2 X 105 cells per well in a 96W1E+ PET 
array chip (Applied BioPhysics Inc.) in standard medium. After 24 hours, medium was removed 
and replaced with serum-free medium for at least 8 hours prior to wounding. A uniform circular 
defect was created in the cell monolayer by lethal electroporation (1200 μA, 40 kHz) for 40 
seconds by 350 μm diameter circular electrodes located in each well of the array chip. The defect 
created in the fibroblast monolayer will be referred to as wound throughout the paper, as 
originally described by Keese et al. [26]. Dead cells were detached from the electrode by gently 
pipetting medium up and down three times before removal. Control CM or MSC-derived CM 
was then added to appropriate wells, and an alternating current (~1 μA, 32 kHz) was applied to 
the electrodes to measure impedance (Ohms) and monitor wound closure in real-time. As cells 
migrate to repair the circular wound, they physically re-cover the electrode causing an increase 
in impedance. The time required for re-covering the electrode was determined as the number of 
hours it took for the impedance levels in wells with the 350 μm circular wound to return to the 
same values as the impedance levels in control wells in which cells were not wounded. Cell 
migration was also documented by phase contrast images captured using an Olympus CCX41 
inverted microscope equipped with an Olympus LC20 digital camera. 
Gene expression analyses 
 NBL-6 cells were cultured in 15 × 100 mm culture dishes until confluent. Cells were 
serum-starved overnight, and scratches were made. After two washes with PBS, 1:1 diluted CM 
derived from MSC (un-stimulated, stimulated or encapsulated), or control NBL-6 was added to 
each NBL-6 culture. After 24 h, CM was removed, monolayers were rinsed with PBS and cells 
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were further cultured for another 24 h. Subsequently, mRNA was extracted from the cells using 
an RNEasy Plus Kit, according to manufacturer’s instructions (QIAGEN, Valencia CA), 
followed by a DNase digestion using DNase I (Invitrogen). cDNA was synthesized using M-
MLV Reverse Transcriptase (USB, Cleveland, OH), according to the manufacturer’s protocol. 
SYBER green-based quantitative polymerase chain reaction (qPCR) assays were carried out on 
an Applied Biosytems 7500 Fast Real Time PCR instrument (Applied Biosystems, Carlsbad, 
CA) to determine fold changes of genes of interest in NBL6 cells incubated with CM of MSC 
compared to NBL6 incubated with control CM. The comparative Ct method (2−ΔΔCt) was used to 
quantify gene expression levels where ΔΔCt = ΔCt(sample) – ΔCt(reference). The previously 
validated reference gene SDHA was used to normalize samples [27]. Primers to amplify CCL2, 
CxCL10, IL8, MMP1, MMP2, TMP1, PLAU, PLAT, PAI1, CTSK, ANXA2, COLIII, COL1, 
SDC2, SDC4 and fibronectin were designed using Primer3 software, based on horse sequences 
found in the National Center of Biotechnology Information (NCBI) GenBank, and primer 
sequences are listed in Table 1. All samples were run in triplicate. 
Table 3.1. Overview of primers used for semi-quantitative RT-PCR 
Gene Abbreviation Forward primer (5′-3′) Reverse primer (5′-3′) 
Succinate dehydrogenase 
complex, subunit A 
SDHA TCCATCGCATAAGAGCAAAG GGTGGAACTGAACGAACTCC 
Plasminogen activator urokinase PLAU TGTGAGATCACTGGCTTTGG TGACATTCCTGGTGGGAAAC 
Annexin A2 ANXA2 GCAGTGTCTGTCACCTCCAG CCTCCTTCTTGATGCTCTCC 
Cathepsin K CTSK TCCAGAAGGGAAACAAGCAC TCTTATTCCGAGCCATGAGG 
CC chemokine 2 CCL2 GGCTCAGCCAGATGCAATTA GCTTTCTTGTCCAGCTGCTT 
Metallopeptidase 2 MMP2 GAAGGCTGTGTTCTTTGCAG TCCAGTTAAAGGCAGCATCC 
Syndecan 4 SDC4 GCAGCATCTTTGAGAGGACAG GTTTCTTGCCCAGGTCGTAG 
Metallopeptidase 1 MMP1 GCCAAATGGACTTCAAGCTG TAGGAAAGCCGAAGGATCTG 
Tissue plasminogen activator PLAT AGTTCTTGCTGGCTCCTGTC ATCGGTATGTTCTGCCCAAG 
Interleukin 8 IL8 AGACGCACTCCAAACCTTTC CAGACCTCAGCTCCGTTGAC 
Metallopeptidase inhibitor 1 TIMP1 GCTCCCTGGAACAGTCTGAG CGTCCACAAGCAATCAGTGTC 
Plasminogen activator inhibitor-1 PAI1 CCCTGGAGAGTGAAGTGGAC CCTGCGATACATGGAGAAGC 
Collagen type 1A1 COL1 AAGGACAAGAGGCACGTCTG GCAGGAAAGTCAGCTGGATG 
Collagen type 3 COLIII GGGTATAGCTGGTCCTCGTG GCGCCTCTTTCTCCTTTAGC 
Fibronectin Fibronectin AGGTCGTTACTGTGGGCAAC TAATGGGAGACGGTGTAGGG 
Syndecan 2 SDC2 GACTCAGAAAGGAACGTGGAC ATAACTCCGCCAGCAATGAC 
CXC chemokine 10 CxCL10 GACTCTGAGTGGAACTCAAGGAAT GTGGCAATGATCTCAACACG 
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Cell viability assays 
 To ensure mitomycin C was not toxic to NBL-6 fibroblasts, cells were seeded at 10,000 
per well in 96 well microplates. At 90% confluency, mitomycin C was added to triplicate wells 
at 0, 2, 20, 200 and 2000 ng/mL. After 48 h of culture, an MTT in vitro toxicology assay (Sigma 
Aldrich, Saint Louis, MO) was carried out according to manufacturer’s instructions and 
absorbance was measured at 570 nm on a Multiskan EX plate reader (Thermo Fisher Scientific, 
Waltham MA). Optical densities of wells treated with mitomycin C were compared to those of 
untreated wells to determine cell viability. 
 To test the viability of microencapsulated MSC, capsules were dissolved on days 2, 7, 12, 
17, and 22 post encapsulation using a solution of 1% EDTA. The released MSC were washed 
with culture medium, incubated for 3 minutes with trypsin-EDTA to create a single cell 
suspension, washed with culture medium, and percentage of living cells was determined using 
the trypan blue exclusion (TBE) assay. 
Population Doubling Time (PDT) calculations 
 For determination of PDT, 2 × 105 released MSC were plated in a T25 tissue culture flask 
and cultured in expansion medium. The PDT was calculated using the following link: [28]. PDTs 
of microencapsulated MSC were compared to PDTs of non-encapsulated MSC from the same 
horse at the same passages. 
Characterization of MSC post encapsulation 
 MSC removed from capsules 2 days post encapsulation were plated in T75 tissue culture 
flasks containing expansion medium until monolayer was 90% confluent. At that time, cells were 
collected for flow cytometric analyses and seeded for differentiation assays as described 
previously [15]. 
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Proliferation assays 
 The effect of mitomycin C on the proliferation of NBL-6 was evaluated using a 
bromodeoxyuridine (BrdU) proliferation assay kit (Abcam, Cambridge, MA). To this end, NBL-
6 were seeded on a 96-well plate at a density of 5 × 104 cells/well and incubated with mitomycin 
C for 48 h. Regular medium was used to establish baseline proliferation. The BrdU proliferation 
assay kit was used following manufacturer’s instructions and the resulting absorbance was read 
at 450 nm on a Multiskan EX microplate reader using Ascent software (Thermo Scientific, 
Waltham, MA). Empty wells and wells without BrdU were included as controls. 
Statistical analyses 
 Student’s t-test for paired data was used to test for statistically significant differences in 
cell migration (scratch assays and ECIS), mRNA expression (RT-qPCR), cell viability (TBE and 
MTT) and BrdU incorporation (ELISA) between untreated and CM-stimulated NBL6. Data 
given are the mean of 3 replicates and the bars show standard deviations. 
 To compare data from different individuals, statistical analysis was done by means of the 
nonparametric Kruskal-Wallis and Dunn’s multiple comparison test (α = 0.05), and significant 
differences were considered at p < 0.01. 
3.4. Results 
Conditioned medium (CM) from mesenchymal stromal cells (MSC) stimulates migration of 
dermal fibroblasts in scratch assays 
 Since dermal fibroblasts are critically involved in wound healing [29] we decided to 
study the effects of MSC-derived CM on the migration of these cells using in vitro scratch assays 
[30]. We found that equine dermal fibroblast cells (NBL-6) migrated significantly faster when 
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cultured in CM obtained from equine MSC compared to control CM, which was collected from 
NBL-6 (Figure 3.1A). 
 Given the high incidence of hypergranulation formation in equine and human wounds 
[8], it was important to explore whether this increased rate of wound closure was due to 
enhanced migration and/or increased proliferation of the fibroblasts. Therefore, we repeated the 
scratch assays in the presence of mitomycin, an inhibitor of proliferation. No differences in 
migration of NBL-6 cells cultured in MSC-derived CM in the presence or absence of mitomycin 
were found, indicating that the observed effect in the scratch assays was not due to an increased 
proliferation of the cells (Figure 3.1B). To control that the mitomycin concentration used for 
these experiments (ie. 2000 ng/ml) was effective in inhibiting proliferation without affecting cell 
viability, we performed a BrdU ELISA as well as an MMT assay, respectively (Figure 3.1C). 
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Figure 3.1. Mesenchymal stromal cell (MSC) conditioned medium (CM) promotes 
migration of dermal fibroblasts in scratch assays (n = 3). A. Representative phase contrast 
images of wounded NBL-6 cells cultured with MSC-derived CM (lower panels) as compared to 
control CM (upper panels) over a 48-hour period, and migration distances of NBL-6 cells are 
expressed as μm/hr in 48 hrs. **: P < 0.01 B. Migration of NBL-6 cells cultured with MSC-
derived CM as compared to CM from mitomycin C-treated MSC (2000 ng/ml). C. Viability 
(dashed line) and proliferation (solid line) of NBL-6 cells cultured in the presence of various 
concentrations of mitomycin C. 
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 To corroborate our findings on the increased migration of fibroblasts when exposed to 
MSC-derived CM, Electric Cell-substrate Impedance Sensing (ECIS) experiments were used to 
measure in vitro wound closure rates [31]. Again, we found that equine dermal fibroblasts 
migrated significantly faster when cultured in CM obtained from equine MSC compared to 
control CM with a wound closure of 11.8 ± 0.35 h versus to 15.3 ± 0.96 h, respectively (Figure 
3.2A & B). Because the ECIS system creates only a very small wound (350 μm) that normally 
heals in 12–18 hours, cell migration rather than proliferation is the major contributor to closure 
under these conditions (Figure 3.2C). Interestingly, the ending impedance value shown in Figure 
3.2A of the MSC CM treated fibroblasts was higher than the control, indicating that addition of 
the MSC CM may increase either cell-cell or cell-matrix contacts on the healed fibroblast 
monolayer leading to a higher final impedance. 
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Figure 3.2. Mesenchymal stromal cell (MSC) conditioned medium (CM) promotes wound 
closure using electric cell-substrate impedance sensing (ECIS) (n = 3). A. Wound healing 
rates of NBL-6 cells cultured with MSC-derived CM or control CM, as determined by electrical 
impedance in Ohms detected from 0–24 hrs post wounding and B. total wound closure time 
expressed in hrs. **: P < 0.01.  C. Phase contrast images of wounded NBL-6 cells cultured with 
MSC-derived CM (upper panels) as compared to control CM (lower panels) over a 24-hour 
period. Scale bars = 100 μm. 
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The CM of MSC induces alterations in the expression of genes involved in wound healing 
 Semi-quantitative RT-PCR analyses were performed to investigate the relative mRNA 
expression levels of selected inflammatory cytokines, remodeling enzymes, extracellular matrix 
components and adhesion molecules, all associated with wound repair, in NBL-6 cultured with 
MSC-derived CM as opposed to control CM. Figure 3.3A shows the experimental set-up for 
these studies and it was observed that culturing dermal fibroblasts in the CM of MSC 
differentially regulated mRNA expression of several genes involved in wound healing when 
compared to gene expression in dermal fibroblasts cultured in control CM (Figure 3.3B). A 
significant upregulation of the proinflammatory mediator interleukin 8 (IL8) (p < 0.05) and a 
significant downregulation of the chemokine C-X-C motif chemokine 10 (CxCL10) (p < 0.01) 
was observed in dermal fibroblasts cultured in the presence of MSC-derived CM (Figure 3.3B). 
Gene expression levels of extracellular matrix components and adhesion molecules were not 
significantly different, with the exception of Collagenase 3 (COLIII) which was significantly 
lower in dermal fibroblasts cultured in the presence of MSC-derived CM compared to control 
CM (p < 0.05) (Figure 3.3B). Finally, the expression of a variety of remodeling enzymes was 
upregulated when dermal fibroblasts were cultured in CM, with matrix metalloprotease protein 1 
(MMP1) showing a significant higher expression in dermal fibroblasts cultured in the presence 
of MSC-derived CM compared to control CM (p < 0.01) (Figure 3.3B). 
The CM of MSC stimulated with TNFα, IFNγ, or COCl2 further alters gene expression in dermal 
fibroblast cells, but does not result in an increased migration capacity 
 Since it has been reported previously that pre-stimulation of human MSC increased their 
wound healing properties [32-35], we stimulated our equine MSC with TNFα, IFNγ and COCl2 
to evaluate the effects on (i) expression of wound healing-related genes in NBL-6 cells and (ii) in 
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vitro scratch assays. It was observed that stimulation of MSC with TNFα led to a significant 
increase in MMP1 (p < 0.01) and IL8 (p < 0.05) mRNA expression in NBL-6 cells, whereas 
stimulation with IFNγ led to a significant increase in CxCL10 expression (p < 0.05), compared to 
culturing NBL-6 cells with CM of non-stimulated MSC (Figure 3.3C). In contrast, none of the 
stimulating agents influenced the expression of COLIII and stimulation of MSC with CoCl2 had 
no effect on the expression of any of the evaluated genes (Figure 3.3C). When evaluating these 
pre-stimulation treatments in scratch assays, no differences in migration rates were observed 
between fibroblasts exposed to the stimulated MSC-derived CM versus the non-stimulated MSC-
derived CM (Additional file 1: Figure S3.1A&B). 
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Figure 3.3. Mesenchymal stromal cell (MSC) conditioned medium (CM) alters gene 
expression levels in dermal fibroblasts (n = 3). A. Schematic illustration of NBL-6 treatments 
for RNA isolation. B. Fold-change of mRNA levels, as detected by qRT-PCR, in NBL-6 cells 
cultured with MSC-derived CM as compared to control CM C. or NBL-6 cells cultured with CM 
from preconditioned MSC as compared to CM from non-preconditioned MSC. Left panel shows 
genes involved in reduction of hypergranulation and/or enhancement of wound healing and right 
panel shows genes that stimulate hypergranulation and/or delay wound healing. *: P < 0.05; **: 
P < 0.01. 
 
The effects of MSC-derived CM on the expression of wound healing-related genes are donor 
dependent in our study 
 When studying the changes in gene expression in more detail, it became clear that 
potential significant differences in gene expression levels could be masked due to the rather large 
standard deviations (STDEV) we observed for several tested genes. Since we used the CM of 
MSC from three different individual horses for our experiments, we reasoned that these large 
STDEV could possibly be caused by natural inter-horse variations. Therefore, we decided to 
present the results of the gene expression alterations per individual donor horse instead of using 
the average (Additional file 2: Figure S3.2A). By presenting the data this way, several 
observations were made. Firstly, using the non-parametric Kruskal-Wallis test to compare the 
gene expression data between horses, statistically significant differences between individuals 
became apparent in the mRNA expression levels of certain genes (Table 3.2). At a p value of < 
0.01, there were statistically significant differences for two hypergranulation reducers and/or 
wound healing enhancers, namely cathepsin K (CTSK) and matrix metalloproteinase-2 (MMP2) 
(Table 2A). Likewise, statistically significant differences (p < 0.01) between horses were found 
for four hypergranulation enhancers and/or wound healing reducers, namely plasminogen 
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activator inhibitor 1 (PAI1), collagenase type III (COLIII), fibronectin and syndecan 2 (SDC2) 
(Table 2B). Secondly, using the Dunn’s post-hoc test it was observed that culturing NBL-6 cells 
in the MSC-derived CM of Horse B resulted in a significant mean rank difference of ≥ 6 for the 
genes CTSK, MMP2, PAI1 and COLIII, when compared to NBL-6 cells that were cultured in the 
CM of either Horse A- or Horse C-derived MSC (Additional file 2: Figure S3.2B). Overall, the 
increased expression levels of CTSK and MMP2, genes advantageous for wound healing, with a 
simultaneously decreased expression level of PAI1, a gene disadvantageous for wound healing, 
would make Horse B a better donor for providing MSC with the capacity to promote wound 
healing than either Horse A or C. Comparing the effects of Horse B MSC-derived MSC on 
migration of fibroblasts, using scratch assays, with the other two horse MSC samples, revealed 
no statistically significant differences and all three MSC samples could equally increase NBL-6 
migration (p < 0.01, Additional file 2: Figure S3.2C). Taken together, these data indicate that the 
expression level pattern in CM-treated dermal fibroblast cells is donor horse MSC-specific in our 
study. 
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Table 3.2. Statistical analyses of gene expression data from individual horses 
A. Hypergranulation reducers and/or wound healing enhancers: 
Gene Significant difference  
Horse A versus Horse B Horse B versus Horse C Horse A versus Horse C 
PLAU - - - 
ANXA2 - Yes* - 
CTSK - Yes** - 
CCL2 - Yes* - 
MMP2 - Yes** - 
SDC4 - - - 
MMP1 - - - 
PLAT - - - 
IL8 - - Yes* 
B. Hypergranulation enhancers and/or wound healing reducers: 
Gene Significant difference  
Horse A versus Horse B Horse B versus Horse C Horse A versus Horse C 
TIMP1 - Yes* - 
PAI1 - Yes** - 
COLI - - - 
COLIII - Yes** - 
Fibronectin Yes** - - 
SDC2 - - Yes** 
*: p < 0.05; **: p < 0.01. 
 
 
Encapsulated MSC retain stem cell characteristics and remain viable during long-term 
encapsulation 
 After clearly demonstrating that the CM of equine MSC promotes wound healing, we 
were interested in exploring the potential of microencapsulating MSC as a way to deliver the 
critical components of CM to wounded cells in vitro in a controlled manner. 
 In a first set of experiments, we encapsulated equine MSC and 2 days later, removed 
these MSC from their capsules to evaluate whether they retained their stem cell characteristics. 
Overall, the immunophenotypical profile, as detected by flow cytometric analysis using a 
commonly used set of cell surface markers [36], did not differ between MSC removed from 
capsules and MSC that were never encapsulated (Figure 3.4A). There was a significant 
difference (p < 0.05) in the expression of MHC I, but this marker is known to be highly variably 
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expressed by MSC [37]. In addition, MSC removed from capsules retained the capacity to 
differentiate into osteocyte, chondrocyte and adipocyte lineages (Figure 3.4B). Moreover, the 
population-doubling time (PDT) of MSC removed from capsules was virtually identical to MSC 
from the same source, but never encapsulated, from passage 13 up till passage 17 (end of 
experiment) (Figure 3.4C). 
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Figure 3.4. Mesenchymal stromal cells (MSC) retain stem cell characteristics after 
microencapsulation (n = 3). A. Expression of surface markers, as detected by flow cytometry, 
on MSC removed from capsules after 2 days post encapsulation as compared to control MSC 
that were never encapsulated. Percentage of total cells positive are shown left and representative 
histograms are shown right. *: P < 0.05. B. Representative images of MSC stained with alizarin 
red, alcian blue and oil red O to detect osteocyte, chondrocyte and adipocyte differentiation, 
respectively. Left column: undifferentiated MSC cultured in expansion medium; center column: 
control MSC that were never encapsulated cultured in MSC differentiation media; and right 
column: MSC removed from capsules after 2 days post encapsulation cultured in MSC 
differentiation media. Scale bars = 10 μm. C. Population doubling times (PDTs) of MSC 
removed from capsules after 2 days post encapsulation as compared to control MSC that were 
never encapsulated. 
  In a second set of experiments, we cultured MSC in capsules for over three weeks in 
order to test the potential of long-term encapsulation. MSC encapsulated for 2 days were used as 
the short-term encapsulation control time point (day 2) and compared to MSC encapsulated for 
successive 5-day intervals (day 7, 12, 17 and 22). At all these different time points, equine MSC 
were removed from equal numbers of capsules and subsequently plated in culture wells (Figure 
3.5A). Before plating, viability was determined using trypan blue exclusion and the number of 
live cells was determined. Over the course of the experiment, the viability of long-term 
encapsulated cells decreased slightly compared to short-term encapsulation but did not fall below 
80% and this slight decrease was not statistically significant (Figure 3.5B). In addition, the 
number of viable cells present in the capsules for 7 days was significantly increased compared to 
2-day encapsulation, indicating that equine MSC did divide in the capsules, but remained 
constant thereafter (Figure 3.5C). After plating, and upon confluency of the cells, PDTs were 
calculated. Cells encapsulated for 7 days showed a similar PDT to that of the short-term, 2-day, 
encapsulated MSC. In contrast, cells encapsulated for more than 7 days showed a significantly 
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higher PDT, indicating that it took those cells much longer to form a confluent monolayer 
(Figure 3.5D). For the duration of this set of experiments, pictures from confluent monolayers 
were taken daily to confirm that the stem cell morphology was maintained, indicating that the 
change in PDT was not due to differentiation of the MSC which could result in an altered growth 
pattern (Figure 3.5E). 
 
  127 
Figure 3.5. Mesenchymal stromal cells (MSC) remain viable after long-term 
microencapsulation (n = 3). A. Representative images of MSC encapsulated (left), immediately 
after removal of capsules (center), and after several days of culture (right) Scale bars = 50 μm. B. 
Viability, as determined by trypan blue exclusion, of MSC removed from capsules at 5-day 
intervals starting at 2 days post encapsulation. C. Numbers of viable cells removed from equal 
numbers of capsules at 5-day intervals starting at 2 days post encapsulation. **: P < 0.01. D. 
Population doubling times of MSC removed from capsules at 5-day intervals starting at 2 days 
post encapsulation. **: P < 0.01. E. Representative phase contrast images of cultured MSC 
removed from capsules 22 days post encapsulation as compared to control MSC that were never 
encapsulated. Scale bars = 50 μm. 
 
Encapsulated MSC-derived CM stimulates migration of dermal fibroblasts and induces 
alterations in the expression of genes involved in wound healing 
 After showing that microencapsulated MSC remain viable and retain general stem cell 
characteristics, we evaluated the CM from encapsulated MSC in order to determine potential 
positive effects on dermal fibroblast migration and expression of genes involved in wound 
healing. To this end, we repeated the scratch assays and gene expression analyses, as previously 
described, using CM from non-encapsulated MSC (control) and from MSC that were 
encapsulated and cultured for 2 days. 
 Using scratch assays, we found that NBL-6 cells had an equally fast migration when 
cultured in CM obtained from equine MSC compared to CM obtained from encapsulated equine 
MSC (Figure 3.6A). CM that was collected from 2-day cultured empty capsules was also 
included as a control and showed a significant slower migration compared to either MSC-derived 
CM (data not shown). Next, semi-quantitative RT-PCR analyses were performed on NBL-6 cells 
cultured in CM obtained from non-encapsulated MSC (control, set as 1) and compared to gene 
expression in NBL-6 exposed to CM obtained from encapsulated MSC. Specifically, the relative 
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mRNA expression levels of a selected set of genes (ie. IL8, MMP1, ColIII and CxCL10) 
involved in wound healing were determined. A significant up-regulation of IL8 and MMP1 gene 
expression was observed in NBL-6 cells cultured in CM obtained from encapsulated equine 
MSC as compared to NBL-6 cells which were cultured in CM of non-encapsulated MSC (Figure 
3.6B). In contrast, the gene expression levels of COLIII and CxCL10 were indistinguishable 
between NBL-6 cells cultured in either CM from encapsulated MSC or non-encapsulated MSC 
(Figure 3.6B). 
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Figure 3.6. Conditioned medium (CM) from microencapsulated mesenchymal stromal cells 
(MSC) promotes NBL-6 migration and alters gene expression (n = 3). A. Migration distances 
of NBL-6 cells cultured in CM from encapsulated MSC as compared to MSC CM in in vitro 
scratch assays. Data are expressed as μm/hr in 48 hrs. B. Fold-change of mRNA, as detected by 
qRT-PCR, in NBL-6 cells cultured with encapsulated MSC CM as compared to control MSC 
CM. Left panel shows genes involved in reduction of hypergranulation and/or enhancement of 
wound healing and right panel shows genes that stimulate hypergranulation and/or delay wound 
healing. *: P < 0.05. 
3.5. Discussion 
 The present study is the first to evaluate the effects of conditioned medium (CM) from 
equine mesenchymal stem cells (MSC) on wound-healing properties of equine dermal 
fibroblasts, and to explore the potential of encapsulated equine MSC to deliver these critical 
components to equine target cells. Our salient findings were that the CM of equine MSC 
stimulates the migration of equine dermal fibroblasts in vitro and increases the expression levels 
of genes that positively contribute to wound healing. Importantly, similar results were obtained 
using CM from MSC that were encapsulated in core-shell hydrogel microcapsules, indicating the 
potential of microencapsulated MSC to deliver the bioactive factors present in CM. 
 During our studies on the expression levels of genes involved in wound healing when 
equine fibroblasts were exposed to MSC-derived CM, two interesting observations were made. 
First, we found a highly significant, 4-fold, increase in the mRNA expression of the matrix 
metalloproteinase 1 (MMP1). MMP1, also designated interstitial collagenase or fibroblast 
collagenase, is a critical remodeling enzyme required for re-epithelialization during wound 
healing [38,39]. In vitro studies have shown that CM from amnion-derived human MSC alters 
the expression of MMP1 in human dermal fibroblasts [35], which is similar to our present 
findings with CM from peripheral blood (PB)-derived equine MSC and equine dermal 
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fibroblasts. Interestingly, the CM collected from MSC that were microencapsulated even further 
altered the expression of MMP1 as evidenced by a significantly higher MMP1 expression in 
dermal fibroblasts when exposed to the CM from microencapsulated MSC compared to CM 
from non-encapsulated MSC (Figure 6B). A similar observation was made for IL8 expression in 
dermal fibroblasts (Figure 6B), another critical component in cutaneous wound healing known to 
stimulate migration and proliferation of keratinocytes [40]. Although speculative at this point, we 
hypothesize that the close contact between the MSC in these capsules and/or the capsule 
microenvironment changes the secretion pattern of MSC, or alternatively, that the MSC 
secretome is influenced by adherent (non-encapsulated) versus non-adherent (encapsulated) 
culture conditions. An increased expression level of MMP1 and IL8 in dermal fibroblasts was 
also observed when equine MSC were preconditioned using tumor necrosis factor alpha (TNFα). 
TNFα has been described to stimulate human MSC to secrete elevated levels of IL-6 and IL8, 
resulting in accelerated wound healing [32], and our study indicates that IL8 is also upregulated 
in the target cells exposed to this preconditioned MSC-derived secrete. For the two other agents 
that we used to precondition equine MSC in our present study, however, we did not observe an 
upregulation of IL8 nor MMP1 in dermal fibroblasts when exposed to CM from these stimulated 
MSC. The first agent, CoCl2, is a chemical known to mimic hypoxia and our results in our 
equine model reflect results from a previous study in which no significant alterations were found 
in the expression levels of MMP1 in human dermal fibroblasts incubated with CM from hypoxic 
human MSC when compared to CM from normoxic human MSC [35]. In addition, no significant 
alterations were found in any of the other genes that were tested, ie. IL8, COLIII and CxCL10, 
when equine fibroblasts were exposed to the CM of CoCl2-treated equine MSC. The second 
agent we used to stimulate equine MSC was interferon gamma (IFNγ), a cytokine known to 
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stimulate MSC to increase wound healing in aged mice [33] but for which the specific effects on 
the expression of wound related factors in target cells, like dermal fibroblasts, have not 
previously been investigated. We found in our present study that equine dermal fibroblasts 
showed a significant increase in CxCL10 expression when incubated with CM of IFNγ pre-
conditioned MSC. CxCL10 is a chemokine known to delay wound healing and to disorganize 
neovascularization [41], and although more in-depth studies are needed, we would like to argue 
that pretreating MSC with IFNγ might not be beneficial as a regenerative treatment to promote 
cutaneous wound healing. 
 Secondly, we observed that the expression level pattern in CM-treated dermal fibroblast 
cells was donor horse MSC-specific. Although our current study is too limited in experimental 
numbers and is lacking repeated isolations from the same donor horse to draw definite 
conclusion about donor dependency, our data are the first to indicate a donor-specific effect of 
MSC-derived CM on skin target cells specifically. This study, together with other studies 
describing donor variation in the cytokine expression level and in vitro bone tissue repair 
potency of human MSC [42,43], collectively suggest that screening of candidate MSC donors is 
critical in order to take full advantage of the therapeutic effects of MSC on cutaneous wound 
healing. Moreover, it is important to consider the specific purpose of the regenerative therapy, as 
the CM of one donor MSC might prove more beneficial than the CM of another donor MSC, 
depending on the desired therapeutic effect. 
 Despite the exciting potential of the MSC-derived CM as an effective cell-free 
therapeutic treatment in regenerative medicine, a major impediment to its use is the fact that 
these MSC formulations are not fully optimized in terms of delivery methods. The ability to 
control secretion of MSC-derived bioactive factors is critical given the limitations of 
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pharmacokinetics and stability of proteins in vivo. To begin exploring the potential of such 
delivery methods, we microencapsulated our equine MSC using core-shell hydrogel 
microcapsules. Conventional alginate microcapsules have been used successfully to encapsulate 
human MSC [44-47]. However, our study demonstrated that this approach is feasible for equine 
MSC, by using core-shell capsules which were designed to provide a more relevant extracellular 
environment and to better protect the encapsulated cells [24]. Indeed, we showed that equine 
MSC survive and divide within these microcapsules and retain their stem-cell characteristics. 
Importantly, we found that CM collected from these encapsulated equine MSC equally promotes 
dermal fibroblast migration when compared to the CM from non-encapsulated MSC, suggesting 
that encapsulating of MSC may be an ideal strategy to control the delivery of secreted products 
to equine wounds in vivo. Based on data we have collected thus far, future experiments are 
planned in which we will evaluate the healing promoting effects of equine MSC, non-
encapsulated as well as microencapsulated, in an in vivo horse model, like e.g. the horse model 
established by the group of Theoret et al. in which skin wounds are experimentally induced to 
heal both normally as well as with the formation of exuberant granulation tissue [48]. 
3.6. Conclusions 
 Mesenchymal stromal cells (MSC) have been reported to provide paracrine signals that 
promote wound healing, but (i) how they exert their effects on target cells is unclear and (ii) a 
suitable delivery system to supply these MSC-derived secreted factors in a controlled and safe 
way is unavailable. The present study was designed to provide answers to these questions using 
the horse as a translational model. Our results suggest that conditioned medium (CM) of MSC 
might be a promising new therapy for impaired cutaneous wounds and that microencapsulation 
may be a suitable way to effectively deliver CM to wounded cells in vivo. Moreover, our data 
  133 
showed that the effects of MSC-derived CM appear to be donor specific, suggesting that a proper 
screening of candidate MSC donors is critical in order to take full advantage of the therapeutic 
effects of MSC on cutaneous wound healing. 
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Figure 3.S1. A. Conditioned medium (CM) from preconditioned mesenchymal stromal cells 
(MSC) does not affect migration of dermal fibroblasts. Representative phase contrast images 
of wounded NBL-6 cells cultured with CM of MSC stimulated with TNFα, IFNγ or CoCl2 as 
compared to control MSC CM at 0, 24 and 48 h. B. Migration distances of NBL-6 cells cultured 
with CM of MSC stimulated with TNFα, IFNγ or CoCl2 as compared to control MSC CM. Data 
ere expressed as μm/hr in 48 hrs. (n = 3). 
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Figure 3.S2. Mesenchymal stromal cell (MSC) conditioned medium (CM) alters NBL-6 
gene expression in a donor-specific manner. A. Fold-change of mRNA, as detected by qRT-
PCR, in NBL-6 cells cultured with MSC CM from 3 different donor horses as compared to 
control NBL-6 CM. Left panel shows genes involved in reduction of hypergranulation and/or 
enhancement of wound healing and right panel shows genes that stimulate hypergranulation 
and/or delay wound healing. B. Expression levels of CTSK and MMP2 (genes involved in 
reduction of hypergranulation and/or enhancement of wound healing), and PAI1 and ColIII 
(genes that stimulate hypergranulation and/or delay wound healing) with a significant mean rank 
difference of ≥ 6 upon incubation with Horse B MSC-derived CM. C.  Migration distances of 
NBL-6 cells cultured with CM of MSC from 3 different donor horses as compared to control 
CM. Data are expressed as μm/hr in 48 hrs. **: P < 0.01. (n = 3). 
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CHAPTER FOUR: SECRETED FACTORS FROM EQUINE MESENCHYMAL 
STROMAL CELLS DIMINISH THE EFFECTS OF TGF-β1 ON EQUINE DERMAL 
FIBROBLASTS AND ALTER THE PHENOTYPE OF DERMAL FIBROBLASTS 
ISOLATED FROM CUTANEOUS FIBROPROLIFERATIVE WOUNDS 
 
 
 
 
 
 
 
 
*The results of this study were published in Harman RM, Bihun IV, Van de Walle GR. Secreted 
factors from equine mesenchymal stromal cells diminish the effects of TGF-β1 on equine dermal 
fibroblasts and alter the phenotype of dermal fibroblasts isolated from cutaneous 
fibroproliferative wounds: Mesenchymal stromal cell effects on fibroblasts. Wound Repair 
Regen. 2017;25:234–247. 
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4.1. Summary 
 The prevalence of cutaneous fibroproliferative disorders (CFPDs) is high and almost 
exclusively occurs in humans (keloids and hypertrophic scars) and horses (exuberant granulation 
tissue), making the horse a valuable translational model for studies on prevention and treatment 
of human CFPDs. CFPDs arise as a result of dysregulated wound healing characterized by 
persistently high levels of cytokines, such as transforming growth factor beta 1 (TGF-1), that 
contribute to excessive extracellular matrix deposition, and the physical disorganization of 
dermal fibroblasts. The mesenchymal stromal cell (MSC) secretome, consisting of all factors 
secreted by MSC, has been shown to promote normal wound healing in both humans and horses, 
but its potential to treat CFPDs remains largely unexplored. Therefore, the objective of this study 
was to examine the effects of the equine MSC secretome on equine dermal fibroblasts (DF) 
influenced by cytokines that contribute to the development of CFPDs. First, primary equine DF 
were treated with TGF-1 in vitro in the presence or absence of MSC secreted products. We 
found that MSC secreted products could block TGF-1-induced changes in DF morphology, 
proliferation rate, gene expression, and contractile-capacity. We then isolated primary DF from 
equine exuberant granulation tissue, to evaluate the potential of the MSC secretome to alter the 
phenotype of cells derived from a complex CFPD environment. These results showed that MSC 
secreted factors did not change proliferation or migration of these cells but did lead to changes in 
expression of genes and proteins involved in extracellular matrix remodeling and did affect 
contractile capacity. These results warrant future studies designed to evaluate the potential of the 
MSC secretome to minimize the pathologies associated with CFPD in vivo. 
4.2. Introduction 
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 Successful cutaneous wound healing involves a network of synchronized biological 
processes that restore the integrity of the skin after injury. However, this is often not achieved as 
healing may be sacrificed in favor of quickly filling in a wound with fibrotic tissue [1]. While 
fibrotic tissue serves to prevent immediate secondary infection by limiting the area exposed to 
bacteria, it is compromised in terms of mechanical strength and is more sensitive to pain than 
healthy skin [2]. In addition, if control of fibrotic tissue formation is lost, e.g. due to chronic 
inflammation, CPFDs may develop. The chronic inflammation characteristic of most CFPDs 
sustains the production of cytokines, such as TGF-1, growth factors, angiogenic compounds 
and proteolytic enzymes that contribute to the continuous deposition of extracellular matrix 
components. This process progressively alters normal skin architecture and can lead to the 
accumulation of fibrotic tissue that protrudes beyond the margins of the wound, subjecting it to 
abrasion, disruption, and secondary infection [3]. The abnormal deposition of cutaneous fibrotic 
tissue may lead to physical complications, increased health-care costs and psychological 
problems for affected patients [4]. 
 Laboratory rodents are commonly used to evaluate novel preventative and treatment options 
for CFPDs. Although these models provide valuable information, wound healing in rodents does 
not accurately mimic human tissue regeneration [5-8]. Cutaneous wounds in mice heal by 
contraction of the panniculus carnosus, a subcutaneous muscle that humans lack. Humans rely 
on epithelialization and contraction by myofibroblasts to close cutaneous wounds [9]. There is a 
need for translational models that closely mimic the natural processes of cutaneous healing and 
CFPDs in humans. The horse is an ideal model since horses, like humans, depend on epithelial 
cell activity and contractile fibroblasts to heal cutaneous wounds. In addition, horses and humans 
are the only mammals known to naturally suffer from pathologic CFPDs during wound closure, 
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characterized by excessive deposition of extracellular matrix and cessation of healing [10]. 
Common features of human and equine CFPDs make the horse an attractive translational model 
in which to study CFPDs as well as to evaluate the potential of novel treatments [11].  
 MSC are adult multipotent progenitor cells that can differentiate into fat, bone and cartilage. 
They reside in a variety of tissues and organs, including bone marrow, adipose tissue and blood, 
and have been shown to actively contribute to healing processes [12-15]. Originally, MSC were 
believed to contribute to healing by trans-differentiating into cell types needed to restore injured 
tissue, but now it is generally accepted that paracrine signaling by these cells is the primary 
mechanism [16]. Cellular products secreted by MSC, collectively referred to as the secretome, 
instead of MSC themselves are currently being evaluated as a safe and effective “stem cell-free” 
therapy for healing of wounds [17]. Such an approach offers advantages over traditional cellular 
MSC therapies in that it avoids (i) recipient immune reactions, (ii) the risk of tumor formation by 
donor MSC and (iii) ectopic tissue formation from donor MSC [18, 19]. We recently showed that 
the equine MSC secretome promotes dermal fibroblast (DF) migration and upregulation of genes 
involved in wound healing in vitro [20], but its potential to minimize the pathologies associated 
with equine CFPDs has not yet been explored. 
 The aim of the present study was to examine the effects of the secretome, collected as 
conditioned medium (CM), of equine MSC on primary DF influenced by cytokines that 
contribute to CFPD. For the first set of experiments we treated DF from normal skin tissue with 
TGF-1 in the presence or absence of MSC CM. These experiments allowed us to determine if 
MSC CM could block the effects of a specific inflammatory cytokine involved in the 
development of CFPD, by TGF-1 treatment of a homogeneous population of DF. In the second 
set of experiments, we isolated DF from equine exuberant granulation tissue to examine the 
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effects of MSC CM on a heterogeneous population of dysregulated DF derived from a complex 
CFPD environment. 
4.3. Methods 
Cells  
 Equine MSC were isolated from the peripheral blood of healthy donor horses, as described 
previously [20-22]. Blood collection was approved by the Cornell Institutional Animal Care and 
Use Committee (IACUC # 2014-0038). Equine MSC were characterized by 
immunophenotypical protein profiling using flow cytometry and their potential for trilineage 
differentiation [21,22]. Equine MSC were confirmed to be positive for CD29, CD44, CD90 and 
CD105, and negative for CD45, CD79α, MHC II and a monocyte/macrophage marker. The 
successful trilineage differentiation of MSC toward osteoblasts, chondroblasts and adipocytes 
was confirmed using histochemical stains [20, 21]. MSC cultures were maintained at 37°C with 
5% CO2 in culture medium, consisting of low glucose Dulbecco’s modified Eagle medium 
(Corning, Tewksbury, MA), supplemented with 30% fetal bovine serum (Atlanta Biological, 
Flowery Branch, GA), 1x penicillin-streptomycin and and 2 mM L-glutamine (both from Life 
Technologies, Grand Island, NY). At 75- 80% confluency, cells were removed from flasks using 
0.25% trypsin–EDTA and passaged for further culture. MSC used for experiments were between 
passage 3 to 9.  
 Normal equine DF cells were derived from the dermis of healthy research horses euthanized 
for reasons not related to this study. DF were also isolated from equine exuberant granulation 
tissue (EGTDF) from patients admitted to the College of Veterinary Medicine, Cornell 
University, with owner consent. For isolating both DF types, a 5 mg piece of tissue was minced 
and placed in 40 mL standard medium, consisting of Dulbecco’s modified Eagle medium, 10% 
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fetal bovine serum (Atlanta Biochemicals) and 1% penicillin/streptomycin (Invitrogen), 
supplemented with 0.5 g/mL Dispase II (Worthington Biochemical, Lakewood, NJ) and filtered 
through a 22 µm filter. Tissue was incubated for 8 h at 37oC on a stir plate, to obtain in a single 
cell suspension, which was filtered through a 100 m cell strainer to remove any undigested 
tissue. Cells were washed twice in standard medium by centrifugation, counted, and plated at a 
density of 1 x 106 cells per flask in T75 flasks with standard medium. Cultures were maintained 
at 37°C with 5% CO2. At 80% confluency, cells were removed from flasks using 0.25% trypsin–
EDTA and passed for further culture. Primary DF and EGTDF used for experiments were 
passage 5 or lower. For experiments using primary DF and EGTDF, cell lines from 3 
independent donors were used for each cell type. 
 The equine dermal fibroblast cell line NBL-6 (ATTC® CCL-57) was cultured in standard 
medium and maintained at 37°C with 5% CO2. 
Recombinant proteins and chemicals 
 TGF-β1 (R&D Systems, Minneapolis, MN) was used at 10 ng/mL for 48 h to induce changes 
in. DF and EGTDF were exposed to 10 nM staurosporin (EMD Millipore, Billericam MA) or 
100 µM busulfan (Sigma Aldrich, St. Louis, MO) for 24 h to induce apoptosis and senescence, 
respectively. 
Generation of CM 
 CM was collected from MSC at 80% confluency. For this, 6 x 105 MSC were seeded in a 
T75 flask. After 24 h, medium was removed, the monolayer was rinsed with PBS, and 8 mL 
standard medium was added. Twenty-four h later, medium was collected, centrifuged twice for 7 
min at 300 × g to remove cellular debris, and diluted 1:1 in standard medium to use as CM for 
further experiments. For each assay requiring MSC CM, cell lines from 3 donor horses were 
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used to generate CM. CM from the equine dermal fibroblast cell line NBL-6 cells was collected 
exactly as described for MSC-derived CM and used as a control for all CM experiments.  
Cell viability assays 
To assess cell viability, 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
(MTT) and lactate dehydrogenase (LDH)-based in vitro toxicology assays (Sigma Aldrich, Saint 
Louis, MO) were carried out according to manufacturer’s instructions. Absorbance was 
measured on a Multiskan EX plate reader using Ascent software (Thermo Fisher Scientific, 
Waltham MA). Beta-galactosidase activity was measured to determine senescence using a 
senescence cells histochemical staining kit, according to manufacturer’s instructions (Sigma 
Aldrich, Saint Louis, MO).  
Cell proliferation assays 
i) Population doubling time (PDT) calculations  
For the determination of the PDT, 2 x 105 primary DF or EGTDF were plated in a T25 
tissue culture flask and cultured in standard medium. The PDT was calculated using the 
following link, www.doubling-time.com/compute.php, on cell isolations from 3 different horses. 
ii) Cell counts 
 To quantify cell division in response to CM treatments, 5 x 104 cells were plated per well in 
four wells of a 96-well tissue culture plate for each treatment condition and incubated for 24 h. 
Treatments were then administered for 48 h, culture medium was removed, cell monolayers were 
rinsed with PBS and 25 µl 0.25% trypsin–EDTA was added to each well for 4 minutes. Detached 
cells were incubated with 25 µl Trypan Blue and number of viable cells was counted using a 
hemocytometer.  
iii) ELISA-based detection of cell proliferation 
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 To evaluate cell proliferation, a bromodeoxyuridine (BrdU) assay kit was used following 
manufacturer’s instructions (Abcam, Cambridge, MA). The resulting absorbance was read on a 
Multiskan EX microplate reader using Ascent software. 
Gene expression analyses  
 Fibroblasts were seeded at a density of 2 x 105 in T25 tissue culture flasks. After 24 h, culture 
medium was removed, cell monolayers were rinsed with PBS, and cells were incubated in the 
appropriate treatment medium for 48 h. Subsequently, mRNA was extracted from the cells using 
an RNEasy Plus Kit (QIAGEN, Valencia CA) and cDNA was synthesized using M-MLV 
Reverse Transcriptase (USB, Cleveland, OH), both according to the manufacturer’s protocols. 
SYBER green-based quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
assays were carried out on an Applied Biosytems 7500 Fast Real Time PCR instrument (Applied 
Biosystems, Carlsbad, CA) to determine fold changes in gene expression. The comparative Ct 
method (2−ΔΔCt) was used to quantify gene expression levels where ΔΔCt = ΔCt(sample) – 
ΔCt(reference). The previously validated reference gene beta-2-Microglobulin (B2M) was used 
to normalize samples [26]. Primers to amplify fibronectin 1 (FN1), smooth muscle actin 
(ACTA2), collagen type III alpha 1 (COL3A1), collagen type I alpha 2 (COL1A2), matrix 
metallopeptidase 1 (MMP1), yes-associated protein 1(YAP1), tafazzin (TAZ), and plasminogen 
activator inhibitor 1 (SERPINE1) were designed using Primer3 software, based on horse 
sequences found in the National Center of Biotechnology Information (NCBI) GenBank. Primer 
sequences are listed in Table 1. All samples were run in triplicate.  
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Immunofluorescence analyses 
 Cells for immunofluorescence were grown in 24 well culture dishes fitted with 35 mm 
coverslips, rinsed with PBS and fixed in 4% paraformaldehyde for 10 min. Following 3 rinses 
with PBS, cells were permeabilized using PBS + 1% Triton-X 100 + 1% bovine serum albumin 
for 30 min at room temperature (RT). Primary antibodies Alexa 488-conjugated rabbit anti- 
matrix metallopeptidase 1 (Biorybt, Cambridge, UK), rabbit anti-fibronectin (Sigma Aldrich), 
mouse anti-smooth muscle actin (Dako, Carpinteria, CA), all at 1:00 dilution in PBS, and Alexa 
647-conjugated phalloidin, diluted 1:200 in PBS, were added to the wells for 1 h at 37°C. Wells 
were rinsed 3 times with PBS, and Alexa 488- or 647-conjugated secondary antibodies (Jackson 
ImmunoResearch Labs, West Grove, PA), diluted 1:100 in PBS, were added to appropriate 
wells. After 30 min at RT, cells were washed 3 times with PBS and DAPI was added for 5 min. 
After a PBS wash, coverslips were removed from wells and mounted on slides using mounting 
medium (Dako, Carpenteria, CA). Cells were examined with a Zeiss LSM confocal microscope 
(Oberkochen, Germany) and images were captured with a camera controlled by ZEN imaging 
Table 4.1. Primers used for semi-quantitative RT-PCR. 
Gene Product Abbreviation Forward primer (5’-3’) Reverse primer (5’-3’) 
Fibronectin 1 FN1 AGGTCGTTACTGTGGGCAAC TAATGGGAGACGGTGTAGGG 
Smooth Muscle Actin ACTA2 CCAGCACCATGAAGATCAAG CTGGAAGGTGGACAGAGAGG 
Collagen Type III alpha 1 COL3A1 GACCTGAAATTCTGCCATCC ACGTGGAACATTCGAAGGAC 
Collagen Type I alpha 2 COL1A2 TCAAGGTTTCCAAGGACCTG TTTCCAGGGTGACCATCTTC 
Matrix Metallopeptidase 1 MMP1 GCCAAATGGACTTCAAGCTG TAGGAAAGCCGAAGGATCTG 
Yes-Associated Protein 1 YAP1 TCAGGTCCTCTTCCTGATGG GCCAAGAGGTGGTCTTGTTC 
Tafazzin TAZ CTCCCACTTCTTCAGCTTGG TGAAGTCCATTCCCTTCTGG 
Plasminogen activator inhibitor 1 SERPINE1 CCCTGGAGAGTGAAGTGGAC CCTGCGATACATGGAGAAGC 
Beta-2-Microglobulin B2M TCTTTCAGCAAGGACTGGTCTTT CATCCACACCATTGGGAGTAAA 
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software. Anisotropy scores were calculated using the ImageJ plugin FibrilTool 
(http://imagej.nih.gov/ij/). 
Western blot analyses 
 Cells were lysed in RIPA buffer containing a 1X general protease inhibitor. Protein 
concentration was determined with a BCA protein assay (Thermo Fisher Scientific, Waltham, 
MA) prior to gel loading to ensure loading of an equal amount of protein (10 μg). 6X reducing 
sample buffer was added to yield a final concentration of 1X and lysates were boiled for 10 min 
at 95°C. Samples were subjected to SDS polyacrylamide gel electrophoresis on a 10% gel and 
transferred to Immobilin PVDF membranes (Millipore, Billerica, MA) using a transblot turbo 
system (Biorad, Hercules, CA). Membranes were blocked in 5% bovine serum albumin diluted 
in Tris buffered saline (TBS) and incubated with mouse anti-smooth muscle actin (Dako), rabbit 
anti-fibronectin (Sigma Aldrich) or rabbit anti- matrix metallopeptidase 1 (Biorybt) diluted 
1:1000 in TBS + 5% bovine serum albumin for 2 h at RT on a rotating platform. Blots were 
washed for 50 min (10 x 5 min) with TBS-Tween, then incubated with a 1:20,000 dilution of 
HRP conjugated goat anti-rabbit or HRP conjugated goat anti-mouse (Jackson ImmunoResearch 
Labs) for 1 h at RT. All blots were washed for 50 min (10 x 5 min) with TBS-Tween and then 
visualized by chemiluminescence using Clarity Western ECL (BioRad, Hercules, CA). 
Membranes were probed in parallel with rabbit anti-lamin B1 antibody (Cell Signaling, Danvers, 
MA), diluted 1:5000, as a control. Gels were imaged on a BioRad ChemiDoc MP system 
(BioRad) and band intensities were determined using Image Lab software. Intensities of the 
bands of interest were divided by the intensities of loading control bands to calculate relative 
band intensity. 
Gel contraction assays 
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 Cells were resuspended at a concentration of 2 x 106 cells/mL in EZCol Pure Gel Solution 
(Sigma Aldrich). Volumes of 500 µl cells in collagen solution were pipetted into 6.5 mm 
transwells fitted in 24-well culture plates and incubated for 30 min at 37°C and 5% CO2 to allow 
collagen solution to solidify before 1 mL appropriate medium was added per well. After 5 days, 
images were taken of the collagen gel and plug diameter was measured in a blinded manner 
using ImageJ. 
In vitro scratch assays 
 Scratch assays were carried out, exactly as previously described [20]. Images of scratches 
were captured using a Nikon Diaphot-TMD inverted light microscope with an attached Cohu 
CCD camera (Nikon, Melville, NY) leaving the reference marks outside the capture image field 
but within the eye-piece field of view for repeatable orientation of scratches. Photographs of 
scratches were taken at 0, 24 and 48 h post scratching, and migration distances of cells were 
measured in a blinded-manner using ImageJ. Widths of scratches were recorded in two places in 
each of 3 wells scratched per treatment, for a total of 6 measurements per treatment. Scratch 
width was subtracted from the time 0 scratch widths at the same location to determine cell 
migration distance. Migration distances within treatments were then averaged to determine 
overall migration.  
Statistical analyses. 
 The student’s t-test for paired data was used to test for statistically significant differences. 
When multiple t-tests were performed on a single response variable within an experiment, the 
Holm-Šídák method was used to counteract the problems associated with multiple comparisons.  
GraphPad software was used for analysis. Data given are the mean of 3 replicates and the bars 
show standard deviations.  
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4.4. Results 
CM from equine MSC inhibits TGF-1-induced changes in equine DF morphology and 
proliferation rates but does not alter untreated DF.  
 It is documented that treatment of rodent and human DF with TGF-1 changes cell 
morphology [23, 24]. Since persistent TGF-1 expression is a hallmark of CFPD in vivo [25], we 
treated primary cultures of normal equine DF with TGF-1 in the presence of MSC CM to see if 
factors secreted by MSC can dampen the effects of TGF-1, helping DF maintain a phenotype 
found in healthy skin. First, morphology was assessed by light microscopy of hematoxylin 
stained cells. It was observed that DF exposed to MSC CM during TGF-1 stimulation retained 
their elongated fibroblastic phenotype as seen in unstimulated DF, exposed to either control or 
MSC CM (Figure 1A). In contrast, TGF-1 stimulated DF exposed to control CM adapted a 
more spread-out cell shape, indicative of the transition into a myofibroblast-like phenotype 
(Figure 4.1A). Since TGF-1 treatment has been shown previously to increase human DF 
proliferation in culture [26], we evaluated proliferation to determine if this holds true for equine 
DF as well. We found that TGF-1 stimulated DF exhibited a significantly higher proliferation 
rate when compared to unstimulated DF, as measured by both cell counts (Figure 4.1B, P < 0.05) 
and BrdU ELISA (Figure 4.1C, P < 0.01), when exposed to control CM. However, when DF 
were exposed to MSC CM during TGF-1 stimulation, the proliferation rate was significantly 
reduced compared to cells exposed to control CM (P < 0.01 cell counts). MSC CM did not have 
a positive effect on proliferation rate of unstimulated normal DF when assessed by cell counts 
and BrdU ELISA (Figure 4.1B & C). To ensure that alterations in cell proliferation were not due 
to a toxic effect of either TGF-1 stimulation or MSC CM treatment, LDH release assays were 
performed. No significant differences in total LDH release between unstimulated and TGF-1 
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stimulated DF, exposed to either control CM or MSC CM, were observed (Supplementary Figure 
4.1A). 
 
Figure 4.1. Mesenchymal stromal cell conditioned medium (MSC CM) inhibits TGF-β1 
induced changes in dermal fibroblast (DF) morphology, proliferation and gene expression. 
A. Morphology of untreated and TGF-β1 treated DF in the presence of control and MSC CM. B-
C. Proliferation of untreated and TGF-β1 treated DF in the presence of control and MSC CM 
measured by cell counts (B) and BrdU incorporation (C). D. Expression of genes involved in 
extracellular matrix production and cytoskeleton composition in untreated and TGF-β1 treated 
DF in the presence of control and MSC CM, as measured by qRT-PCR. n=3, scale bars=20 µm 
*: P < 0.05, **: P < 0.01. 
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CM from MSC inhibits TGF-1-induced changes in DF gene and protein expression and reduces 
contractile capacity of these cells.  
 Human DF exposed to TGF-1 exhibit a change in expression of genes and proteins involved 
in cytoskeletal organization and secreted extracellular matrix components [27]. Using qRT-PCR, 
we found that expression of the genes FN1, ACTA2, COL3A1 and COL1A2, were significantly 
increased in TGF-1 stimulated DF compared to unstimulated DF when exposed to control CM 
(Figure 1D, P < 0.05 or P < 0.01). In contrast, exposing DF to MSC CM during TGF-1 
stimulation resulted in FN1 and COL3A1 gene expression levels that were undistinguishable 
from unstimulated DF (Figure 1D). ACTA2 and COL1A2 gene expression levels did decrease in 
response to MSC CM, but not to levels that were comparable to unstimulated DF (Figure 1D, P < 
0.05 or P < 0.01). The MSC CM did not have any effect on gene expression levels in 
unstimulated normal DF (Figure 1D). Next, expression of fibronectin and smooth muscle actin 
was followed up on a protein level, using both immunofluorescence and Western blot analyses. 
Overall, expression patterns of both proteins followed gene expression results. An increase in 
antibody binding was observed in TGF-1 stimulated DF as compared to unstimulated DF in 
immunofluorescence analyses, when exposed to control CM (Figure 4.2A). However, when DF 
were exposed to MSC CM during TGF-1 stimulation, the fluorescence signals of both proteins 
were weak and comparable to unstimulated DF (Figure 4.2A). These results were examined 
quantitatively by calculating intensities of protein bands detected on Western blot membranes. 
Stimulated DF exposed to control CM expressed more fibronectin and smooth muscle actin 
protein than unstimulated DF exposed to control CM. When DF were exposed to MSC CM 
during TGF-1 stimulation, levels of both proteins decreased to levels undistinguishable from 
those of unstimulated DF exposed to control CM (Figure 4.2B). 
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Figure 4.2. Mesenchymal stromal cell conditioned medium (MSC CM) inhibits TGF-β1 
induced changes in dermal fibroblast (DF) protein expression. A. Fibronectin and smooth 
muscle actin proteins visualized by immunofluorescent antibody binding. Fibronectin was 
labeled with Alexa 488 (green), smooth muscle actin labeled with Alexa 647 (red), and nuclei 
counterstained with DAPI (blue). B. Quantification of bands in Western blots (i). Representative 
images of Western blots for fibronectin (top panel) and smooth muscle actin (middle panel), with 
loading control (bottom panel) (ii).  n=3, scale bars=20 µm, *: P < 0.05. 
  
 Finally, we evaluated the effects of MSC CM on contractility since well-organized actin 
stress fibers in TGF -1 stimulated DF contribute to the characteristic contractile phenotype of 
these cells [28]. DF stimulated with TGF-1 and cultured in control CM adapted a contractile 
phenotype as measured by a decreased diameter of collagen plugs (Figure 3A, P < 0.05). This 
change in contractile capacity was not observed in DF stimulated with TGF-1 in the presence of 
MSC CM, and MSC CM did not affect the contractile capacity of unstimulated normal DF 
(Figure 4.3A). To further examine the contractile capacity of unstimulated and TGF-1-
stimulated cells, anisotropy was determined using an F-actin filament staining. Anisotropy is 
defined as the level of organization of actin filaments and is based on how parallel these 
filaments are in relation to one another within individual cells [29]. We found that DF treated 
with TGF-1 in the presence of control CM had more organized filaments than untreated DF, as 
reflected by high anisotropy scores (Figure 4.3B, P < 0.01). In contrast, DF treated with TGF- 1 
in the presence of MSC CM exhibited anisotropy scores indistinguishable from untreated DF 
(Figure 4.3B), indicating a less organized actin network within each cell. MSC CM did not affect 
anisotropy of unstimulated normal DF (Figure 4.3B). 
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Figure 4.3. Mesenchymal stromal cell conditioned medium (MSC CM) inhibits TGF-β1 
induced contractile phenotype of dermal fibroblasts (DF). A. Quantification of the diameter 
of collagen plugs containing cells, as measured using ImageJ software (i). Representative images 
of collagen plugs containing cells (ii). B. Quantification of anisotropy scores (directional 
dependence), as calculated by the ImageJ plugin FibrilTool (i). Representative images of F-actin 
staining using 647-Phalloidin (ii). n=3, scale bars=20 µm, *: P < 0.05, **: P < 0.01. 
 
DF derived from equine exuberant tissue behave differently in culture than DF derived from 
healthy equine skin. 
 Based on our results showing that MSC CM inhibited the well-documented effects of TGF-
1 on a homogeneous population of DF isolated from healthy skin, we decided to expand our 
study in order to determine whether MSC CM is also capable of acting on a diverse population 
of dysregulated primary fibroblasts isolated from exuberant granulation tissue. Before carrying 
out assays to explore this question however, we needed to determine if EGTDF differed from DF 
collected from healthy skin, since we observed that MSC CM did not affect the proliferation, 
normal gene and protein expression or contractile capacity of DF isolated from healthy skin. Our 
goals for this set of experiments were (i) to determine if EGTDF were dysregulated as compared 
to DF from healthy skin and (ii) if so, to evaluate the effect of MSC CM on these cells. 
Representative hematoxylin-eosin stained histology sections clearly showed that exuberant 
granulation tissues are disorganized when compared to healthy skin tissue sections (Figure 4.4A, 
left panels). Specifically, these tissue sections lacked an epithelial layer, did not contain hair 
follicles or glands, and were highly vascular (Figure 4.4A, left panels). Primary fibroblast 
cultures established from these tissue samples differed morphologically from DF isolated from 
healthy skin; EGTDF were more spread out and exhibited a cuboidal shape as compared to 
normal DF (Figure 4.4A, right panels). We characterized these fibroblast cultures by calculating 
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PDT and found significantly higher PDT values at passage 3, 4 and 5, indicative of slower 
growth in EGTDF cultures as compared to normal DF cultures (Figure 4.4B, P < 0.05). At later 
passages, EGTDF started to divide more quickly, as shown by lower PDT values, and a 
difference in PDT was no longer observed by passage 6 (Figure 4.4B). Since it has been 
postulated that fibroblasts in exuberant granulation tissue are more resistant to cell death 
compared to normal DF [30], we decided to expose both types of fibroblasts to busulfan and 
staurosporin in order to induce senescence and apoptosis, respectively [31]. Exposing fibroblast 
cultures to busulfan did not significantly increase the level of senescence in normal DF cultures, 
in contrast to EGTDF cultures, were a significantly increase in -galactosidase-positive cells was 
observed indicating that EGTDF are more susceptible to senescence than DF (Figure 4.4C, P < 
0.05). No such difference was observed upon treatment with staurosporin with both types of 
fibroblast cultures being equally susceptible to apoptosis (Figure 4.4D-F, Supplementary Figure 
4.S1B). 
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Figure 4.4. Dermal fibroblasts isolated from normal skin (DF) or exuberant granulation 
tissue (EGTDF) differ in morphology, population doubling time and susceptibility to 
senescence, but not susceptibility to apoptosis. A. Hematoxylin-eosin stained tissue sections 
from healthy horse skin (upper left) and exuberant granulation tissue (EGT, lower left). Phase 
contrast images of cultured cells isolated from DF (upper right) and EGTDF (lower right). B. 
Population doubling time of DF and EGTDF over 5 passages in culture (P3 through P7). C. 
Busulfan induced senescent cells in DF and EGTDF, as measured by -galactosidase activity (i). 
Representative high-power images of DF and EGTDF treated with busulfan and stained with -
galactosidase (ii). D-F. Staurosporine induced apoptosis in DF and EGTDF, as measured by 
MTT processing (D), LDH release (E) and cells positive for active caspase-3 (F). n=3, scale 
bars=20 µm, *: P < 0.05, **: P < 0.01. 
 
 After determining that EGTDF behave differently in culture than DF derived from healthy 
equine skin, we compared this heterogeneous population of cells isolated from clinical biopsies 
to the relatively homogeneous population of TGF-1 stimulated DF used in our first set of 
experiments. Proliferation rates, as well as the expression of FN1, ACTA2, COL3A1 and 
COL1A2 were directly compared between these two cell types, and normal DF were included for 
reference. The results indicate that although EGTDF and TGF-1 stimulated DF differ from 
normal DF in terms of proliferation rate as measured by BrdU incorporation (Supplementary 
Figure 4.S2B, P < 0.05 or P < 0.01) and FN1 and ACTA2 gene expression (Supplementary 
Figure 4.S2C, P < 0.05 or P < 0.01), these cell types are not analogous to each other.  
CM from MSC does not alter proliferation or migration of EGTDF but does affect gene and 
protein expression in EGTDF and reduces their contractile capacity. 
 Our lab previously showed that MSC CM does not alter proliferation, but does increase 
migration of NBL-6 cells, a commercially available equine fibroblast cell line [20]. Repeating 
those experiments with primary DF cultures confirmed these observations (Figure 4.5A-B, P < 
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0.01). As with DF, no significant effects on proliferation were observed in EGTDF cultures 
treated with MSC CM, as measured by cell counts (Figure 4.5A) and BrdU incorporation 
(Supplementary Figure 4.S1C). However, and in contrast to DF, the migration rate of EGTDF 
treated with MSC CM did not increase, as measured by scratch assays (Figure 4.5B).  
 As part of our characterization of EGTDF, we used qRT-PCR to compare the expression of 
13 genes we predicted might be differentially expressed between EGTDF and DF based on 
previous work by other groups [11, 30, 32-38]. Expression of 7 of these genes; transgelin, 
secreted phosprotein 1, tumor protein p53, decorin, transforming growth factor beta 3, COL3A1 
and COL1A2 did not differ in EGTDF as compared to DF (data not shown & Supplementary 
Figure 4.2C). In contrast, we consistently detected significant differences in the expression of 6 
genes between DF and EGTDF (Figure 4.5C, P < 0.05 or P < 0.01). These genes are involved in 
cell proliferation and apoptosis (YAP and TAZ), extracellular matrix remodeling (SERPINE1, 
FN1 and MMP1) and cytoskeletal composition (ACTA2). An upregulation of MMP1 expression 
has been described previously in both horse and human CFPDs [38,39]. Since the expression of 
these 6 genes was reliably altered in EGTDF as compared to DF isolated from healthy skin, we 
decided to use these genes as read-outs to determine if MSC CM could affect a heterogeneous 
population of dysregulated fibroblasts isolated from an exuberant granulation tissue 
environment. When cultured in MSC CM, gene expression levels of 4 of the 5 genes up-
regulated in EGTDF decreased to levels that were virtually identical to expression levels in DF. 
The expression of FN1, while decreased in the presence of MSC CM, did not reach a level 
similar to that in DF (Figure 4.5C, P < 0.05).  The expression level of ACTA2, which was lower 
in EGTDF as compared to DF, did not increase to a level equivalent to that in DF when EGTDF 
were cultured in MSC CM (Figure 4.5C, P < 0.05). In addition, fibronectin and matrix 
  166 
metallopeptidase 1 protein expression decreased when EGTDF were cultured in MSC CM as 
compared to control CM, while the protein expression of smooth muscle actin did not change 
(Figure 4.6A & B, P < 0.05). 
 Finally, we determined whether MSC CM alters contractility in EGTDF cultures. Using gel 
contraction assays, we found that treatment with MSC CM reduced the contractile nature of 
EGTDF, as detected by an increased diameter of collagen plugs (Figure 4.6C, P < 0.05), and 
evaluating anisotropy scores showed less organized actin networks in EGTDF treated with MSC 
CM, as shown by lower anisotropy scores (Figure 4.6D, P < 0.05).  
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Figure 4.5. Mesenchymal stromal cell conditioned medium (MSC CM) does not affect 
proliferation of dermal fibroblasts (DF) and exuberant granulation tissue DF (EGTDF), 
but differentially affects DF and EGTDF migration and induces changes in gene expression 
in EGTDF. A. Proliferation of DF and EGTDF treated with MSC CM, as measured by cell 
counts. For clarity, cell count data has been reformatted from Figure 1. B. Migration of DF and 
EGTDF treated with MSC CM, as measured by in vitro scratch assays. C. Expression of YAP1, 
TAZ, SERPINE1, FN1, MMP1 and ACTA2 in EGTDF compared to normal DF in the presence of 
MSC CM, as measured by qRT-PCR. n=3, *: P < 0.05, **: P < 0.01. 
 
 
Figure 4.6. Mesenchymal stromal cell conditioned medium (MSC CM) reduces fibronectin 
and matrix metalloproteinase 1 (MMP1), but not smooth muscle actin, protein expression 
and reduces contractile capacity in exuberant tissue dermal fibroblasts (EGTDF). A. 
Fibronectin, matrix metallopeptidase 1 (MMP1) and smooth muscle actin proteins visualized by 
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immunofluorescent antibody binding. Proteins of interest were labeled with Alexa 488 (green) or 
Alexa 647 (red), and nuclei counterstained with DAPI (blue). B. Quantification of bands in 
Western blots (i). Representative images of Western blots for fibronectin (top panel), MMP1 
(second panel), smooth muscle actin (third panel) and loading control (bottom panel) (ii). C. 
Quantification of the diameter of collagen plugs containing cells, as measured using ImageJ 
software (i). Representative images of collagen plugs containing cells (ii). D. Quantification of 
anisotropy scores (directional dependence), as calculated by the ImageJ plugin FibrilTool (i). 
Representative images of F-actin staining using 647-Phalloidin (ii). n=3, scale bars=20 µm, *: P 
< 0.05. 
 
4.5. Discussion 
 This study is the first to evaluate the effects of CM from equine MSC on DF treated with 
TGF-1 as well as on dysregulated primary DF isolated from equine exuberant granulation 
tissue. We found that MSC CM significantly dampens the effects of TGF-1 on DF in terms of 
cell proliferation, gene expression, and contractile capacity. We also found that MSC CM alters 
gene and protein expression in EGTDF cultures, as well as reduces the contractile capacity of 
these cells.  
 Successful wound healing in humans and horses depends on appropriately oriented 
contractile cells and cycles of deposition and remodeling of extracellular matrix proteins, each 
cycle leading to more highly organized, mechanically functional tissue [40]. As DF are the 
resident skin cells involved in contraction and extracellular matrix remodeling, it is encouraging 
to find that treatment with MSC CM alters contraction and the expression of extracellular matrix 
components in DF that are either pushed towards an altered phenotype by TGF-1 or that are 
isolated from exuberant granulation tissue. Importantly, we found that the MSC CM had little to 
no effects on these phenotypical characteristics in normal DF. This pattern of targeting 
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dysregulated cells while leaving normal cells unaffected, may be one of the most valuable 
therapeutic features of MSC secreted products. 
 The two types of dysregulated DF used in this study each had unique characteristics that 
allowed us to evaluate the potential of MSC CM to reduce CFPD. First, we examined the effects 
of MSC CM on DF treated with TGF-1. This approach provided us with a uniform population 
of cells with a discrete phenotype. Since it is well-documented that TGF-1 treatment leads to 
the upregulation of fibronectin, smooth muscle actin and type 1 and type III collagens, as well as 
the formation of prominent actin-based contractile fibers [26,27], we chose these features as 
read-outs for our assays. TGF-1 is detected at relatively low levels immediately after wounding 
of the lower limb in horses. During the proliferative phase of lower limb wound healing, 
however, when granulation tissue is being formed to fill the wound space, TGF-1 levels in 
horse limb wounds increase and persist, providing a constant stimulus to DF to proliferate. In 
vivo, this enhanced and persistent DF proliferation ultimately leads to excessive granulation 
tissue that extends beyond the wound margins and inhibits wound closure [41]. Blocking the 
activity of TGF-1, therefore, may reduce the formation of exuberant granulation tissue. 
 We then proceeded to examine the effects of MSC CM on primary DF isolated from 
naturally occurring exuberant granulation tissue. Our rationale for this set of experiments was 
that if MSC CM could affect a heterogeneous population of dysregulated fibroblasts derived 
from a complex wound environment in vitro, it may be effective as a therapy for CFPDs in vivo. 
We characterized these cells before using them in our MSC CM experiments and observed that 
the morphology of EGTDF from different equine patients was consistently distinct from that of 
DF isolated from healthy skin. In addition, we found higher PDTs for cultured EGTDF as 
compared to cultured DF. This was an unexpected result as we predicted that fibroblasts from 
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exuberant granulation tissue would proliferate more rapidly, resulting in lower doubling time, 
than those isolated from healthy skin. This suggests that in exuberant granulation tissue, DF may 
persist in excess due to reasons other than accelerated proliferation. Resistance to senescence or 
apoptosis might explain why DF can persist in vivo, although this was not observed in our in 
vitro studies. Similarly, studies in which samples from experimentally-induced exuberant 
granulation tissue were examined histologically did not find evidence of increased resistance to 
cell death when compared to wounded skin that healed normally [30]. Using EGTDF cultures 
gave us the opportunity to evaluate the effects of the MSC CM on a naturally occurring 
population of DF derived from a dysregulated wound environment. We found that MSC CM 
affects the phenotype of EGTDF cultures, causing them to be more like normal DF, suggesting 
that MSC therapy might be beneficial to reduce CFPD in vivo.  
 A limitation of the current studies is that many of the experiments were carried out in a two-
dimensional (2D) culture system. DF and EGTDF grown in this type of system are subject to an 
environment that is quite different from the tissue the cells were derived from, particularly in 
terms of cell-cell contacts and substrate rigidity. Because of this, observations made in a 2D 
culture system do not necessarily reflect what occurs in vivo. The contraction experiments 
described were performed in a three-dimensional (3D) culture system, which more closely 
resembles the in vivo environment. Our results showing that MSC CM affects the contractile 
capacity of both DF stimulated with TGF-1 and EGTDF cultured in 3D systems, suggests that 
MSC CM may indeed influence EGTDF in vivo.  
 Although beyond the scope of this study, we initiated experiments designed to identify the 
bioactive factors in the MSC CM that might account for the effects observed in our present 
study. Preliminarily we found, taking a biased approached using commercially available 
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cytokine, protease and protease-inhibitor antibody arrays (R&D Systems, Minneapolis MN), 
several proteins of interest that were present in at least two-fold higher concentrations in MSC 
CM compared to control fibroblast CM (Supplementary Figure 1D). Currently, we are evaluating 
these proteins in more detail to confirm the role of these factors, which will allow us to optimize 
future protocols to enhance the secretion of these factors and/or to allow their individual 
synthesis. 
 Taken together, this study aimed to evaluate the functional effects of CM from equine 
peripheral blood-derived MSC on DF influenced by cytokines that contribute to CFPD. Our 
results indicate that MSC CM does affect these cells, and warrant studies in more complex model 
systems in order to determine if MSC CM does have the potential to improve CFPDs in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  173 
4.6. References 
1. Van den Broek LJ, Limandjaja GC, Niessen FB, Gibbs S. Human hypertrophic and keloid scar 
models: principles, limitations and future challenges from a tissue engineering perspective. 
Exper Dermatol 2014;23:382–386. 
2. Clark JA, Leung KS, Cheng JC, Leung, PC. The hypertrophic scar and microcirculation 
properties. Burns 1996;22:447–450. 
3. Wynn TA. Common and unique mechansims regulate fibrosis in various fibroproliferative 
diseases. J Clin Invest 2007;117:524-529. 
4. Ding J, Tredget EE. The role of chemokines in fibrotic wound healing. Adv Wound Care 2015;4: 
673-686. 
5. Morris DE, Wu L, Zhao LL, Bolton L, Roth SI, Ladin DA, Mustoe, TA. Acute and chronic 
animal models for excessive dermal scarring: quantitative studies. Plast. Reconstr. Surg. 
1997;100:674–681. 
6. Aksoy MH, Vargel I, Canter IH, Erk, Y, Sargon M, Pinar A, Tezel G. A new experimental 
hypertrophic scar model in guinea pigs. Aesthetic Plastic Surgery 2002, 26:388–396. 
7. Dorsett-Martin WA. Rat models of skin wound healing: A review. Wound Repair and 
Regeneration 2004;12:591–599. 
8. Theoret CL, Wilmink JM. Aberrant wound healing in the horse: Naturally occurring conditions 
reminiscent of those observed in man. Wound Repair and Regeneration 2013;21:365–371. 
9. Greenwood JE. Function of the panniculus carnosus-a hypothesis. Vet Rec 2010;167:760. 
  174 
10. Widgerow AD, Leak K: Hypergranulation tissue: evolution, control and potential elimination. 
Wound Healing South Africa 2010;3:1-3. 
11. Theoret CL, Olutoye OO, Parnell LKS, Hicks J. Equine exuberant granulation tissue and 
human keloids: a comparative histopathologic study. Veterinary Surgery 2013;42:783-789. 
12. Dittmer J, Leyh B. Paracrine effects of stem cells in wound healing and cancer progression 
(Review). Int J Oncol  2014;44:1789-1798. 
13. Aggarwal S, Pittenger, MF. Human mesenchymal stem cells modulate allogeneic immune cell 
responses. Blood 2005;105:1815–1822. 
14. Ono I, Yamashita T, Hida T, Jin H-Y, Ito Y, Hamada H, Akasaka Y, et al. Local administration 
of hepatocyte growth factor gene enhances the regeneration of dermis in acute incisional wounds. 
J Surg Res 2004;120:47–55. 
15. Gnecchi M, Zhang Z, Ni A, and Dzau VJ. Paracrine mechanisms in adult stem cell signaling 
and therapy. Circ Res 2008;103:1204–1219.  
16. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel 
opportunities in (stem) cell-free therapy. Front Physio. 2012;3:359.17. Kim J-M, Kim J, Kim Y-
H, Kim K-T, Ryu SH, Lee TG, Suh P-G. Comparative secretome analysis of human bone marrow-
derived mesenchymal stem cells during osteogenesis. J Cell Physiol 2013;228:216-224. 
18. Hanson S, D’Souza RN, Hematti P. Biomaterial-mesenchymal stem cell constructs for 
immunomodulation in composite tissue engineering. Tissue Eng Part A 2014;20:2162-2168. 
  175 
19. Sutton MT, Bonfield TL. Stem cells: innovations in clinical applications. Stem Cells Int 
2014;516278. 
20. Bussche L, Harman RM, Syracuse BA, Plante EL, Lu Y, Curtis TM, Ma M, et al. 
Microenapsulated equine mesenchymal stromal cells promote cutaneous wound healing in vitro. 
Stem Cells Res and Therapy 2015;6:66. 
21. Pennington MR, Curtis TM, Divers TJ, Wagner B, Ness SL, Tennant BC, Van de Walle GR. 
Equine mesenchymal stromal cells from different sources efficiently differentiate into 
hepatocyte-like cells. Tissue Eng Part C Methods 2016;6:596-607. 
22. Bussche L, Van de Walle GR: Peripheral blood-derived mesenchymal stromal cells promote 
angiogenesis via paracrine stimulation of vascular endothelial growth factor secretion in the 
equine model. Stem Cells Transl Med 2014;3:1514–1525. 
23. Desmourliere A, Geinoz A, Gabbiani, F, Gabbiani G. Transforming growth factor-1 induces 
-smooth muscle actin expression in granulation tissue and in quiescent and growing cultured 
fibroblasts. J Cell Biol 1993;122:103-111.  
24. Evans RA, Tian YC, Steadman R, Phillips AO. TGF-1-mediated fibroblast-myofibroblast 
terminal differentiation-the role of Smad proteins. Exper Cell Res 2003;282:90-100.  
25. Sarrazy V, Billet F, Micallef L, Coulomb B, Desmourliere A. Mechanisms of pathological 
scarring: role of myofibroblasts and current developments. Wound Rep Reg 2011;19:S10-S15. 
  176 
26. Spiekman M, Przybyt E, Plantinga B, Gibbs S, van der Lei B, Harmsen MC. Adipose tissue-
derived stromal cells inhibit TGF-1-induced differentiation of human dermal fibroblasts and 
keloid fibroblasts in a paracrine fashion. Plast Reconstruct Surg 2014;134:699-712. 
27. Darby IA, Laverdet B, Bonte F, Desmouliere A. Fibroblasts and myofibroblasts in wound 
healing. Clin Cosmet Investig Dermatol 2014;7: 01-311.  
28. Sandbo N, Dulin N. The actin cytoskeleton in myofibroblast differentiation: Ultrastructure 
defining form and driving function. Transl Res 2011;158:181-196. 
29. Boudaoud A, Burian A, Borowska-Wykret D, Uyttewaal M, Wrzalik R, Kwiatkowska D, 
Hamant O. FibrilTool, an ImageJ plug-in to quantify fibrillary structures in raw microscopy 
images. Nat Protoc 2014;9:457-463. 
30. Lepault E, Céleste C, Doré M, Martineau D, Theoret CL. Comparative study on 
microbascular occlusion and apoptosis in body and limb wounds in the horse. Wound Rep Reg 
2005;13:520-529. 
31. Childs BG, Baker DJ, Kirkland JL, Campisi J, van Deursen JM. Senescence and apoptosis: 
dueling or complementary cell fates? EMBO Reports 2014;15:1139-1153. 
32. Theoret CL, Barber SM, Moyana TN, Gordon, JR. Expression of transforming growth factor 
1, 3, and basic fibroblast growth factor in full-thickness skin wounds of equine limbs and 
thorax. Vet Surg 2001;30:269-277. 
33. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell.Physiol 2012;227:493–507.  
34.  Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22 are the 
  177 
same protein, the expression of which is down-regulated in many cell lines. Cell Motil 
Cytoskeleton 1997;38:250–257.  
35. Piccolo S, Dupont S, Cordenonis M. The biology of YAP/TAZ: hippo signaling and beyond. 
Physiol Rev 2104;94:1287-1312.  
36. Tan EML, Hoffren J, Rouda S, Greenbaum S, Fox JW, More JH, Dodge GR. Decorin, 
versican, and biglycan gene expression by keloid and normal dermal fibroblasts: differential 
regulation by basic fibroblast growth factor. Exp Cell Res 1993:209:200-207. 
37. Satish L, Lyons-Weiler J, Hebda PA, Wells A. Gene expression patterns in isolated keloid 
fibroblasts. Wound Rep Reg 2006;14:463-470. 
38. Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of 
fators involved in collagen turnover and depend on matrix metalloproteinase for migration. Brit J 
Dermatol 2005;153:295-300. 
39. Miragliotta V, Lefebvre-Lavoie J, Lussier, JG, Theoret CL.  Equine ANXA2 and MMP1 
expression analysis in an experimental model of normal and pathological wound repair. J Derm 
Sci 2008;51:103-112. 
40. Xue M and Jackson CJ. Extracellular matrix reorganization during wound healing and its 
impact on abnormal scarring. Adv Wound Care 2015;4:119-136. 
41. Wilmink JM, vanWeeren PR: Second-intention repair in the horse and pony and management 
of exuberant granulation tissue. Vet Clin Equine 2005;1:5-32. 
  178 
 
Figure 4.S1. Supplementary data. A. TGF-β1 treatment is not toxic to DF as measured by 
LDH release. B. Representative images of normal DF and EGTDF, treated with staurosporine 
and labeled with an antibody against active caspase-3. C. Treatment with MSC CM does not 
increase EGTDF proliferation as measured by BrdU incorporation. D. Potentially relevant 
proteins detected by antibody arrays in MSC CM that are present in at least two-fold higher 
concentrations in MSC CM compared to control fibroblast CM. Mode of action and references 
are also provided. n=3, scale bars=20µm, P < 0.05. 
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Figure 4.S2. Comparison of dermal fibroblasts (DF), TGF-β1 treated DF, and exuberant 
granulation tissue DF (EGTDF). A-B. Proliferation measured by cell counts (A) and BrdU 
incorporation (B).  C. Expression of genes involved in extracellular matrix production and 
cytoskeleton composition in DF, TGF-β1 treated DF and EGTDF as measured by qRT-PCR. 
n=3, *: P < 0.05, **: P < 0.01. 
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CHAPTER FIVE: ANTIMICROBIAL PEPTIDES SECRETED BY EQUINE 
MESENCHYMAL STROMAL CELLS INHIBIT THE GROWTH OF BACTERIA 
COMMONLY FOUND IN SKIN WOUNDS 
 
 
 
 
 
 
 
 
 
The results of this study were published in Harman RM, Yang S, He MK, Van de Walle GR. 
Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of 
bacteria commonly found in skin wounds. Stem Cell Res Ther. 2017;8:157. 
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5.1. Summary 
 The prevalence of chronic skin wounds in humans is high, and treatment is often 
complicated by the presence of pathogenic bacteria. Therefore, safe and innovative treatments to 
reduce the bacterial load in cutaneous wounds are needed. Mesenchymal stromal cells (MSC) are 
known to provide paracrine signals that act on resident skin cells to promote wound healing, but 
their potential antibacterial activities are not well described. The present study was designed to 
examine the antibacterial properties of MSC from horses, as this animal model offers a readily 
translatable model for MSC therapies in humans. Specifically, we aimed to (i) evaluate the in 
vitro effects of equine MSC on the growth of representative gram negative and gram-positive 
bacterial species commonly found in skin wounds and (ii) define the mechanisms by which MSC 
inhibit bacterial growth.  
 MSC were isolated from the peripheral blood of healthy horses. Gram negative E. coli and 
gram-positive S. aureus were cultured in the presence of MSC and MSC conditioned medium 
(CM), containing all factors secreted by MSC. Bacterial growth was measured by plating 
bacteria and counting viable colonies or by reading the absorbance of bacterial cultures. Bacterial 
membrane damage was detected by incorporation of N-phenyl-1-naphthylamine (NPN). 
Antimicrobial peptide (AMP) gene and protein expression by equine MSC were determined by 
RT-PCR and Western blot analysis, respectively. Blocking of AMP activity of MSC CM was 
achieved using AMP-specific antibodies.  
 We found that equine MSC and MSC CM inhibit the growth of E. coli and S. aureus, and 
that MSC CM depolarizes the cell membranes of these bacteria. In addition, we found that 
equine MSC CM contains AMPs, and blocking these AMPs with antibodies reduces the effects 
of MSC CM on bacteria.  
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 Our results demonstrate that equine MSC inhibit bacterial growth and secrete factors that 
compromise the membrane integrity of bacteria commonly found in skin wounds. We also 
identified four specific AMPs produced by equine MSC. The secretion of AMPs may contribute 
to the value of MSC as a therapy for cutaneous wounds in both horses and humans. 
5.2. Introduction 
 Chronic cutaneous wounds are a rapidly growing health care burden in human medicine. In 
the United States, chronic leg and foot ulcers alone affect 2.4-4.5 million people [1,2]. Chronic 
skin wounds are defined as wounds that do not improve after 4 weeks or do not heal within 8 
weeks [3]. Chronic wounds are classified into different categories and are caused by a variety of 
insults. A common feature of chronic wounds, regardless of initial cause, is colonization by 
pathogenic bacteria, which leads to an inflammatory host response and delayed wound healing 
[4,5]. Chronic wounds typically contain a diversity of bacterial species that may interact to form 
matrices on wound surfaces called biofilms. Biofilms are particularly problematic as they show 
greater resistance to traditional antibiotics compared to planktonic cells of the same species [6]. 
 Antibiotic-resistant organisms are a challenge for the field of medicine in general, and for 
health care workers caring for patients with chronic cutaneous wounds in particular [7]. 
Alternatives to conventional antibiotics are currently being explored, with a focus on finding 
compounds that can kill bacteria directly rather than by disrupting metabolic activity and 
proliferation. Bacteria can survive insults to metabolic and proliferative pathways and evolve to 
avoid them, but they are less likely to become resistant to compounds that kill them directly 
[8,7]. Naturally-occurring or synthetic antimicrobial peptides (AMPs) could be used for the 
design of new classes of antibiotics [9-11]. The diverse array of AMPs act through different 
mechanism, and because many AMPs are bactericidal as opposed to bacteriostatic, it is unlikely 
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that bacteria will be able to respond to these AMPs by adopting resistance strategies [12-14]. 
This makes AMPs a promising class of molecules to be explored as novel antimicrobial 
therapies. A disadvantage of synthetic AMPs as an alternative to conventional antibiotics, 
however, is that they are costly to generate and purify [15]. Therefore, naturally-occurring AMPs 
for therapeutic use may be a more practical and cost-effective substitute for traditional antibiotic 
therapy.  
 To explore this, a suitable animal model that allows for proper testing of the efficacy of 
naturally-occurring AMPs to kill bacteria in chronic wounds of humans is warranted. Like 
humans, horses suffer from naturally-occurring chronic wounds [16,17] and bacterial infection of 
horse wounds delays the normal healing process by prolonging inflammation, reducing resident 
skin cell migration, and disrupting extracellular matrix formation [18,5].  
 Mesenchymal stromal cells (MSCs) are adult multipotent progenitor cells, present in a 
variety of tissues and organs [19] and contribute to healing processes by participating in the 
inflammatory, proliferative and remodeling phases of tissue repair [20-22]. Recent data show 
that paracrine signaling is the primary mechanism by which MSC contribute to tissue repair 
[23,24]. Our lab has previously demonstrated that equine MSC CM, comprising all factors 
secreted by MSC, can increase equine dermal fibroblast migration and block the effects of 
transforming growth factor beta-1 on equine dermal fibroblasts, providing the rationale for their 
potential in cutaneous wound management [25,26]. The potential of equine MSC to contribute to 
wound healing by reducing bacterial loads has not been explored to date, although this seems 
achievable based on previous reports showing that human MSC possess antimicrobial properties 
such as killing E. coli in rodent lung infection models, as well as reducing overall bacterial loads 
in septic mice [27-29].  
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 Therefore, the aims of the present study were to (i) evaluate the in vitro effects of equine 
MSC on the growth of representative gram negative and gram-positive bacterial species 
commonly found in skin wounds and (ii) define the mechanisms by which MSC inhibit bacterial 
growth. Our notable findings were that equine MSC and MSC CM, can inhibit the growth of E. 
coli and S. aureus and that MSC CM can depolarize the cell membranes of these bacteria. In 
addition, we identified four AMPs produced by MSC, and observed that blocking these AMPs in 
MSC CM with antibodies reduces the effects of MSC CM on bacteria.  
5.3. Methods 
 Cells  
 Equine mesenchymal stromal cells (MSC) were isolated from the peripheral blood of 3 
healthy warmblood mares between 8 and 12 years old, exactly as described previously [30]. The 
blood collection was approved by the Cornell Institutional Animal Care and Use Committee 
(IACUC # 2014-0038). Cells were seeded at a density of 1.6 x 105 cells/cm2 in a T75 flask in 
culture medium, consisting of low glucose Dulbecco’s modified Eagle medium (DMEM) (Life 
Technologies, Grand Island, NY) supplemented with 30% fetal bovine serum (FBS) (Atlanta 
Biological, Flowery Branch, GA), 10-7 M low dexamethasone (Sigma Aldrich, St. Louis, MO), 
50 g /mL gentamycin, 1x penicillin-streptomycin (P/S), and 2 mM L-glutamine (all from Life 
Technologies). Cultures were maintained at 37°C with 5% CO2. At 70% confluency, cells were 
removed from flasks using 0.25% trypsin–EDTA and further cultured in expansion medium, 
which is identical to the culture medium but without dexamethasone. Equine MSC were 
characterized by immunophenotypical protein profiling using flow cytometry and their potential 
for trilineage differentiation, exactly as described previously [31].  
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 The equine dermal fibroblast line NBL6 (ATCC, Manassas, VA) was cultured in standard 
medium, consisting of DMEM supplemented with 10% FBS and 1x P/S, and maintained at 37°C 
with 5% CO2. 
Bacterial cultures 
 Escherichia coli (E. coli) 10536 and Staphylococcus aureus (S. aureus) 25923 (ATCC) 
colonies were maintained on Luria-Bertani (LB) agar (Life Technologies) plates at 4ºC for up to 
one month. For each experiment, a colony of the appropriate species was picked and used to 
inoculate 4 ml LB broth (Life Technologies), which was incubated on a shaker at 200 rpm, 
overnight at 37ºC, in a warm room with ambient air. Overnight cultures were diluted 1:100 in 4 
ml LB broth and allowed to incubate, shaking at 200 rpm, at 37ºC until cultures reached the 
exponential growth phase, as determined by the absorbance reading of 1 ml culture at 600 nm 
using an Ultraspec 2100 pro spectrophotometer (Amersham Pharmacia, Cambridge, UK). 
Bacteria in the exponential growth phase were used for all experiments, unless stated otherwise.  
MSC-bacterial co-cultures 
 For experiments in which MSC and bacteria were co-cultured in direct contact with each 
other, 150,000 MSC or control NBL6 cells were plated per well in 6 well plates in expansion or 
standard culture medium, respectively. After 24 hours (h), culture medium was removed, cell 
monolayers were rinsed twice with phosphate buffered saline (PBS) and 1 mL DMEM was 
added to wells. Bacteria were added at 1.5 x 106 per well. Control cultures contained bacteria in 
plain DMEM or DMEM with 2x P/S without eukaryotic cells. All cultures were incubated for 6 
h at 37ºC in a warm room with ambient air, while shaking at 100 rpm. The pH of the culture 
medium was measured at the start and end of the incubation period and remained constant at a 
pH of 7.5 throughout the experiments. Culture media and cell monolayers, lysed with 1% 
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saponin (Sigma Aldrich) in distilled water, from each well were transferred to 5 ml tubes, 
vortexed to evenly distribute bacteria, and subsequently diluted in 10-fold dilutions ranging from 
1: 10 to 1: 1,000,000. Three 10 µl drops of each dilution were spotted on LB agar plates and 
allowed to incubate overnight at 37ºC. Bacterial colonies were counted and colony forming units 
(CFU) per ml were calculated for each treatment. 
 Transwell experiments were carried out using the same numbers of cells and bacteria as were 
used for the direct contact co-cultures. For these assays, MSC or NBL6 cells were plated in 0.4 
µm transwell inserts (Corning, Oneonta, NY) fitted in 6 well culture plates. Bacteria were added 
to lower chamber, and after incubation for 6 h at 37ºC while shaking at 100 rpm, in a warm room 
with ambient air, culture medium from the lower chamber was collected for assessment of live 
bacteria, as described above.   
Conditioned medium (CM) collection and treatments 
 CM was collected from MSC and NBL6 cells after 2 days of culture, when cells were 70% 
confluent. To this end, 6 x 105 cells were seeded in a T75 flask with expansion medium. After 24 
h, medium was removed, cell monolayers were rinsed twice with PBS, and 8 ml DMEM were 
added. Medium was collected 24 h later, centrifuged twice for 7 min at 300 x g to remove 
cellular debris, and used for subsequent experiments.  
 Experiments were also performed with equine MSC CM that was treated as follows: To 
inactivate large secreted proteins, CM was heat inactivated at 80ºC for 30 min or treated with 1 
U/ml proteinase K (Qiagen, Valencia, CA) for 6 h at 37 ºC before use. To determine if the active 
factors responsible for the antibacterial effects of MSC CM are biologically stable, CM was 
frozen and thawed, or lyophilized and reconstituted before being used in assays.  To determine 
the active sub fraction of the CM responsible for inhibiting bacterial growth, CM was filtered 
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using Amicon Ultra-15 centrifugal filters (EMD Millipore, Darmstadt, Germany), as per 
manufacturer’s instructions, and individual fractions containing secreted factors of specific 
molecular weights were used for subsequent experiments. To confirm the bioactive roles of 
identified AMP, CM was incubated with primary rabbit monoclonal antibodies (Ab) against 
cystatin C (clone EPR4413) or rabbit polyclonal Ab against elafin, lipocalin 2, cathelicidin 
(Abcam, Cambridge, MA), combined equally for a final concentration of 4 µg/ml, for 1 h prior 
to the start of the experiments. CM incubated with 4 µg/ml rabbit IgG (Abcam) was used as a 
control.  
CM-bacterial co-cultures 
 CM collected as described above, was diluted 1:2 in LB broth for a total volume of 200 µl 
and plated in triplicate wells of 96 well plates. 500 bacteria were added per well. Plates were 
incubated shaking at 100 rpm at 37ºC, in a warm room with ambient air, for 8 h and 16 h for E. 
coli and S. aureus, respectively. Wells containing DMEM diluted 1:2 in LB (negative control) 
and DMEM diluted 1:2 in LB with 2x P/S (positive control) were also included. For the first 
experiment, the absorbance of the cultures was read using a 96 well Multiskan EX plate reader 
(Thermo Fisher Scientific, Waltham, MA) at 600 nm and relative bacterial growth was 
calculated by comparing the absorbance of the CM wells or antibiotic positive control wells to 
the absorbance of the DMEM negative control wells. In addition, medium from each well was 
transferred to 1.5 ml tubes, vortexed to evenly distribute bacteria, and subsequently diluted in 10-
fold dilutions, spotted on LB agar plates and allowed to incubate overnight at 37ºC as described 
above. Bacterial colonies were counted and colony forming units (CFU) per ml were calculated 
for each treatment. By comparing the 2 read-outs (CFU and absorbance), we determined that 
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absorbance adequately reflected the CFU results, and used it as the read-out for subsequent CM-
bacterial co-culture assays.  
 A subset of CM co-culture experiments was done using bacterial cultures in the post-
exponential, stationary, growth phase CM. To this end, stationary bacterial cultures were washed 
with PBS, and bacterial pellets containing 1 x 109 CFU E. coli or 1 x 108 CFU S. aureus were 
resuspended in either 12.5 mg/ml polymixin B, 50 mg/ml nisin, or MSC CM. After 1 h at 4°C, 
bacteria were rinsed twice with PBS by centrifugation, diluted in 10-fold dilutions in PBS, 
spotted on LB agar plates and allowed to incubate overnight at 37ºC, as described above. 
Bacterial colonies were counted and CFU per ml were calculated for each condition. 
Biofilm assays 
 Biofilm assays were carried out based on a method described by O’Toole [32]. Briefly, 50 µl 
of equine MSC and NBL6 cell CM was pipetted into triplicate wells of u-bottom microtiter 
plates. DMEM and DMEM with 2x P/S were included as negative and positive controls, 
respectively. An equal volume of bacteria from cultures in the exponential growth phase was 
added to each well, and plates were incubated for 72 h to allow for biofilm formation. E. coli 
biofilms were grown at room temperature, S. aureus biofilms were grown at 37°C, in a warm 
room with ambient air. At 24 and 48 h, 50 µl CM or control medium was added to appropriate 
wells. After 72 h, medium was removed from wells and wells were rinsed 2 x with distilled 
water. E. coli biofilms were stained with 2.5% safranin and S. aureus biofilms were stained with 
0.1% crystal violet for 10 min, after which stains were removed by rinsing biofilms twice with 
distilled water and allowed to air dry. Dye retained in biofilms was then solubilized using 30% 
acetic acid and transferred to wells of 96-well flat bottom microtiter plates. Absorbance of 
solubilized dye was measured at 550 nm on an Infinite 200 pro plate reader. 
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Bacterial membrane depolarization assays 
 In brief, CM was added to an equal volume of DMEM in the first column of wells in a 96 
well microtiter plate and titered in 1:2 dilutions in DMEM. One-N-phenylaphthylamine (NPN) 
(Sigma Aldrich) was added to each well for a final concentration of 10 µm, and 50 µl of bacteria 
from cultures in the exponential growth phase were added. Plates were analyzed immediately in 
an Infinite 200 pro plate reader (Tecan, Morrisville, NC) using an excitation of 355 nm and 
emission of 444 nm.    
Antibody arrays 
 A human proteome profiler antibody array, previously shown to cross-react with horse 
proteins [31, 33] was used, as per manufacturer’s instructions (R&D Systems, Minneapolis, 
MN), to screen CM from equine MSC and equine dermal fibroblasts for the presence of AMPs. 
Positive signals were visualized using the ChemiDoc MP Imaging system (Bio-Rad, Hercules, 
CA), normalized to the background, and data were quantified by measuring the sum of the 
intensities of the pixels within the spot boundary pixel area using image analysis software (Image 
Laboratory 4.1; Bio- Rad).  
Reverse transcription-polymerase chain reaction (RT-PCR) 
 RNA was extracted from cells using an RNeasy Mini Plus kit (Qiagen) and cDNA was 
synthesized using M-MLV Reverse Transcriptase (USB, Cleveland, OH), per manufacturers’ 
protocols. Primers were designed using Primer3 software, based on sequences found in the 
National Center of Biotechnology Information (NCBI) GenBank, and where possible, primer 
sets spanned an intronic region to prevent amplification of genomic DNA (Table 5.1). RT-PCR 
using Taq DNA Polymerase (Life Technologies) was performed to amplify the AMP genes 
cystatin C (CST3), elafin (PI3), lipocalin 2 (LCN2), cathelicidin (CAMP) and beta defensin 2 
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(DEFB4A). Beta-2-microglobulin (β2M) was included as a reference gene. PCR products were 
run on a 1.5% agarose gel containing GelRed intercalating dye (Thermo Fisher Scientific) at 97 
V for 1 h and gels were imaged on a BioRad ChemiDoc MP system (BioRad). Band intensities 
were measured using BioRad Image Lab software and the intensities of the AMP gene bands 
were divided by the intensity of reference gene bands, to calculate relative band intensities.  
Table 5.1. Primers used for RT-PCR. 
 
Western blot and immunocytochemistry (ICC) analyses 
 Western blot analyses were performed, exactly as previously described [26], using the same 
Ab that were used to block AMP activity in MSC CM, diluted 1:500, followed by HRP-
conjugated goat anti rabbit secondary Ab (Jackson ImmunoResearch Labs, West Grove, PA), 
diluted 1: 20,000.  
 ICC was performed, exactly as previously described [34], using the same Ab that were used 
to block AMP activity in MSC CM, diluted 1:100, followed by HRP-conjugated goat anti rabbit 
secondary Ab, diluted 1: 100.  
Statistical analyses 
 The student’s t-test for unpaired data was used to test for statistically significant differences 
in relative bacterial growth (filtration experiments), and relative band intensities (RT-PCR and 
Western blot analyses). When multiple t-tests were performed on a single response variable 
Gene Product Abbreviation Forward primer (5’-3’) Reverse primer (5’-3’) 
Cystatin C CST3 TTTCCTGTCACCGTACAGC GCACAATGTCCGTGGTGAA 
Elafin PI3 GAGAAGGCTGAGTGCCAGAG ACCAGCGAAATCATCTCCAG 
Lipocalin 2 LCN2 TCAAGGATGACCAGTTCCAG CCTTCCTGAAGAACACGATG 
Cathelicidin CAMP GGGTAGATGGTCACTGTTGC AGCCCATTCTCCTTGAAGTC 
Beta Defensin 2 DEFB4A CGTTCCTCGTTGTCTTCCT CACAGGTGCCAATCTGTTTC 
Beta-2-
Microglobulin 
B2M GGGCTACTCTCCCTGACTGG TACCTGCCCACACAGGTCAA 
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within an experiment, the Holm-Šídák method was used to counteract the problems associated 
with multiple comparisons. One-way ANOVA, followed by the Tukey’s multiple comparison 
test was used to determine statistically significant differences in bacterial viability (co-culture 
experiments, CM experiments and bactericidal vs bacteriostatic effects of MSC CM 
experiments), relative growth (biofilm, CM experiments excluding filtration experiments, 
antibody blocking experiments and NPN experiments, excluding filtration experiments. 
GraphPad software was used for analysis. Data given are the mean of 3 replicates and the bars 
show standard deviations.  
5.4. Results 
Equine mesenchymal stromal cells (MSC) inhibit bacterial growth via paracrine signaling 
 To begin assessing the antimicrobial potential of equine MSC, we designed in vitro 
experiments to determine if MSC can inhibit the growth of representative gram positive and 
negative bacteria, E. coli and S. aureus, respectively, that are commonly found in cutaneous 
wounds. Plain medium (DMEM) and antibiotics were included as negative and positive controls, 
respectively, and experiments were also performed with the equine dermal fibroblast cell line 
NBL6, since skin fibroblasts are known to secrete antimicrobial compounds [35-37]. 
 When culturing bacteria in direct contact with equine MSC for 6 hours, like experiments 
previously carried out by Sung et al. with human MSC [38], we found that the growth of both 
bacterial species was significantly inhibited when compared to DMEM (Figure 5.1A). Based on 
these encouraging results, we repeated these experiments with equine MSC cultured in transwell 
inserts to determine if the observed inhibition of bacterial growth was dependent on direct cell-
to-cell contact. Equine MSC cultured in transwell inserts were still capable of effectively 
inhibiting the growth of bacteria within the time frame of the experiment (Figure 5.1B), 
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indicating that the observed effects are at least in part mediated by factors secreted by equine 
MSC, similar to what has been reported for human MSC [27,38]. To determine whether equine 
MSC constitutively secrete factors with antimicrobial properties or if secretion is induced upon 
bacterial sensing, we cultured bacteria in conditioned medium (CM) collected from MSC and 
found that the relative bacterial growth, as assessed by CFU after 8 h for E. coli, and after 16 h 
for S. aureus, was significantly inhibited in the presence of MSC CM when compared to DMEM 
(Figure 5.1C(i)). These results were directly compared to an alternative read-out for bacterial 
growth inhibition, namely the measurement of absorbance of bacterial cultures at 600 nm using a 
spectrophotometer. Although these two read-outs are not 100% similar (CFU/ml detects only 
live bacteria within a culture, while absorbance detects all bacteria that grew in the culture 
regardless of their viability at the time of measurement), the results obtained with absorbance 
reading reflected the results obtained by calculating CFU/ml (Figure 5.1C(ii)). Since absorbance 
measurements are less time-consuming and allowed us to perform more technical replicates 
within each experiment, we decided to use absorbance as a read-out for subsequent CM 
experiments. 
 When comparing the results obtained with the equine MSC to the results obtained with the 
positive antibiotic control (Abx) and the NBL6 cells, we found that the levels of bacterial growth 
inhibition were not statistically different from the positive antibiotic control or NBL6 cells when 
we used CFU/ml as a read-out, except that fewer CFU/ml E. coli were detected when cultured in 
MSC CM as compared to NBL6 CM (Figure 5.1A, B &C). When using relative growth as a read 
out, the results suggest that the levels of bacterial growth inhibition caused by equine MSC CM 
are situated between the levels of inhibition obtained by Abx and NBL6 cells (Figure 5.1C). This 
may reflect the mechanism by which MSC secreted factors inhibit bacterial growth. 
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 Taken together, these results show that equine MSC secrete factors that effectively inhibit the 
growth of both E. coli and S. aureus, to levels comparable or even greater than those observed 
with antibiotics or dermal fibroblasts.  
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Figure 5.1. Equine mesenchymal stromal cells (MSC) inhibit bacterial growth. A. CFU per 
ml of E. coli (left panel) and S. aureus (right panel) following culture with DMEM, DMEM with 
antibiotics (Abx), MSC or NBL6 cells. B. CFU per ml of E. coli (left panel) and S. aureus (right 
panel) following culture with DMEM, DMEM with antibiotics, MSC or NBL6 cells using 
transwell inserts. B. CFU per ml (i) and relative growth based on absorbance readings at 600 nm 
(ii) of E. coli (left panels) and S. aureus (right panels). Cultures were grown in DMEM, DMEM 
with antibiotics, MSC CM or NBL6 CM each diluted 1:2 in LB broth. Different letters indicate 
statistically significant (P < 0.05) differences.  
 
Equine MSC secrete factors that inhibit bacterial biofilm formation  
  Because biofilms contribute to the inhibition of cutaneous wound healing [39,7] we assessed 
the effect of equine MSC CM on biofilm formation using an in vitro biofilm assay established by 
O’Toole [32]. Again, equine MSC CM significantly reduced the growth of both E. coli and S. 
aureus biofilms, to an extent that was virtually identical to that observed with the antibiotic 
control for both types of bacteria, and to levels that differed significantly from NBL6 CM for S. 
aureus (Figure 5.2). 
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Figure 5.2. Equine mesenchymal stromal cells (MSC) constitutively secrete factors that 
inhibit bacterial biofilm formation. Relative growth of E. coli (left panel) and S. aureus (right 
panel) biofilms grown in DMEM, DMEM with Abx, MSC CM or NBL6 CM. Representative 
images of dye taken up by biofilms are shown below graphs. Different letters indicate 
statistically significant (P < 0.05) differences. n = 3.  
 
Equine MSC secrete stable, low molecular weight molecules that inhibit bacterial growth  
 To determine the characteristics of the bioactive factors with antimicrobial properties 
secreted by equine MSC, the following set of experiments was performed. First, we used boiling 
(heat inactivation = HI) and proteinase K treatment (PK) to inactive large proteins in the MSC 
CM, and compared the levels of bacterial growth inhibition to those obtained with untreated 
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MSC CM. We found that HI CM still significantly inhibited the growth of both types of bacteria 
when compared to medium control, more specifically to levels indistinguishable from those 
obtained with the same MSC CM that was left untreated (Figure 5.3A). Similar results were 
observed for the PK treated CM, although the growth inhibition of E. coli was not as robust 
when compared to the untreated CM (Figure 3A). Next, we froze and thawed, as well as 
lyophilized and reconstituted, CM before its use in the bacterial assays in order to determine the 
stability of the active factors. We observed that neither freezing nor lyophilizing significantly 
altered the growth inhibitory effects of CM on either bacterial species tested, as compared to 
fresh CM (Figure 5.3B). Finally, we filtered the MSC CM to obtain sub fractions containing 
secreted factors of specific sizes and found that secreted factors of less than 10 kDa and less than 
30 kDa significantly inhibited the growth of E. coli and S. aureus, respectively (dotted lines, 
Figure 5.3C).  
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Figure 5.3. Equine mesenchymal stromal cells (MSC) secrete stable, low molecular weight 
factors that inhibit bacterial growth. A. Relative growth of E. coli (left panel) and S. aureus 
(right panel) based on absorbance readings at 600 nm. Cultures were grown in DMEM, MSC 
CM, heat inactivated MSC CM (HI) or proteinase K treated CM (PK) each diluted 1:2 in LB 
broth. B. Relative growth of E. coli (left panel) and S. aureus (right panel) based on absorbance 
readings at 600 nm. Cultures were grown in DMEM, MSC CM, frozen-thawed MSC CM (FT) or 
lyophilized-reconstituted CM (Lyoph) each diluted 1:2 in LB broth. C. Relative growth of E. coli 
(left panel) and S. aureus (right panel) based on absorbance readings at 600 nm. Cultures were 
grown in DMEM, MSC CM, and MSC CM fractioned by size of secreted factors. Different 
letters indicate statistically significant (P < 0.05) differences. n = 3. 
 
Equine MSC secrete factors that depolarize bacterial cell membranes, but do not appear to 
immediately kill bacteria 
 In parallel, we decided to evaluate whether the observed MSC CM-mediated bacterial growth 
inhibition is caused by a membrane depolarizing mechanism. To this end, we exposed bacteria to 
MSC CM in the presence of 1-N-phenylaphthylamine (NPN), a compound that is excluded by 
intact outer membranes of bacteria but taken up into the hydrophobic interior of outer 
membranes that have been depolarized. Consequently, a strong fluorescent NPN signal is 
correlated with disrupted bacterial membranes [40,41]. The results from these experiments 
demonstrated that the equine MSC CM causes membrane depolarization of E. coli as well as S. 
aureus (i) in a concentration-dependent manner and (ii) to degrees similar to Abx known to 
depolarize gram negative and gram-positive bacterial membranes; polymixin B and nisin, 
respectively (Figure 5.4A). Since polymixin B and nisin are bactericidal by killing bacteria 
shortly after contact [42,43], we decided to evaluate whether the observed equine MSC CM-
mediated bacterial membrane damage resulted in similar immediate killing of bacteria. To this 
end, we directly compared the number of viable bacteria after CM treatment to the numbers 
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obtained after exposure to these two bactericidal Abx. Based on the difference in number of 
bacteria between these two types of treatments, with both bactericidal Abx resulting in 
significantly lower CFU/ml (P < 0.05, Figure 5.4B), we concluded that treatment of stationary, 
non-dividing bacteria with equine MSC CM did not immediately kill bacteria to the same extent 
as the bactericidal control compounds. 
 We then repeated the NPN experiments with the different CM sub fractions and found that E. 
coli exposed to MSC secreted factors greater than 10 kDa took up more NPN than E. coli 
exposed to MSC secreted factors smaller than 10 kDa, indicating that the bioactive factors that 
depolarize E. coli membranes are most likely 10 kDa or greater in size (dotted line, Figure 5.4C). 
Likewise, S. aureus exposed to MSC secreted factors greater than 30 kDa took up more NPN 
than S. aureus exposed to MSC secreted factors smaller than 30 kDa, indicating that the 
bioactive factors that depolarize S. aureus membranes are most likely 30 kDa or greater in size 
(dotted line, Figure 5.3C).  
  Collectively, these data indicate that equine MSC secrete a variety of bioactive factors of 
different sizes that affect bacteria by various modes-of-action, including membrane 
depolarization. 
  201 
 
  202 
Figure 5.4. Equine mesenchymal stromal cells (MSC) secrete factors that depolarize 
bacterial cell membranes, but do not cause immediate cell death. A. Incorporation of NPN 
into depolarized E. coli membranes (left panel) and S. aureus membranes (right panel) treated 
with MSC CM compared to high concentrations of compounds known to depolarize bacterial 
cell membranes. B. CFU per ml of E. coli (left panel) and S. aureus (right panel) following 
culture at 4oC with bactericidal compounds polymixin B (PMB), nisin or MSC CM. *: P < 0.05 
C. NPN incorporation by depolarized E. coli (left panel) and S. aureus (right panel) membranes 
as measured by fluorescent emission at 444 nm. Bacteria were treated with DMEM, MSC CM, 
and MSC CM fractioned by size of secreted factors. Different letters indicate statistically 
significant (P < 0.05) differences. n = 3. 
 
Equine MSC secrete antimicrobial peptides (AMPs) 
 Since AMPs are a class of low molecular weight molecules known to directly kill bacteria by 
forming pores in bacterial membranes [13,14], we decided to evaluate the secretion of AMPs by 
equine MSC. We preliminarily screened the equine MSC CM, and a control dermal fibroblast 
CM for the presence of AMPs using a human proteome profiler array, which can detect the 
relative levels of over 100 proteins simultaneously (n=1). The expression of three AMPs, namely 
cystatin C, elafin, and lipocalin 2, were readily detected in MSC CM, at higher levels than in the 
control CM (Figure 5.5A). The expression of these AMPs, as well as the expression of 
cathelicidin and beta defensin 2 (the most common mammalian AMPs, both of which have 
previously been described in the horse [12,44]), was then evaluated in the 3 equine MSC cultures 
that were used for the bacterial assays by RT-PCR using primers that had previously been 
confirmed by our lab to amplify products of the appropriate lengths in horse cells. Except for the 
gene DEFB4A (encoding beta defensin 2), expression of the AMP transcripts CST3, PI1, LCN2 
and CAMP (encoding cystatin C, elafin, lipocalin and cathelicidin, respectively) could be 
detected (Figure 5.5B). Next, western blot analyses as well as immunocytochemistry (ICC) were 
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performed to confirm protein expression of those AMPs that were detected on a mRNA level 
(Figure 5.5C&D). For comparison, we also performed RT-PCR and Western blot analyses on 
NBL6 cells and found that whereas these cells showed similar expression levels of CST3, PI1, 
LCN2 and CAMP transcripts (Figure 5.5B), the expression of the corresponding proteins cystatin 
C, elafin, lipocalin and cathelicidin, was significantly lower in NBL6 compared to MSC cultures 
(Figure 5.5C). This nicely corresponded with the original preliminary screening of dermal 
fibroblast CM using the human proteome profiler array (Figure 5.5A). 
 
Figure 5.5. Equine mesenchymal stromal cells (MSC) express at least four antimicrobial 
peptides (AMP). A. Detection of three AMPs in MSC CM and control CM as detected by a 
commercially available antibody array. n = 1. B.  (i) Relative band densities of five AMP 
transcripts in equine MSC and NBL6 compared to the reference transcript B2M as detected by 
RT-PCR. (ii) Representative images of PCR products run on agarose gels. Lane 1 = molecular 
weight marker, Lanes 2, 3 and 4 = equine MSC derived from 3 different horses, Lane 4 = NBL6. 
C. (i) Relative band densities of four AMPs in equine MSC and NBL6 compared to the reference 
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protein β-actin as detected by Western blot. (ii) Representative images of protein lysates run on 
polyacrylamide gels, transferred to PVDF membranes and probed with anti-AMP antibodies.  
Lane 1 = molecular weight marker, Lanes 2, 3 and 4 = equine MSC derived from 3 different 
horses, Lane 4 = NBL6. D.  Images of equine MSC labeled with four anti-AMP antibodies (red). 
Scale bars = 10 µm, *: P < 0.05, n = 3. 
 
The ability of equine MSC to inhibit bacterial growth and induce bacterial membrane damage is 
greatly reduced by pretreatment of CM with anti-AMP antibodies 
 To provide a link between the AMPs detected in equine MSC and the observed antimicrobial 
effects of the MSC CM, we repeated the bacterial growth inhibition assays using MSC CM that 
was pretreated with antibodies against these AMPs. Although we found that anti-AMP antibody-
pretreated CM still reduced bacterial growth significantly when compared to the DMEM control 
(Figure 5.6A), the bacterial growth inhibition by pretreated CM was significantly lower 
compared to untreated MSC CM or CM pretreated with isotype control antibodies (Figure 5.6A). 
This suggests that cystatin C, elafin, lipocalin and/or cathelicidin are involved in, but not solely 
responsible for, the MSC CM-mediated growth inhibition of E. coli and S. aureus. We then 
corroborated these results by repeating the NPN experiments using antibody-pretreated MSC 
CM. A significant difference in E. coli membrane depolarization was observed compared to the 
DMEM control that was significantly less pronounced than the effects of untreated MSC CM or 
CM pretreated with isotype control antibodies (Figure 5.6B (i&ii)). Interestingly, no significant 
difference in the membrane depolarization of S. aureus was observed between the antibody-
pretreated MSC CM and untreated MSC CM or CM pretreated with isotype control antibodies, 
indicating that MSC secreted factors other than cystatin C, elafin, lipocalin or cathelicidin, are 
responsible for the membrane damage detected in this bacterial species (Figure 5.6B (iii&iv)). 
 Taken together, these results demonstrate that the equine MSC secreted AMPs cystatin C, 
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elafin, lipocalin and cathelicidin, are, at least in part, responsible for the observed growth 
inhibition of E. coli and S. aureus cultured in MSC CM. In addition, these AMPs also contribute 
to the membrane damage detected in E. coli, but not S. aureus. 
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Figure 5.6. Blocking antimicrobial peptide (AMP) activity decreases the effects of 
mesenchymal stromal cell conditioned medium (MSC CM) on bacteria. A.  Relative growth 
of E. coli (left panel) and S. aureus (right panel) based on absorbance readings at 600 nm. 
Cultures were grown in DMEM, MSC CM, MSC CM pre-incubated with anti-AMP antibodies 
or MSC CM pre-incubated with an isotype control antibody, each diluted 1:2 in LB broth. B. 
Incorporation of NPN into depolarized E. coli and S. aureus membranes in the presence of 
decreasing concentrations of DMEM, MSC CM, MSC CM pre-incubated with anti-AMP 
antibodies or MSC CM pre-incubated with an isotype control antibody as measured by 
fluorescent emission at 444 nm (i & iii). Emission values from E. coli and S. aureus with 
treatments diluted 1:2 (ii & iv). Different letters indicate statistically significant (P < 0.05) 
differences. n = 3. 
 
5.5. Discussion 
 This study is the first to demonstrate that equine mesenchymal stromal cells (MSC) possess 
antibacterial properties by showing that MSC inhibit the growth of E. coli and S. aureus and 
depolarize the membranes of these bacteria in vitro. Moreover, this study describes the presence 
of four distinct antimicrobial peptides (AMPs) in the equine MSC secretome, namely cystatin C, 
elafin, lipocalin 2, and cathelicidin, and demonstrates that these AMPs are at least partially 
responsible for the antimicrobial effects of MSC. 
 The MSC-produced AMPs identified in this study represent several classes of antimicrobial 
compounds, some of which have been documented to be produced by MSC from other sources 
and species. Cystatin C has a mode-of-action that has not been fully elucidated to date but has 
been identified as a secreted product of both murine bone marrow-derived and human adipose 
tissue-derived MSC [45,46]. Lipocalin 2 limits bacterial growth by sequestering iron-containing 
siderophores and has been identified in the secretome of mouse bone marrow-derived MSC [47]. 
Cathelicidin is a cationic a that kills bacteria directly by disrupting membrane polarization and 
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produces a cleavage product (LL-37) that has previously been described as a secreted product of 
human bone marrow-derived MSC [27,48]. Elafin is known to kill bacteria by disrupting the 
membrane integrity. To our knowledge, elafin has not been reported as a product of MSC, so this 
study is the first to report on the production of this AMP by MSC.  
 Besides these four AMPs, we also evaluated the presence of beta defensin 2 in equine MSC 
since this AMP (i) has been described to be secreted by human umbilical cord-derived MSC 
[49,38] and (ii) belongs to a ubiquitous family of AMPs that are found in most mammals, 
including horses [50,44]. However, and to our surprise, we could not detect beta defensin 2 in 
equine MSC. This was not due to an improperly functioning of the PCR primers, as we have 
used the same primers to confirm expression of this AMP transcript in equine keratinocytes (data 
not shown). To identify the complete spectrum of equine MSC-derived AMPs, we plan to use a 
more unbiased and global approach (e.g. liquid chromatography–mass spectrometry (LC-
MS/MS)) in future experiments. 
 The bacterial growth inhibition and biofilm assays were run in parallel with an equine dermal 
fibroblast cell line, based on the knowledge that the skin of most mammals produces AMPs 
[50,51] and AMP mRNA and proteins have been identified in horse skin [44]. As expected, we 
found that equine dermal fibroblasts inhibit bacterial growth and produce specific AMPs. To the 
best of our knowledge, the AMP production by horse skin fibroblasts had not been evaluated 
previously. Interestingly, the expression of AMPs by the horse dermal fibroblast cell line NBL6 
was not equivalent to that of equine MSC, with equine MSC producing higher levels of cystatin 
C, elafin, lipocalin 2 and cathelicidin. This further emphasizes the therapeutic potential of equine 
MSC in cutaneous wound management, as the administration of MSC or MSC secreted products 
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could supplement AMPs expressed at low levels in the skin, therefore expanding the range of 
AMPs locally present to fight skin infections.  
 Although the results of this study clearly demonstrate that equine MSC have antimicrobial 
properties against both E. coli and S. aureus, there appears to be a difference in the underlying 
mechanisms targeting each species. Based on the CM fractionation experiments, we 
demonstrated that secreted factors less than 10 kDa in size are responsible for the observed 
growth inhibition of E. coli whereas secreted factors less than 30 kDa appear to inhibit the 
growth of S. aureus. Moreover, MSC secreted factors greater than 10 kDa contributed to most 
membrane damage seen in E. coli, whereas secreted factors greater than 30 kDa caused 
membrane damage to S. aureus. And although in the current study, we did not fully investigate 
the exact underlying mechanisms by which equine MSC CM affects different bacteria species, 
our results do clearly show that MSC secreted factors (i) inhibit bacterial growth and (ii) 
depolarize the outer membranes of bacteria. It will be interesting, therefore, to study the effects 
of MSC CM on additional bacterial species commonly found in equine skin wounds, such as the 
gram negative bacteria Pseudomonas aeruginosa and Acinetobacter baumannii, and the gram 
positive Aerococcus viridians, Staphylococcus warneri, and Staphylococcus epidermidis [39], to 
determine whether there are indeed distinct mechanisms used by equine MSC to target gram 
positive versus gram negative bacteria. As most of these bacterial species are also found in 
human skin wounds [52,53], results will be relevant to human as well as veterinary medicine.  
 Since we found that equine MSC secrete a variety of AMPs that appear effective against both 
gram positive and negative bacteria, these cells may serve as a broad-spectrum treatment to 
control bacterial growth and kill bacteria, without leading to resistance. Work by other groups 
has shown that in addition to controlling bacteria, AMPs and other host defense peptides directly 
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contribute to wound healing by inducing cell migration and proliferation, promoting 
angiogenesis, and in general, accelerating the healing process [54]. This dual-function of 
peptides to promote wound healing, combined with the ease and low cost of isolating MSC and 
collecting CM, makes MSC CM an ideal biological source for naturally-occurring peptides as 
well as other factors that promote wound healing. Our data indicating that equine MSC CM can 
be lyophilized and still retain anti-bacterial activity suggest that using MSC CM therapeutically 
may be practical as well, providing a stable, off-the-shelf product for clinical use.  
 Taken together, our group focuses on the potential of equine MSC to be used as a therapy for 
skin wounds and the data generated in this study suggests that in addition to positively affecting 
resident skin cells, as we have demonstrated previously [31,25,26], equine MSC may also 
improve cutaneous wound healing by reducing the bacterial load in wounds. Next, we intend to 
evaluate the efficacy of equine MSC in vivo by assessing how these cells promote skin wound 
healing and affect bacterial burden, in both acute and chronic wounds.  
5.6. Conclusions 
 Mesenchymal stromal cells (MSC) have been reported to provide paracrine signals that 
promote cutaneous wound healing, but (i) the effects of equine MSC on the growth of gram 
negative and gram-positive bacterial species commonly found in skin wounds and (ii) the 
mechanisms by which equine MSC inhibit bacterial growth had not been explored thus far. The 
present study is the first to show that equine MSC possess antimicrobial properties by inhibiting 
the growth of E. coli and S. aureus, in part by secreting antimicrobial peptides (AMPs) and 
depolarizing bacterial cell membranes. This antibacterial activity may contribute to the value of 
MSC as a therapy for chronic cutaneous wounds in both horses and humans, where colonization 
by pathogenic bacteria commonly inhibits normal healing. 
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CHAPTER SIX: PLASMINOGEN ACTIVATOR INHIBITOR-1 AND TENASCIN-C 
SECRETED BY EQUINE MESENCHYMAL STROMAL CELLS STIMULATE 
DERMAL FIBRBLAST MIGRATION IN VITRO AND CONTRIBUTE TO WOUND 
HEALING IN VIVO 
 
 
 
 
 
 
 
 
 
The results of this study were published in Harman RM, He MK, Zhang S, Van De Walle GR. 
Plasminogen activator inhibitor-1 and tenascin-C secreted by equine mesenchymal stromal cells 
stimulate dermal fibroblast migration in vitro and contribute to wound healing in vivo. 
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6.1. Summary 
 Impaired cutaneous wound healing is common in humans, and treatments are often ineffective. 
Based on the significant emotional and economic burden of impaired wound healing, innovative 
therapies are needed. The potential of mesenchymal stromal cell (MSC) secreted factors to treat 
cutaneous wounds is an active area of research that is in need of refinement before effective clinical 
trials can be initiated. The aims of the present study were to (i) study which MSC secreted factors 
stimulate dermal fibroblast (DF) migration in vitro and (ii) evaluate the potential of these factors 
to promote wound healing in vivo.  
 To this end, MSC were isolated from the peripheral blood of healthy horses, a physiologically 
relevant large animal model appropriate for translational wound healing studies. Conditioned 
medium (CM) from cultured equine MSC was analyzed by liquid chromatography-mass 
spectrophotometry (LC-MS/MS) to identify secreted proteins of interest. Double-stranded RNA-
mediated interference (RNAi) was used to silence the genes encoding selected proteins, and the 
effects of CM from these transfected MSC on migration of cultured equine DF cells in vitro and 
full-thickness wounds in mice were evaluated.  
 We found that MSC-derived plasminogen activator inhibitor-1 (PAI-1) and tenascin-C 
significantly increased DF migration in vitro and improved wound healing in vivo by decreasing 
time to wound closure.  
 These results suggest that in a complex wound environment, MSC-secreted factors PAI-1 and 
tenascin-C contribute to the positive effect of therapeutically applied MSC CM on wound healing. 
6.2. Introduction 
 Yearly, more than 11 million people in the United States are impacted by acute wounds [1]. 
When the healing of these wounds is compromised, affected patients may suffer physical and 
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emotionally, and an economic strain may be put on individuals as well as the health care system. 
The prevalence rate of chronic non-healing wounds in wealthy countries is 1-2 percent of the 
population [2]. In the United States alone, 5.7 million patients are affected by chronic wounds 
annually, at an estimated cost of $20 billion [3, 4].  
 The complexity of the cutaneous wound healing process contributes to difficulties in executing 
successful treatment protocols when natural wound healing is not adequate. It is now well-
established that healing of skin wounds is far more involved than the traditional description of the 
4 phases of wound healing implies. Indeed, each of the “phases” (hemostasis, inflammation, 
proliferation, and remodeling) is comprised of interdependent events involving resident skin cells, 
migrating immune cells, extracellular matrix components, as well as the growth factors, cytokines 
and chemokines released by cells and the supportive environment [5]. Consequently, the events 
required for successful wound healing are a continuous cascade that is initiated by wounding and 
continues until long after wound closure is achieved [6]. Standard treatments for cutaneous wounds 
aim to improve the wound bed by keeping it moist, free of pathogens, and adding or removing 
pressure, depending on the type of wound [7]. In recent years, there has been an effort to 
incorporate more sophisticated treatment strategies based on what has been learned about cellular 
responses to injury, such as the administration of platelet-derived growth factor, vascular 
endothelial growth factor and fibroblast growth factor to wounds. However, malignancy risks 
associated with adding recombinant growth factors to cutaneous wounds have been recognized, 
and these therapies have not yet been fine-tuned for clinical use [8]. Hyperbaric oxygen therapy, 
which consists of breathing pure oxygen while in a total body chamber where pressure is 
controlled, is also being studied as a method to positively influence cells involved in wound healing 
by altering clotting, cell proliferation, angiogenesis and tissue repair [9]. Although there are few 
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negative side effects to this therapy, it is currently not widely used as the equipment and technical 
expertise needed to provide it are not universally available, and long-term positive results are not 
well documented [9, 10]. 
 Stem cell therapies may be used to augment the natural events required for successful wound 
healing, while avoiding the side effects associated with administering recombinant growth factors 
and the limits associated with a technology-heavy procedure like hyperbaric oxygen therapy [11]. 
Mesenchymal stromal cells (MSC) are adult, multipotent progenitor cells that can be isolated 
easily from a variety of adult tissues and readily expanded in culture [12]. These cells actively 
secrete a rich composite of bioactive factors that may prove to be a safe, easy-to-deliver therapy 
to improve tissue repair [13]. Our laboratory studies MSC isolated from the peripheral blood of 
horses, a physiologically relevant large animal model appropriate for translational wound healing 
studies [14, 15]. We have used in vitro assays to demonstrate that equine MSC secreted factors act 
on target cell types present in the skin in ways that suggest they may promote cutaneous wound 
healing in vivo. For example, we demonstrated that equine MSC secrete cytokines and chemokines 
that promote endothelial cells to form vessel-like structures [16], as well as antimicrobial peptides 
that inhibit the growth of bacterial commonly found in skin wounds [17]. We also found that 
conditioned medium (CM) from equine MSC cultures stimulates dermal fibroblast (DF) migration 
[18], although the bioactive factors responsible for this effect were not identified. 
 The aims of the present study were to determine (i) which factors secreted by equine MSC 
promote DF migration in vitro and (ii) if these factors also contribute to cutaneous wound healing 
in vivo. We identified MSC-derived plasminogen activator inhibitor-1 (PAI-1) and tenascin-C as 
stimulators of DF migration in vitro. Moreover, using a murine full thickness wound model, we 
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demonstrated that the presence of these proteins in MSC CM decreased time to wound closure in 
vivo. 
6.3. Methods 
Cell isolation and culture 
 Equine MSC were isolated from the peripheral blood of 3 healthy warmblood mares between 
8 and 12 years old and cultured exactly as we described previously [19]. Blood collection was 
approved by the Cornell Institutional Animal Care and Use Committee (IACUC # 2014-0038). 
The equine and murine cell lines NBL6 and NIH3T3 (ATCC, Manassas, VA), respectively, were 
cultured in standard medium consisting of Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1x penicillin-streptomyin and maintained at 37°C 
with 5% CO2. 
CM collection and treatments 
 CM from untransfected MSC, NBL6 and NIH3T3 cells was collected after 2 days of culture, 
when cells were 70% confluent, as described previously [18]. CM from cells transfected with small 
interfering RNA (siRNA) was generated by removing culture medium 24 hours (h) post 
transfection, rinsing monolayers 2x with phosphate buffered saline (PBS), and adding 2 ml DMEM 
per well. CM was collected 24 h later. All in vitro experiments, except mass spectrometry, were 
carried out using the CM from MSC isolated from 3 different horses, with technical replicates as 
described for each assay. 
Experiments were also performed with equine MSC CM that was treated as follows: To inactivate 
large secreted proteins, CM was heat inactivated at 80ºC for 30 min or frozen and thawed before 
use. To determine the active sub fraction of the CM responsible for stimulating fibroblast 
migration, CM was filtered using Amicon Ultra-15 centrifugal filters (EMD Millipore, Darmstadt, 
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Germany), as per manufacturer’s instructions, and individual fractions containing secreted factors 
of specific molecular weights were used for subsequent experiments.  
Extracellular vesicle (EV) isolation and inhibition 
 MSC-derived EV were isolated by centrifugation of CM at 300 xg, 10 min to pellet out cellular 
debris. Supernatant containing EV was transferred to clean tubes and centrifuged first at 2,000 xg 
for 30 min, transferred to clean tubes, and then centrifuged 100,000 xg for 60 min to pellet out EV. 
Supernatant was saved as the EV-free CM fraction, and EV were resuspended in DMEM and 
centrifuged again at 100,000 xg for 60 min. After discarding the supernatant, EV were resuspended 
in 16 ml DMEM, equivalent to the starting volume of CM. To inhibit EV formation by MSC, 10 
µm GW4869 (Sigma Aldrich, St. Louis, MO) was added to MSC cultures during the generation 
of CM. 
Protein identification by Liquid chromatography-mass spectrophotometry (LC-MS/MS) 
 In solution digestion was performed following a protocol by Zhang, with slight 
modification [20]. The protein pellet from 10 mL medium culture was dissolved in 300 µL 
denaturing solution containing 6.0 M guanidine-HCl, and 100 mM PBS pH 7.0, sonicated for 5 
min, centrifuged and supernatant was collected. Repeat above extraction three times and a total 
of 800 µL extracts were incubated at 56 °C for 45 min. The denatured sample was reduced with 
10 mM DTT and alkylated with 55 mM Iodoacetamide for 1hr in dark at room temperature. 
Excess Iodoacetamide was quenched with 30 mM DTT for 30mins at room temperature.  The 
samples were diluted to a final volume of 3,775 µL with 50mM Tris HCL pH 8.0 to reduce the 
Guanidine HCL concentration to less than 1M.  The samples were digested by adding 25 µg 
trypsin (Promega, Madison, WI) and incubated at 37 ºC for 16 hours.   Digestions were stopped 
by the addition of 25 µL TFA.  The digests were further desalted by solid phase extraction using 
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Sep-Pack Cartridge (Waters Corporation, Milford, MA) and the eluted peptides were evaporated 
to dryness by a Speedvac SC110 (Thermo Savant, Milford, MA). The in-solution tryptic digests 
were reconstituted in 20 μL of 0.5% FA for nanoLC-ESI-MS/MS analysis, which was carried out 
using an Orbitrap FusionTM TribridTM (Thermo-Fisher Scientific, San Jose, CA) mass 
spectrometer equipped with a nanospray Flex Ion Source, and coupled with a Dionex 
UltiMate3000RSLCnano system (Thermo, Sunnyvale, CA) as reported previously [21].  The gel 
extracted peptide samples (5 μL) were injected onto a PepMap C-18 RP nano trap column (5 µm, 
100 µm i.d x 20 mm, Dionex) with nanoViper Fittings at 20 µL/min flow rate for  rapid sample 
loading and then separated on a PepMap C-18 RP nano column (3 µm, 75 µm x 25 cm) at 35 °C, 
and eluted in a 90 min gradient of 5% to 35% acetonitrile (ACN) in 0.1% formic acid at 300 
nL/min., followed by a 7 min ramping to 90% ACN-0.1% FA and an 8 min hold at 90% ACN-
0.1% FA. The column was re-equilibrated with 0.1% FA for 25 min prior to the next run.  The 
Orbitrap Fusion is operated in positive ion mode with spray voltage set at 1.6 kV and source 
temperature at 275°C. External calibration for FT, IT and quadrupole mass analyzers was 
performed. In data-dependent acquisition (DDA) analysis, the instrument was operated using FT 
mass analyzer in MS scan to select precursor ions followed by 3 second “Top Speed” data-
dependent CID ion trap MS/MS scans at 1.6 m/z quadrupole isolation for precursor peptides with 
multiple charged ions above a threshold ion count of 10,000 and normalized collision energy of 
30%.  MS survey scans at a resolving power of 120,000 (fwhm at m/z 200), for the mass range of 
m/z 375-1575.  Dynamic exclusion parameters were set at repeat count 1, an exclusion list size 
of 500, 40 s of exclusion duration with ±10 ppm exclusion mass width. The activation time was 
10 ms for CID analysis. All data were acquired under Xcalibur 3.0 operation software (Thermo-
Fisher Scientific). The DDA raw files for CID MS/MS only were subjected to database searches 
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using Proteome Discoverer (PD) 2.2 software (Thermo Fisher Scientific, Bremen, Germany) 
with the Sequest HT algorithm [22].  The MS/MS spectra were searched against a NCBI 
database for Equus_caballus_RefSeq database that contained 30,927 entries. Oxidation of M, 
deamidation of N,Q residues and protein N-terminal acetylation were specified as variable 
modifications; carbamidomethyl C was specified as a static modification. The peptide precursor 
tolerance was set to 10 ppm and fragment ion tolerance was set to 0.6 Da. Only high confidence 
peptides defined by Sequest HT with a 1% FDR by Percolator [23] were considered for the 
peptide identification. The final protein IDs contained protein groups that were filtered with at 
least 2 peptides per protein.  Results were further analyzed using PANTHER [24] and STRING 
software [25]. 
Double-stranded RNA-mediated interference (RNAi)  
 Custom Silencer Select siRNA targeting equine plasminogen activator inhibitor-1 
(SERPINE1) and tenascin-C (TNC) were designed (Ambion, Foster City, CA). Silencer Select 
Negative Control #2 siRNA (Ambion) was confirmed to not have complementarity to any equine 
genes using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and was used as a non-specific 
(scramble) control. For RNAi, 3 x 105 MSC were seeded per well in a 6 well plate, and 
Lipfofectamine RNAiMAX Reagant (Invitrogen, Carlsbad, CA, USA) was used to transfect cells 
following manufacturer’s protocol.  
Viability assays 
 To assess cell viability, 3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) 
and lactate dehydrogenase (LDH)-based in vitro toxicology assays (Sigma Aldrich) were carried 
out as we previously described [19, 17]. Absorbance was measured on a Multiskan EX plate reader 
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using Ascent software (Thermo Fisher Scientific). Triplicate wells were assessed for each 
condition tested.  
Reverse transcription-polymerase chain reaction (RT-PCR) 
 SYBR green-based quantitative RT-PCR was performed to determine fold change in 
SERPINE1 and TNC transcripts, and data were analyzed, as previously described [26, 27]. The 
previously validated reference gene beta-2-Microglobulin (B2M) was used to normalize samples 
[28] and all samples were run in triplicate. Semi-quantitative RT-PCR using Taq DNA 
Polymerase (Life Technologies) was performed to amplify genes for cell surface receptors of 
PAI-1 and tenascin-C; integrin alpha-5 (ITGA5), integrin beta-1 (ITGB1), urokinase receptor 
(uPAR), annexin II (Annexin II), epidermal growth factor receptor (EGFR), integrin subunit 
alpha V (ITGAV) and integrin beta-3 (ITGB). Primers are shown in Table 6.1.  
Table 6.1. Primers used for RT-PCR. 
 
 
 
Gene Product Abbreviation Forward primer (5’-3’) Reverse primer (5’-3’) 
integrin alpha-5 ITGA5 TGCTCCTAGGTCTGCTCATC TGGCCCTTCAAGTATGTCTC 
integrin beta-1 ITGB1 CACTGAAGAGGTGGAGGTTG GTGTAGTTGGGGTTGCATTC 
urokinase 
receptor 
uPAR GAATAGGCATGCAGGTCATC TCCCCTCACAGCTGTAACAC 
annexin II Annexin II AGATATTGCCTTCGCCTACC TTCCTCTTCACTCCAGCATC 
epidermal growth 
factor receptor 
EGFR GTACCTCAACACCACCCATC GCCCTTAGGACAGGAGTAGC 
integrin subunit 
alpha-V 
ITGAV TCGACAGGCTCATATTCTCC GCAGCTAAAACAGCAAGGTC 
integrin beta-3 ITGB3 AGGCACTTAACGACAAGCAG CTGAGGACAAAGCTGAGGAG 
plasminogen 
activator 
inhibitor-1 
SERPINE1 CCCTGGAGAGTGAAGTGGAC CCTGCGATACATGGAGAAGC 
tenascin TNC CGGCCAAGTTTGACCATTAC TTCCTGTCCAGGTTCCAGAC 
beta-2-
microglobulin 
B2M TCTTTCAGCAAGGACTGGTCTTT CATCCACACCATTGGGAGTAAA 
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Western blot (WB) analyses 
 WB were carried out as we previously described [17,28]. CM was collected from culture 
wells seeded with identical numbers of cells, to compare protein levels detected in CM to 
number of cells seeded. Membranes were incubated with rabbit anti-tenascin-C (Millipore) or 
rabbit anti-PAI-1 (Abcam, Cambridge, MA) antibodies (Abs) diluted 1:1000, and then incubated 
with HRP conjugated goat anti-rabbit Abs diluted 1:20;000 (Jackson ImmunoResearch Labs). 
Where appropriate, membranes were probed in parallel with the loading control Abs rabbit anti-
fibronectin (Sigma Aldrich) or rabbit anti-beta actin antibody (Abcam), each diluted 1:1000. 
Blots were visualized by chemiluminescence using Clarity Western ECL (BioRad, Hercules, 
CA), imaged on a BioRad ChemiDoc MP system (BioRad), and band intensities were 
determined using Image Lab software. Intensities of the bands of interest were divided by the 
intensities of loading control bands to calculate relative band intensity. 
Cell migration assays 
 In vitro scratch assays with NBL6 or NIH3T3 cells were performed, exactly as we previously 
described [18]. Photographs of scratches were taken at 0 and 48 h post scratching, and migration 
distances of cells were calculated in a blinded-manner using ImageJ software 
(http://imagej.nih.gov/ij/). Oris cell migration assays were carried out according to the 
manufacturer’s instructions. Reference wells were used to determine the area with no cells at the 
time of stopper removal. For analysis, cells were stained with a crystal violet solution (0.5% crystal 
violet in 20% (v/v) methanol) for 20 min, washed 2x with PBS, and dried overnight. Images of 
wells were captured using an Olympus inverted light microscope and migrated cells were counted 
by a blinded-observer. Numbers of cells migrated from duplicate wells were averaged. 
Cell adhesion assay 
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 Cell adhesion strength was quantitated using a centrifugation assay that applies a controlled 
detachment force [29]. Briefly, DF were seeded in replicate 96-well plates and 24 h later, culture 
medium was removed and replaced with CM for 48 h. Triplicate wells were assessed for each 
condition assayed. The lid from one plate was replaced by microplate adhesive tape, and 
centrifuged inverted at 4,000 x g for 5 min to remove loosely adherent cells. Medium was removed 
from the replicate, non-centrifuged control, plate. All wells were washed once with PBS to remove 
detached cells and stained with a crystal violet as described above. Crystal violet was solubilized 
by adding methanol to each well followed by rocking for 30 min, after which absorbance was 
quantitated spectrophotometrically at 570 nm on a Multiskan EX plate reader. Cell adhesion 
strength was presented as absorbance of the wells on the centrifuged plate relative to the replicate 
control wells. Cells were not seeded in the outer two wells of the 96-well plate and treatment group 
locations were randomized to prevent biasing the adhesion data based on the small changes in 
centrifugal forces present in different locations of the plate.  
Analysis of actin cytoskeleton 
 Actin was labeled using Alexa 647-phalloidin, as we previously described [28]. Cells were 
examined with a Zeiss LSM confocal microscope (Oberkochen, Germany) and images were 
captured with a camera controlled by ZEN imaging software. Anisotropy scores were calculated 
using the ImageJ plugin FibrilTool [30]. 
Mouse full-thickness wound experiments 
 These experiments were approved by the Cornell Institutional Animal Care and Use 
Committee (IACUC # 2017-0116). A 4 mm biopsy punch was used to created two full thickness 
wounds on the back of 6-8-week-old female C57/B6 mice. Wounds were treated daily with 50 µl 
vehicle control (DMEM) or various CM. Wounds were photographed and measured daily until 
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complete wound closure. One set of mice, representing each treatment group, was euthanized at 
day 4 post wounding, and wounded skin was collected, fixed, and stained with hematoxylin and 
eosin (H&E) for histological analysis.   
Statistical analyses 
 GraphPad software was used to determine statistically significant differences. One-way 
ANOVA, followed by the Tukey’s multiple comparison test was used for all experiments, with 
exception of experiments where only two conditions were compared. In those cases, the 
student’s t-test for unpaired data was used. Data given are the mean of 3 replicates and the bars 
show standard deviations. For experiments with multiple comparisons, significance is expressed 
by letters printed above data points on graphs. The same letter indicates no difference between 
conditions, while different letters indicate significant differences between conditions. For 
experiments where only two conditions are compared, significance is expressed by asterisks 
printed above data points on graphs. P-values are defined in figure legends. 
6.4. Results 
 MSC secreted factors that stimulate DF migration in vitro are temperature sensitive and are, 
at least in part, associated with EV.  
 We demonstrated previously that equine MSC CM stimulated DF migration in vitro [18]. To 
explore which MSC secreted factors play a role in this, we first performed experiments to 
determine the characteristics of the active factors. As we previously reported, DF in the presence 
of MSC CM migrated more quickly than DF in the presence of control CM (i.e. CM collected from 
DF) as measured by in vitro scratch assays (Figure 1). When MSC CM was boiled (CM HI) or 
frozen and thawed (CM FT), however, this stimulating effect was abolished (Figure 6.1A&B). 
This indicates that the active factors in MSC CM are temperature sensitive. Next, we fractionated 
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MSC CM using 30 kD centrifugal filters, and found that the fraction retained by these filters (i.e. 
factors > 30 kD) stimulated DF migration to levels comparable to complete MSC CM, whereas 
the fraction that passed through the filters (i.e. factors < 30 kD) did not (Figure 6.1C). This suggests 
that the active factors are larger than 30 kD or are engaged in complexes that are larger than 30 
kD. Since MSC from other species have been shown to produce EV that are >30 kD and can deliver 
cargo to target cells [31], we decided to compare the effects of control CM, MSC CM, MSC-
derived EV and EV-deficient MSC CM on DF migration. As expected, MSC CM significantly 
increased DF migration as compared to control CM (Figure 1D). MSC-derived EV as well as EV-
deficient MSC CM also increased DF migration as compared to control CM, although this effect 
didn’t reach significance (Figure 6.1D), suggesting that some of the migration-stimulating factors 
in MSC CM are associated with EV, while others are not. To further explore the potential role of 
MSC EV in stimulating DF migration, we treated MSC with the EV inhibitor GW4869 and 
collected CM from these cells. DF migration in the presence of this CM was not statistically 
different from the migration observed in the presence of control CM and was statistically lower 
than the migration in the presence of CM collected from untreated MSC (Figure 6.1E), indicating 
that EV from MSC do, at least in part, deliver factors that promote DF migration. To ensure that 
the absence of increased migration in the presence of GW4869-treated MSC CM was not due to 
the presence of residual inhibitor in the CM, we supplemented untreated MSC CM with GW4869 
just before it was applied to the DF. This GW4869-supplemented CM did stimulate DF migration 
to similar levels as non-supplemented CM (Figure 1E), indicating that GW4869 by itself does not 
inhibit DF migration.  
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Figure 6.1. The mesenchymal stromal cell (MSC) secreted factors that stimulate dermal 
fibroblast (DF) migration in vitro are temperature sensitive and are, at least in part, 
associated with extracellular vesicles (EV).  As measured by scratch assays, the increase in DF 
migration induced by culture with MSC conditioned medium (CM): A. B. was not observed 
when MSC CM was heat inactivated or frozen and thawed, C. was maintained in the fraction of 
MSC CM retained by a 30 kD filter, and lost in the fraction that flowed through, and D. E. was 
in part attributable to EV in MSC CM. n = 3; p < 0.05; Different letters above data points 
indicate significant differences between conditions, the same letter indicates no difference.  
 
LC-MS/MS analysis of MSC CM and control CM reveals differences in protein composition. 
 To better define the nature of the active factors responsible for DF migration, we decided to 
perform LC-MS/MS for identification of proteins in medium culture samples. We suspected 
proteins to be important migration-stimulating active factors based on our findings that the equine 
MSC secreted factors responsible for promoting DF migration (i) are temperature sensitive and (ii) 
are either > 30 kD, or in complexes that are > 30 kD. To this end, we submitted the > 30 kD 
fractions of both MSC CM and control (DF) CM for LC-MS/MS analysis, to identify and compare 
the protein compositions of each CM. A total of 103 proteins were confidently identified in MSC 
CM and 92 proteins were confidently identified in control CM. The complete lists can be found in 
Suppl Table 6S.1. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis by 
PANTHER revealed that the proteins detected in control CM were associated with 15 biological 
pathways, whereas the proteins detected in MSC CM were associated with 19 biological pathways 
(Figure 6.2A). Analysis using STRING indicated that proteins detected in control CM had 49 
edges, representing protein-protein associations that are specific and contribute to a common 
function, while proteins detected in MSC CM had 157 edges (Figure 6.2B). Collectively, these 
  233 
analyses show that MSC CM contains a greater number of proteins and that these proteins are 
involved in more diverse biological pathways compared to control CM.  
 Comparative analysis further showed that 43 proteins were uniquely detected in MSC CM 
(Table 6.2). We performed a literature search on these 43 proteins and prioritized proteins for 
further analyses based on (i) reported involvement in cell migration and (ii) whether they had 
previously been described as being secreted by MSC from other species. Two top candidate 
proteins were PAI-1 and tenascin-C, both of which were reported to contribute to cell motility [32, 
33, 34, 35]. PAI-1 has been described as a secretory product of human MSC [36] and tenascin-C 
mRNA has been detected in MSC isolated from both humans and horses [37]. We first confirmed 
their presence in the CM from MSC isolated from 3 different horses by Western blot analysis and 
found higher levels of PAI-1 and tenascin-C in CM from all 3 MSC cultures compared to CM 
collected from an equal number of DF cultures (Figure 6.2C). In addition, we used RT-PCR to 
look for transcripts of receptors for these two proteins in DF. We confirmed that DF do express 
the PAI-1 receptors ITGA5, ITGB1 and uPAR. as well as the tenascin-C receptors Annexin II, 
EGFR, ITGAV and ITGB3 (Figure 6.3).  
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Figure 6.2. Mass Spectrophotometric analysis of mesenchymal stromal cell (MSC) 
conditioned medium (CM) and control CM reveals differences in protein composition. A. 
PANTHER pathway analysis indicates that proteins detected in MSC CM are involved in more 
biological pathways than those detected in control CM. B. STRING analysis suggests that 
proteins detected in MSC CM exhibit more protein-protein associations that are specific and 
contribute to a common function, than proteins detected in control CM. C. Western blots were 
used to confirm that plasminogen activator inhibitor-1 (PAI-1) and tenascin-C (TNC) are 
detected in higher levels in MSC CM than in control CM. n = 1 for mass spectrophotometry; n = 
3 for Western blots; * p < 0.05; *** p < 0.001. 
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Table 6.2. Proteins detected in mesenchymal stromal cell (MSC), but not control, 
conditioned medium (CM) by mass spectrometry. 
 
Accession Description 
NP_001075250.1 elongation factor 1-alpha 1 [Equus caballus] 
NP_001157345.1 endoplasmin precursor [Equus caballus] 
NP_001157328.1 glyceraldehyde-3-phosphate dehydrogenase [Equus caballus] 
NP_001075247.1 heat shock cognate 71 kDa protein [Equus caballus] 
NP_001157427.1 heat shock protein HSP 90-alpha [Equus caballus] 
NP_001075407.1 heat shock protein HSP 90-beta [Equus caballus] 
NP_001333133.2 keratin 4 [Equus caballus] 
NP_001157446.1 lactotransferrin precursor [Equus caballus] 
XP_001504337.1 14-3-3 protein epsilon isoform X1 [Equus caballus] 
XP_014583708.1 14-3-3 protein zeta/delta [Equus caballus] 
XP_005601929.1 alpha-2-HS-glycoprotein [Equus caballus] 
XP_005602671.1 angiotensinogen [Equus caballus] 
XP_014586433.1 apolipoprotein B-100 [Equus caballus] 
XP_005602045.1 coiled-coil domain-containing protein 80 [Equus caballus] 
XP_001914777.1 collagen alpha-1(XII) chain isoform X1 [Equus caballus] 
XP_003363907.1 complement C1q tumor necrosis factor-related protein 3 isoform X1 [Equus caballus] 
XP_001492943.1 complement C4-A [Equus caballus] 
XP_005606524.1 decorin isoform X1 [Equus caballus] 
XP_005597812.1 eukaryotic initiation factor 4A-I isoform X1 [Equus caballus] 
XP_014592455.1 fibulin-1 [Equus caballus] 
XP_014594516.1 filamin-C [Equus caballus] 
XP_014589771.1 histone H3.1-like [Equus caballus] 
XP_003364388.2 integrin beta-1 isoform X1 [Equus caballus] 
XP_014594379.1 laminin subunit beta-1 [Equus caballus] 
XP_014595948.1 L-lactate dehydrogenase B chain isoform X1 [Equus caballus] 
XP_001915132.1 elongation factor 2 [Equus caballus] 
XP_001915328.2 filamin-A [Equus caballus] 
XP_014595805.1 glypican-1 [Equus caballus] 
XP_014595409.1 histone H2A type 2-C-like [Equus caballus] 
XP_001917737.2 lysyl oxidase homolog 1 [Equus caballus] 
XP_001916657.1 tenascin [Equus caballus] 
XP_014596747.1 neural cell adhesion molecule 1 isoform X1 [Equus caballus] 
XP_005615050.2 nucleophosmin isoform X1 [Equus caballus] 
XP_001496993.3 peptidyl-prolyl cis-trans isomerase A [Equus caballus] 
XP_001492567.3 plasminogen activator inhibitor 1 [Equus caballus] 
XP_005603239.1 purine nucleoside phosphorylase-like [Equus caballus] 
XP_005614707.2 rab GDP dissociation inhibitor alpha [Equus caballus] 
XP_005612091.1 serpin H1 [Equus caballus] 
XP_005602120.1 target of Nesh-SH3 isoform X19 [Equus caballus] 
XP_005610680.2 tubulin alpha-1D chain [Equus caballus] 
XP_001491228.1 tubulin beta chain [Equus caballus] 
NP_001137266.1 pyruvate kinase PKM isoform M2 [Equus caballus] 
NP_001230074.1 vimentin [Equus caballus] 
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Figure 6.3. Dermal fibroblasts (DF) express genes corresponding to plasminogen activator 
inhibitor-1 (PAI-1) and tenascin-C (TNC) receptors. RT-PCR was used to amplify genes 
corresponding to PAI-1 and TNC surface receptors in DF. n = 3. 
 
RNAi effectively knocks down PAI-1 and tenascin-C in MSC and MSC CM. 
 We decided to use gene silencing to study the functional role of PAI-1 and tenascin-C in DF 
migration. To this end, we transfected equine MSC with siRNAs specific to PAI-1, tenascin-C or 
both. Significant knock-down of the genes SERPINE1 and TNC was confirmed by qRT-PCR 
(Suppl Figure 6S.1A) and knock-down of the corresponding proteins (PAI-1 and tenascin-C, 
respectively) in MSC was confirmed by Western blot (Suppl Figure 6.S1B). Transfected MSC 
appeared morphologically healthy, and cell metabolism and viability were not negatively affected 
as determined by MTT metabolism (Figure 6.4A) and LDH release (Figure 6.4B) assays. 
Importantly, significantly less PAI-1, tenascin-C, or both, were detected in the CM collected from 
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these transfected MSC (Figure 6.4C). Scrambled control siRNA did not affect the expression of 
either protein in MSC or MSC CM (Suppl Figure 6S.1B, Figure 6.4C), despite the observation of 
a slight significant decrease in SERPINE1 gene expression (Suppl Figure 6S.1A). Taken together, 
these results indicate that we successfully reduced the expression and secretion of these proteins 
by MSC. 
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Figure 6.4. RNAi does not affect viability of equine mesenchymal stromal cells (MSC) and 
knocks down plasminogen activator inhibitor-1 (PAI-1) and tenascin-C (TNC) expression 
in equine MSC conditioned medium (CM). A. B. Following transfection of equine MSC with 
siRNA cells remained metabolically stable as measured by the reduction of 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT), and did not undergo increased 
death, as measured by lactate dehydrogenase (LDH) release. C. Transfection of MSC with 
siRNA led to decreased PAI-1 and TNC in MSC CM. n = 3; p < 0.05; Different letters above 
data points indicate significant differences between conditions, the same letter indicates no 
difference. 
 
DF migration is decreased using MSC CM with reduced PAI-1 and tenascin-C levels.  
 CM from siRNA transfected equine MSC was used in in vitro scratch assays. Significantly 
reduced DF migration was observed using PAI-1-, tenascin-C-, or PAI-1/tenascin-C-deficient CM 
when compared to CM from untransfected MSC (Figure 6.5A). These results indicate that PAI-1 
and tenascin-C are involved in the stimulation of MSC CM-induced fibroblast migration. To 
corroborate these results, we used the Oris cell migration assay and found that significantly fewer 
DF migrated into empty spaces in culture wells within 48 h when they were treated with MSC CM 
lacking PAI-1, tenascin-C, or both, as compared to CM from untransfected MSC (Figure 6.5B). 
CM from MSC that were transfected with non-specific scramble siRNA did not affect MSC CM-
induced DF migration in either assay (Figure 6.5).  
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Figure 6.5. Dermal fibroblast (DF) migration is decreased when plasminogen activator 
inhibitor-1 (PAI-1), tenascin-C (TNC), or both are reduced in mesenchymal stromal cell 
(MSC) conditioned medium (CM). A. DF cultured in MSC CM depleted of PAI-1, TNC or 
both by transfection of siRNA, did not migrate as far in a given period of time as DF cultured in 
the CM from untransfected MSC as measured by scratch assay and B. Oris cell migration assay. 
n = 3; p < 0.05; Different letters above data points indicate significant differences between 
conditions, the same letter indicates no difference. 
 
DF adhesion is increased using MSC CM with reduced PAI-1 and tenascin-C levels. 
  As decreased cell migration is often associated with increased adhesion of cells to substrate, 
we performed an experiment to determine whether PAI-1 and tenascin-C are involved in DF 
adhesion to culture wells. A significantly increased DF adhesion was observed using PIA-1-, 
tenascin-C, or PAI-1/tenascin-C-deficient CM when compared to CM from untransfected or 
scramble siRNA-transfected MSC (Figure 6.6A). Since a diffuse actin cytoskeleton is a cellular 
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phenotype associated with decreased adhesion and increased migration in the presence of tenascin-
C [34], we decided to evaluate whether tenascin-C affects the arrangement of actin filaments in 
DF by assessing anisotropy. Anisotropy describes the property of actin filaments being 
directionally dependent, and a low anisotropy score is indicative of a more motile phenotype of 
cells [30]. Anisotropy scores of DF cultured in tenascin C-deficient CM were significantly higher 
than those of DF cultured in either complete MSC CM or scramble siRNA-transfected MSC CM, 
and the actin filaments in these cells adopted a parallel orientation in contrast to the web like actin 
in DF cultured in either complete MSC CM or scramble siRNA-transfected MSC CM (Figure 
6.6B). Together, these results suggest that tenascin-C contributes to the diffuse web like pattern of 
actin filaments in DF cultured in untransfected MSC CM, which is associated with decreased 
adhesion and increased migration.  
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Figure 6.6. Dermal fibroblast (DF) adhesion to substrate is increased when plasminogen 
activator inhibitor-1 (PAI-1), tenascin-C (TNC), or both are reduced in mesenchymal 
stromal cell (MSC) conditioned medium (CM). A. DF cultured in MSC CM depleted of PAI-
1, TNC or both by transfection of siRNA, adhered more tightly to substrate than DF cultured in 
the CM from untransfected MSC as measured by adhesion assay. B. Actin filaments of DF 
cultured in MSC CM depleted of TNC took on a more parallel orientation than actin filaments of 
DF cultured in the CM from untransfected MSC, as determined by calculating anisotropy scores. 
n = 3; p < 0.05; Different letters above data points indicate significant differences between 
conditions, the same letter indicates no difference. 
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Wound closure is delayed in a murine full-thickness wound model using MSC CM with reduced 
PAI-1 and tenascin-C levels.  
 Based on the role of equine MSC-secreted PAI-1 and tenascin-C in DF migration in vitro, we 
hypothesized these proteins would also promote cutaneous wound healing in vivo. To this end, we 
used the well-established murine full-thickness wound model [38]. First, we confirmed that factors 
secreted by equine MSC can stimulate the migration of murine target cells by performing a scratch 
assay on NIH3T3 cells, a cell line derived from the mouse embryonic mesoderm, in the presence 
of MSC CM (Figure 6.7).  
 
Figure 6.7. Factors in mesenchymal stromal cell (MSC) conditioned medium (CM) promote 
migration of mouse dermal fibroblasts (DF). Mouse DF cultured in MSC CM migrated farther 
in a given period of time than mouse DF cultured in control (mouse DF) CM as measured by 
scratch assay. n = 3; p < 0.01. 
 
 Next, we inflicted two 4 mm full-thickness wounds on the backs of immunocompetent mice 
using a biopsy punch. Wounds were then treated daily with either a vehicle control (DMEM), 
complete CM from untransfected MSC, PAI-1/tenascin-C-deficient MSC CM, and CM from 
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scramble siRNA-transfected MSC. Wounds from one set of mice were photographed and 
measured daily, until complete wound closure. The other set of mice were euthanized at day 4 
post-wounding for histological wound assessment. We found that wounds treated with CM from 
untransfected MSC closed more quickly compared to wounds treated with the vehicle control, 
indicating that equine MSC CM promotes wound healing in this model. Interestingly, wounds 
treated with PAI-1/tenascin-C-deficient MSC CM had a slower wound closure rate compared to 
wounds treated with CM from untransfected MSC (Figure 6.8A), although this difference did not 
reach statistical significance. These data suggest that these two proteins are, at least in part, 
responsible for wound closure in vivo. As expected, the closure rate of wounds treated with CM 
from untransfected MSC was not statistically different from that of treatment with scramble 
siRNA-transfected MSC CM (Figure 6.8A). Histological analyses of distance between epithelial 
tongues and number of new capillaries in the wound bed 4 days post-wounding did not reveal any 
statistically significant differences between treatments (data not shown). A larger granulation 
tissue area, which is associated with early stages of successful would closure [1], was measured in 
the wound beds of wounds treated with untransfected MSC CM as compared to PAI-1/tenascin-
C-deficient CM, but this difference did not reach statistical significance (Figure 6.8B). 
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Figure 6.8. Wound closure is delayed in a murine full-thickness wound model when 
plasminogen activator inhibitor-1 (PAI-1) and tenascin-C (TNC) are reduced in 
mesenchymal stromal cell (MSC) conditioned medium (CM) A. As compared to the vehicle 
control, wounds treated with MSC CM closed more quickly, while wounds treated with MSC 
CM depleted of PAI-1 and TNC did not. B. Wounds treated with MSC CM appeared to have a 
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greater amount of granulation tissue than wounds treated with the vehicle control, while wounds 
treated with MSC CM depleted of PAI-1 and TNC appeared more like those treated with the 
vehicle control. n = 6 wounds; p < 0.05; Different letters above data points indicate significant 
differences between conditions, the same letter indicates no difference. 
 
6.5. Discussion 
 Our research focuses on the potential of equine peripheral blood-derived MSC to be used as a 
therapy for cutaneous wounds. We study MSC from peripheral blood, as this method of collection 
is non-invasive as compared to collecting MSC from bone marrow or adipose tissue, two other 
common sources of equine MSC, and the success rate of MSC isolation from equine peripheral 
blood is high [47,48]. 
 The present study demonstrates that equine peripheral blood-derived MSC CM (i) stimulates 
fibroblast migration in vitro and (ii) promotes wound healing in vivo. Importantly, we identified at 
least two proteins secreted by these cells, namely PAI-1 and tenascin-C, to be involved in these 
processes.  
 We decided to examine the effects of these two proteins in our experimental systems based on 
their unique expression in MSC CM and the fact that they both have well-established roles in cell 
migration. PAI-1 is an acute phase glycoprotein, expressed highly in response to elevated 
cytokines, such as transforming growth factor beta (TGF-β) and epidermal growth factor released 
at the time of tissue injury. PAI-1 contributes to wound closure by promoting cell migration and 
granulation tissue formation [39, 32]. Although PAI-1 expression is important during normal 
wound healing, prolonged or pathologic expression of PAI-1 is associated with fibrotic diseases 
and excessive collagen deposition. Fibroblasts isolated from keloids as well as those isolated from 
the skin of scleroderma patients exhibit high levels of PAI-1 as compared to normal skin fibroblasts 
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[40]. PAI-1 expression must be modulated temporally for successful wound healing, which should 
be considered when testing the efficacy of MSC-derived PAI-1 as a therapy for cutaneous wounds. 
The extracellular matrix molecule tenascin-C is highly expressed during normal cutaneous wound 
healing [35]. It was initially described as a modulator of adhesion, but since has been identified as 
a molecule involved in cell migration, proliferation, apoptosis, and transdifferentiation. Expression 
of active tenascin-C is tightly regulated at both the gene and protein levels [41]. This is important 
as the overexpression of tenascin-C is associated with cancer, often at the invasive front, and has 
been linked to metastasis [42]. As with PAI-1, the timing of the administration of therapeutic 
tenascin-C should be optimized to ensure successful wound healing, without undesirable side 
effects. In addition to PAI-1 and tenascin-C, the secreted molecules lactotransferrin, complement 
C1q, complement C4, decorin, fibulin, lactate dehydrogenase, lysyl oxidase homolog 1, target of 
Nesh-SH3, and fibulin 1, were also uniquely detected in the CM from equine MSC. However, with 
the exception of fibulin 1, which has been shown to reduce migration velocity in vitro of breast 
cancer cells by suppressing cellular interactions with fibronectin [43], these molecules have not 
been previously described as contributing to cell migration.  
 In the present study, we demonstrated that EV from MSC do, at least in part, deliver factors 
that promote DF migration. Although we did not specifically perform LC-MS/MS on MSC-
secreted EV, LC-MS/MS of the complete MSC CM revealed proteins that have been identified in 
EV secreted by various cell types, such as filamin A, the tubulins, and integrin beta-1 [44, 45, 46]. 
Since these proteins are associated with cell adhesion and migration through interactions with 
actin, it will be interesting to study the roles of these EV-associated proteins in cell migration and 
wound healing in more detail. To our knowledge, no data exist to suggest that these molecules can 
be transported from one cell to integrate and act as cytoskeletal components of a recipient cell. 
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 We have previously shown that factors secreted by equine MSC promote the migration of both 
an equine DF cell line [18] as well as primary dermal fibroblasts isolated from horses [28]. In the 
present study, we used equine and mouse cell lines, as well as a mouse model as screening tools 
to evaluate the efficacy of peripheral blood-derived MSC on wound healing and to study the 
contribution of PAI-1 and tenascin-C to the wound healing process. The murine full-thickness 
wound model is a well-established model used to study cell migration, communication between 
different cell types found in the skin and the roles of specific genes in the healing process [38]. 
For example, this model has been used in studies to show that (i) ultraviolet radiation inhibits 
keratinocyte motility [49], (ii) interleukin-33 improves wound closure through increased M2 
macrophage polarization [50], and (iii) a hypoxia response element in the vascular endothelial 
growth factor A promoter is required for optimal granulation tissue formation [51]. Using this 
mouse model, our present study showed that PAI-1 and tenascin-C secreted by equine MSC 
decrease wound closure time in vivo. Based on these encouraging results, we are now planning to 
initiate similar experiments in the horse. The horse is an excellent model for human wound healing 
studies based on the fact that (i) horse skin wounds heal by epithelialization, similar to human skin 
wounds, and (ii) horses naturally develop chronic wounds that resemble human conditions [15]. 
Importantly, this large animal model allows for the design of studies with control and treated 
wounds all in the same animal [52]. In addition, multiple biopsies flanking a wound site can be 
collected throughout an experiment, allowing for a temporal analysis of wound parameters such 
as histology, mRNA expression or protein profiles [53]. This type of analysis is not always feasible 
in smaller animal models such as rodent models. Consequently, the horse model has been used to 
evaluate various therapies for improving wound healing [52, 54] including a recent study in which 
  250 
the potential of bone marrow-derived MSC for skin wounds on the lower legs of horses was 
evaluated [55]. 
 Identifying which factors secreted by MSC act on target cell types found in the skin is 
important as it may allow to refine the CM generated by MSC in order to optimize therapeutic 
benefits. First, it allows for the pre-screening of MSC cultures with a high level of bioactive factors 
of interest. Indeed, we previously found a donor-specific effect of MSC-derived CM on skin target 
cells [16] and confirmed in the present study that the expression of PAI-1 and tenascin-C mRNA 
was significantly different in MSC cultures isolated from different horses (Suppl Figure 6S.2A). 
The observation that MSC from different individuals exhibit different secretion patterns has also 
been described for human MSC [56]. Second, it allows the evaluation of pre-treatment modalities 
of MSC that would result in increased expression of bioactive factors of interest [57]. For example, 
we found that pre-treatment of MSC with TGFβ-1 significantly increased the level of tenascin-C 
in CM, as detected by Western blot analyses (Suppl Figure 6S.2B). Although the levels of PAI-1 
in MSC CM did not increase using the same treatment conditions (data not shown), it may be 
possible to induce higher expression of this protein by pre-treating with a different dose of TGFβ-
1, pre-treating for a longer period of time, or pre-treating with a different cytokine or growth factor. 
Lastly, and although not directly related to MSC therapy per se, knowledge on the bioactive factors 
present in MSC CM could inform the design of recombinant protein therapies, which are being 
intensively explored for wound healing. [58, 59, 60]. 
6.6. Conclusions 
 We previously reported that equine MSC CM stimulates DF migration, but (i) the factors 
responsible for this effect were not defined and (ii) it was not known whether these factors 
contribute to wound healing in vivo. The present study is the first to show that PAI-1 and tenascin-
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C secreted by equine peripheral blood-derived MSC stimulate DF migration, and that these 
proteins are involved in the promotion of wound healing in vivo. Defining the factors secreted by 
MSC that contribute to cutaneous wound healing may increase the value of MSC as a therapy for 
skin wounds in both horses and humans.  
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Figure 6.S1. RNAi knocks down plasminogen activator inhibitor-1 (PAI-1) and tenascin-C 
(TNC) expression in equine mesenchymal stromal cells (MSC). A. Following transfection of 
equine MSC with siRNA; PAI-1 (SERPINE1) and TNC (TNC) gene expression was reduced as 
detected by qRT-PCR and B. PAI-1 and TNC protein expression was reduced as determined by 
Western blot.  n = 3; p < 0.05; Different letters above data points indicate significant differences 
between conditions, the same letter indicates no difference.  
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Figure 6.S2. Variable expression profiles of plasminogen activator inhibitor-1 (SERPINE1) 
and tenascin-C (TNC) transcripts, as well as tenascin-C (TNC) protein levels in equine 
mesenchymal stromal cells (MSC). A. MSC cultures from different horses exhibited variable 
expression of SERPINE1 and TNC as detected by qRT-PCR. B. Treatment of MSC with TGFβ-1 
led to increased levels of TNC in MSC CM as detected by Western blot. n = 3; p < 0.05; 
Different letters above data points indicate significant differences between conditions, the same 
letter indicates no difference. 
 
Table 6S.1. Proteins detected in control (DF) and mesenchymal stromal cell (MSC)  
conditioned medium  (CM).  
Control (DF) CM 
Accession Description 
NP_001075249.1 lumican precursor [Equus caballus] 
NP_001075308.1 biglycan precursor [Equus caballus] 
NP_001075413.1 clusterin precursor [Equus caballus] 
NP_001075415.2 serotransferrin precursor [Equus caballus] 
NP_001075420.1 retinol-binding protein 4 precursor [Equus caballus] 
NP_001075422.1 gelsolin [Equus caballus] 
NP_001075984.1 metalloproteinase inhibitor 1 precursor [Equus caballus] 
NP_001108012.1 ferritin light chain [Equus caballus] 
NP_001137424.1 serpin B10 [Equus caballus] 
NP_001137425.1 SPARC precursor [Equus caballus] 
NP_001137426.1 pigment epithelium-derived factor precursor [Equus caballus] 
NP_001138352.1 L-lactate dehydrogenase A chain [Equus caballus] 
NP_001156589.2 thrombospondin-2 precursor [Equus caballus] 
NP_001157446.1 lactotransferrin precursor [Equus caballus] 
NP_001191672.1 nucleoside diphosphate kinase B [Equus caballus] 
NP_001254532.1 alpha-enolase [Equus caballus] 
NP_001295881.1 thrombospondin-1 precursor [Equus caballus] 
NP_001296443.1 selenium-binding protein 1 [Equus caballus] 
XP_001488401.2 collagen alpha-1(VI) chain [Equus caballus] 
XP_001488418.3 serpin B6 isoform X1 [Equus caballus] 
XP_001489154.4  fibronectin [Equus caballus] 
XP_001489596.2 anionic trypsin [Equus caballus] 
XP_001490291.2 xaa-Pro dipeptidase [Equus caballus] 
XP_001490356.3 plasma kallikrein [Equus caballus] 
XP_001490657.2 glucose-6-phosphate isomerase [Equus caballus] 
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XP_001491000.1 galectin-3-binding protein [Equus caballus] 
XP_001492201.5  N-acetylglucosamine-6-sulfatase [Equus caballus] 
XP_001492989.1 collagen alpha-2(I) chain [Equus caballus] 
XP_001494409.1 cathepsin L2 [Equus caballus] 
XP_001494662.3 EGF-containing fibulin-like extracellular matrix protein 2 [Equus caballus] 
XP_001497522.2 triosephosphate isomerase [Equus caballus] 
XP_001498242.1 cathepsin B [Equus caballus] 
XP_001499854.1 keratin, type I cytoskeletal 10-like isoform X1 [Equus caballus] 
XP_001500887.1 apolipoprotein D isoform X1 [Equus caballus] 
XP_001501867.1 collagen alpha-2(V) chain [Equus caballus] 
XP_001502309.1  fibrillin-1 [Equus caballus] 
XP_001502604.2  EMILIN-1 [Equus caballus] 
XP_001503085.1 actin, aortic smooth muscle [Equus caballus] 
XP_001503419.1 phospholipid transfer protein [Equus caballus] 
XP_001503814.1 prosaposin isoform X1 [Equus caballus] 
XP_001503927.3 thrombospondin-4 [Equus caballus] 
XP_001504911.1 moesin [Equus caballus] 
XP_001505187.1 purine nucleoside phosphorylase [Equus caballus] 
XP_001916726.3  prolow-density lipoprotein receptor-related protein 1 [Equus caballus] 
XP_001917632.1 EGF-containing fibulin-like extracellular matrix protein 1 [Equus caballus] 
XP_001918096.4 sphingomyelin phosphodiesterase [Equus caballus] 
XP_003364083.1 alpha-actinin-1 isoform X1 [Equus caballus] 
XP_003364129.1 noelin isoform X1 [Equus caballus] 
XP_003365612.1 plasminogen activator inhibitor 2 [Equus caballus] 
XP_005598069.1 CD44 antigen isoform X1 [Equus caballus] 
XP_005598858.1 fructose-bisphosphate aldolase A [Equus caballus] 
XP_005599767.1 transforming growth factor-beta-induced protein ig-h3, partial [Equus caballus] 
XP_005600606.1 transketolase [Equus caballus] 
XP_005602923.1 pro-cathepsin H [Equus caballus] 
XP_005602958.1 chondroitin sulfate proteoglycan 4 [Equus caballus] 
XP_005605252.1 galectin-3 [Equus caballus] 
XP_005605710.1  collagen alpha-1(XV) chain [Equus caballus] 
XP_005607055.1  inter-alpha-trypsin inhibitor heavy chain H5 [Equus caballus] 
XP_005607147.1 peroxiredoxin-1 [Equus caballus] 
XP_005607578.1 procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 isoform X1 [Equus caballus] 
XP_005608557.1 N-acetylgalactosamine-6-sulfatase [Equus caballus] 
XP_005609063.1 WD repeat-containing protein 1 [Equus caballus] 
XP_005609834.2 laminin subunit gamma-1 [Equus caballus] 
XP_005610703.1 glia-derived nexin [Equus caballus] 
XP_005611909.1 peroxiredoxin-2 [Equus caballus] 
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XP_005612174.1 hemopexin [Equus caballus] 
XP_014585370.1 procollagen C-endopeptidase enhancer 1 isoform X1 [Equus caballus] 
XP_014586066.1 platelet-derived growth factor receptor beta [Equus caballus] 
XP_014586837.1 fibulin-2 [Equus caballus] 
XP_014587011.1 serotransferrin [Equus caballus] 
XP_014587164.1 alpha-actinin-4, partial [Equus caballus] 
XP_014588510.1 vinculin isoform X1 [Equus caballus] 
XP_014590559.1 CD109 antigen [Equus caballus] 
XP_014590916.1 pantetheinase [Equus caballus] 
XP_014591200.1 latent-transforming growth factor beta-binding protein 2 [Equus caballus] 
XP_014591730.1 collagen alpha-1(V) chain [Equus caballus] 
XP_014591905.1 protein disulfide-isomerase [Equus caballus] 
XP_014591939.1  neuronal pentraxin-1 [Equus caballus] 
XP_014591965.1 collagen alpha-2(VI) chain [Equus caballus] 
XP_014592190.1  C-type mannose receptor 2 [Equus caballus] 
XP_014592250.1 alpha-N-acetylglucosaminidase [Equus caballus] 
XP_014592408.1 collagen alpha-1(I) chain [Equus caballus] 
XP_014592730.1 
basement membrane-specific heparan sulfate proteoglycan core protein,  
partial [Equus caballus] 
XP_014593897.1 72 kDa type IV collagenase [Equus caballus] 
XP_014594947.1 antithrombin-III [Equus caballus] 
XP_014595238.1 extracellular matrix protein 1 [Equus caballus] 
XP_014595871.1 collagen alpha-3(VI) chain [Equus caballus] 
XP_014596179.1 alpha-2-macroglobulin-like [Equus caballus] 
XP_014596564.1 complement C3-like [Equus caballus] 
XP_014596899.1 lysosomal alpha-mannosidase [Equus caballus] 
XP_014597084.1 tripeptidyl-peptidase 1 [Equus caballus] 
XP_014597534.1 transcobalamin-2 isoform X1 [Equus caballus] 
  
MSC CM 
Accession Description 
NP_001075247.1 heat shock cognate 71 kDa protein [Equus caballus] 
NP_001075249.1 lumican precursor [Equus caballus] 
NP_001075250.1 elongation factor 1-alpha 1 [Equus caballus] 
NP_001075308.1 biglycan precursor [Equus caballus] 
NP_001075407.1 heat shock protein HSP 90-beta [Equus caballus] 
NP_001075413.1 clusterin precursor [Equus caballus] 
NP_001075420.1 retinol-binding protein 4 precursor [Equus caballus] 
NP_001075984.1 metalloproteinase inhibitor 1 precursor [Equus caballus] 
NP_001137266.1 pyruvate kinase PKM isoform M2 [Equus caballus] 
NP_001137424.1 serpin B10 [Equus caballus] 
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NP_001137425.1 SPARC precursor [Equus caballus] 
NP_001138352.1 L-lactate dehydrogenase A chain [Equus caballus] 
NP_001156589.2 thrombospondin-2 precursor [Equus caballus] 
NP_001157328.1 glyceraldehyde-3-phosphate dehydrogenase [Equus caballus] 
NP_001157345.1 endoplasmin precursor [Equus caballus] 
NP_001157427.1 heat shock protein HSP 90-alpha [Equus caballus] 
NP_001157446.1 lactotransferrin precursor [Equus caballus] 
NP_001230074.1 vimentin [Equus caballus] 
NP_001254532.1 alpha-enolase [Equus caballus] 
NP_001295881.1 thrombospondin-1 precursor [Equus caballus] 
NP_001333133.2 keratin 4 [Equus caballus] 
XP_001488401.2 collagen alpha-1(VI) chain [Equus caballus] 
XP_001488418.3 serpin B6 isoform X1 [Equus caballus] 
XP_001489154.4 fibronectin [Equus caballus] 
XP_001489596.2 anionic trypsin [Equus caballus] 
XP_001490657.2 glucose-6-phosphate isomerase [Equus caballus] 
XP_001491228.1 tubulin beta chain [Equus caballus] 
XP_001492567.3 plasminogen activator inhibitor 1 [Equus caballus] 
XP_001492943.1 complement C4-A [Equus caballus] 
XP_001492989.1 collagen alpha-2(I) chain [Equus caballus] 
XP_001494409.1 cathepsin L2 [Equus caballus] 
XP_001496993.3 peptidyl-prolyl cis-trans isomerase A [Equus caballus] 
XP_001497522.2 triosephosphate isomerase [Equus caballus] 
XP_001499854.1 keratin, type I cytoskeletal 10-like isoform X1 [Equus caballus] 
XP_001501867.1 collagen alpha-2(V) chain [Equus caballus] 
XP_001502309.1 fibrillin-1 [Equus caballus] 
XP_001502604.2 EMILIN-1 [Equus caballus] 
XP_001503085.1 actin, aortic smooth muscle [Equus caballus] 
XP_001503927.3 thrombospondin-4 [Equus caballus] 
XP_001504337.1 14-3-3 protein epsilon isoform X1 [Equus caballus] 
XP_001505187.1 purine nucleoside phosphorylase [Equus caballus] 
XP_001914777.1 collagen alpha-1(XII) chain isoform X1 [Equus caballus] 
XP_001915132.1 elongation factor 2 [Equus caballus] 
XP_001915328.2 filamin-A [Equus caballus] 
XP_001916657.1 tenascin [Equus caballus] 
XP_001916726.3 prolow-density lipoprotein receptor-related protein 1 [Equus caballus] 
XP_001917632.1 EGF-containing fibulin-like extracellular matrix protein 1 [Equus caballus] 
XP_001917737.2 lysyl oxidase homolog 1 [Equus caballus] 
XP_003363907.1 complement C1q tumor necrosis factor-related protein 3 isoform X1 [Equus caballus] 
XP_003364083.1 alpha-actinin-1 isoform X1 [Equus caballus] 
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XP_003364388.2 integrin beta-1 isoform X1 [Equus caballus] 
XP_003365612.1 plasminogen activator inhibitor 2 [Equus caballus] 
XP_005597812.1 eukaryotic initiation factor 4A-I isoform X1 [Equus caballus] 
XP_005598069.1 CD44 antigen isoform X1 [Equus caballus] 
XP_005598858.1 fructose-bisphosphate aldolase A [Equus caballus] 
XP_005599767.1 transforming growth factor-beta-induced protein ig-h3, partial [Equus caballus] 
XP_005600606.1 transketolase [Equus caballus] 
XP_005601929.1 alpha-2-HS-glycoprotein [Equus caballus] 
XP_005602045.1 coiled-coil domain-containing protein 80 [Equus caballus] 
XP_005602120.1 target of Nesh-SH3 isoform X19 [Equus caballus] 
XP_005602671.1 angiotensinogen [Equus caballus] 
XP_005603239.1 purine nucleoside phosphorylase-like [Equus caballus] 
XP_005606524.1 decorin isoform X1 [Equus caballus] 
XP_005607147.1 peroxiredoxin-1 [Equus caballus] 
XP_005607578.1 procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 isoform X1 [Equus caballus] 
XP_005609063.1 WD repeat-containing protein 1 [Equus caballus] 
XP_005609834.2 laminin subunit gamma-1 [Equus caballus] 
XP_005610680.2 tubulin alpha-1D chain [Equus caballus] 
XP_005610703.1 glia-derived nexin [Equus caballus] 
XP_005611909.1 peroxiredoxin-2 [Equus caballus] 
XP_005612091.1 serpin H1 [Equus caballus] 
XP_005614707.2 rab GDP dissociation inhibitor alpha [Equus caballus] 
XP_005615050.2 nucleophosmin isoform X1 [Equus caballus] 
XP_014583708.1 14-3-3 protein zeta/delta [Equus caballus] 
XP_014585370.1 procollagen C-endopeptidase enhancer 1 isoform X1 [Equus caballus] 
XP_014586433.1 apolipoprotein B-100 [Equus caballus] 
XP_014586837.1 fibulin-2 [Equus caballus] 
XP_014587011.1 serotransferrin [Equus caballus] 
XP_014587164.1 alpha-actinin-4, partial [Equus caballus] 
XP_014588510.1 vinculin isoform X1 [Equus caballus] 
XP_014589771.1 histone H3.1-like [Equus caballus] 
XP_014590559.1 CD109 antigen [Equus caballus] 
XP_014590916.1  pantetheinase [Equus caballus] 
XP_014591200.1 latent-transforming growth factor beta-binding protein 2 [Equus caballus] 
XP_014591730.1  collagen alpha-1(V) chain [Equus caballus] 
XP_014591905.1 protein disulfide-isomerase [Equus caballus] 
XP_014591965.1 collagen alpha-2(VI) chain [Equus caballus] 
XP_014592190.1  C-type mannose receptor 2 [Equus caballus] 
XP_014592408.1 collagen alpha-1(I) chain [Equus caballus] 
XP_014592455.1 fibulin-1 [Equus caballus] 
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XP_014592730.1 
basement membrane-specific heparan sulfate proteoglycan core protein,  
partial [Equus caballus] 
XP_014593897.1 72 kDa type IV collagenase [Equus caballus] 
XP_014594379.1 laminin subunit beta-1 [Equus caballus] 
XP_014594516.1 filamin-C [Equus caballus] 
XP_014594947.1 antithrombin-III [Equus caballus] 
XP_014595238.1 extracellular matrix protein 1 [Equus caballus] 
XP_014595409.1 histone H2A type 2-C-like [Equus caballus] 
XP_014595805.1 glypican-1 [Equus caballus] 
XP_014595871.1 collagen alpha-3(VI) chain [Equus caballus] 
XP_014595948.1 L-lactate dehydrogenase B chain isoform X1 [Equus caballus] 
XP_014596179.1 alpha-2-macroglobulin-like [Equus caballus] 
XP_014596564.1 complement C3-like [Equus caballus] 
XP_014596747.1 neural cell adhesion molecule 1 isoform X1 [Equus caballus] 
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7.1. Summary 
 The aim of this dissertation was to determine if factors secreted by equine mesenchymal 
stromal cells (MSC) act on cell types found in the skin, in ways that suggest they may be a useful 
therapy for cutaneous wounds of horses. The long-term goals of this project are to (i) validate 
equine MSC-secreted factors in vivo as a safe and effective therapy for horse skin wounds, (ii) 
provide equine clinicians with protocols to offer MSC-secreted factors as treatment to their 
patients, and (iii) use what is learned while evaluating this therapy for horses, to improve 
treatments for humans. 
 The impaired healing of cutaneous wounds is problematic for horses and humans, and 
some chronic wounds of horses are reminiscent of those in man. Novel therapies developed for 
horses will not only benefit equine medicine but may fill a need in human medicine as well.  
 The work described here took advantage of in vitro culture methods to assess the effects 
of equine MSC- secreted factors on cell types found in the skin, and defined which factors were 
responsible for these effects. In particular, the target cells of interest were dermal fibroblasts 
(DF), resident skin cells that are tightly regulated during normal wound healing and which may 
contribute to delayed wound healing when their function is impaired.  
 Chapter One reviewed the pertinent aspects of MSC biology, as well as the history of 
equine MSC research and therapy, with the goal of setting the stage for the work described in the 
following research reports. Several critical points were highlighted regarding stem cells and their 
regenerative potential that formed the rationale for the research described in this thesis. For 
example, the therapeutic benefits delivered by MSC from any species are generally a result of 
factors secreted by MSC that act on the local environment, as opposed to the MSC differentiating 
into cells that are damaged or lost due to injury.  Also, previous studies (mainly carried out in 
  271 
mice) generated data suggesting that human MSC can improve the healing of human skin 
wounds. Finally, MSC therapy is an accepted practice in equine medicine, particularly in 
orthopedics, despite the fact that little is known about how these cells affect wounded tissues. 
Combined, this information led us to study the potential of equine MSC-secreted factors to be 
used as a therapy for cutaneous wound healing in horses.  
 The aim of Chapter Two was to present the horse as a relevant large animal model for 
human skin wound healing. We first described that nonhealing cutaneous wounds negatively 
affect both horses and humans, in part because current strategies for wound management are 
inadequate. We then compared the skin physiology and processes involved in normal wound 
healing in these two species and described in detail two types of naturally-occurring chronic skin 
pathologies that are similar in horses and humans; fibroproliferative disorders and atopic 
dermatitis. We concluded that although there are differences between horse and human skin 
repair, the many similarities warrant the use of the horse as a model for human normal and 
impaired wound healing, and so we proposed the horse as a translational model in which to 
explore novel therapeutics for wound management.  
 Chapter Three was the first of four published chapters describing our studies with equine 
MSC. The study was designed to evaluate the effects of MSC-secreted factors delivered as 
conditioned medium (CM) on equine dermal fibroblasts (DF) and determine if secreted factors 
from MSC microencapsulated in core-shell hydrogel beads had similar effects. We chose DF as 
targets because DF migration and specific changes in DF gene expression are critical to 
successful wound healing. We were motivated to encapsulate MSC, because enveloping MSC in 
alginate physically separates them from their target cells. We verified that MSC-secreted factors 
can diffuse through the capsules and affect target cells comparably to the secreted factors from 
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non-encapsulated MSC. This separation may be relevant when allogeneic donor MSC are 
delivered to recipients in vivo. The lack of cell-cell contact may prevent unwanted immune 
reactions from the recipient and prevent MSC from integrating into recipient tissue and forming 
a tumor. Specifically, we found that MSC CM stimulated DF to migrate and skewed the 
expression patterns of a select panel of DF genes toward those that positively contribute to 
wound healing. We also found that encapsulating MSC in core-shell hydrogel beads did not alter 
these effects. From this work, we concluded that MSC CM might serve as a therapy for horse 
skin wounds, and that encapsulation may be an effective way to deliver MSC CM in vivo.  
 Chapter Four described experiments expanding on our work looking at the effects of 
MSC CM on equine DF. The long-term goal of this study was to determine if MSC CM might 
serve as a therapy for a specific class of chronic cutaneous wounds found in horses and humans. 
In horses, the wounds are called exuberant granulation tissue (EGT) or proud flesh, and in 
humans they are generally referred to as fibroproliferative tissue. These wounds are 
characterized by excessive quantities of fibrotic tissue and may be painful and prone to 
additional complications. Fibroblasts in these wound environments are exposed to prolonged 
low-levels of inflammatory cytokines and are dysregulated, contributing to wound pathology. 
The specific aims of our experiments were to assess the effects of MSC CM on fibroblasts 
dysregulated by the influence of inflammatory mediators, by evaluating the effect of MSC CM 
on two different “types” of dysregulated DF.  First, we treated normal DF with transforming 
growth factor beta 1 (TGF-β1) in culture, an established method of inducing a fibroproliferative-
type phenotype. Second, we isolated fibroblasts from clinical EGT cases. We determined that 
MSC CM blocked TGF-β1-induced changes in DF morphology, proliferation rate, gene 
expression, and contractile-capacity. In addition, we found that MSC-secreted factors did not 
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change proliferation or migration rates of DF isolated from EGT but did lead to changes in 
expression of genes and proteins involved in extracellular matrix (ECM) remodeling and altered 
contractile capacity. These results showed that MSC CM changed the phenotype of dysregulated 
DF in ways that seemingly push them toward a more normal phenotype. From this we concluded 
that MSC CM might have potential as a novel therapy for fibroproliferative wounds in horses, 
and potentially in humans as well.  
 The studies reported in Chapter Five diverted from the effects of MSC CM on DF. For 
these experiments we evaluated the effects of MSC CM on the growth of bacterial species 
commonly found as contaminants in equine nonhealing skin wounds; gram-negative E. coli and 
gram-positive S. aureus. We found that factors secreted by MSC inhibited the growth of both 
these bacterial species and that this effect was in part mediated by four specific antimicrobial 
peptides that we identified in MSC CM; cystatin-C, elafin, lipocalin and cathelicidin, Based on 
these data, we provided additional evidence for the value of MSC CM as a therapy for cutaneous 
wounds, as controlling bacterial infection is an important aspect of wound management.  
 The final experiments outlined in this dissertation were described in Chapter Six. They 
were designed to determine which MSC-secreted factors stimulate DF migration in vitro, as well 
as to evaluate the potential of those factors to promote wound closure in vitro. We were 
motivated to perform these experiments because (i) we observed previously that the profile of 
secreted factors by MSC lines isolated from different horses can vary and (ii) we know that the 
secretory profile of MSC can be manipulated by stimulating MSC with various compounds in 
culture. Therefore, if we know which secreted factors stimulate DF migration, we can focus our 
work on MSC lines that are high producers of those factors and/or stimulate MSC to secrete 
more of the factors of interest. First, we analyzed CM from MSC cultures using liquid 
  274 
chromatography-mass spectrophotometry (LC-MS/MS) to identify all proteins secreted by MSC. 
A literature search of directed us to focus on several MSC-secreted proteins that are involved in 
cell migration. Then, we used double-stranded RNA-mediated interference (RNAi) to silence the 
genes encoding these proteins in MSC, in order to evaluate the effects of CM from silenced MSC 
on migration of DF cells in vitro and wound closure in mice in vivo. We found that MSC-derived 
plasminogen activator inhibitor-1 (PAI-1) and tenascin-C significantly increased DF migration in 
vitro and decreased time of wound closure in vivo. This work is significant, as it is the first 
demonstration that equine MSC-secreted factors improve skin wound healing in vivo, and it is 
the first to identify specific factors that contribute to this effect.  
 Based on the results found in these studies, we feel justified in designing experiments to 
test the efficacy of MSC-secreted factors as a therapy for equine skin wounds in vivo (Figure 
7.1.) 
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Figure 7.1. Qualities of equine mesenchymal stromal cell (MSC)-secreted factors defined by 
work in this dissertation. Work described in this dissertation was the first to determine that 
equine MSC secrete specific factors that exert defined effects on target cell types found in horse 
skin.  
 
7.2. Future prospects 
 We achieved the goal of this dissertation by determining that factors secreted by equine 
mesenchymal stromal cells (MSC) do act on cell types found in the skin, in ways that suggest 
they may be a useful therapy for cutaneous wounds of horses. However, before MSC-secreted 
factors are used clinically, in veterinary or human medicine, several challenges must be 
overcome.  
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 The therapeutic potential of MSC has been extensively explored in multiple species by 
both basic scientists and clinicians since the term MSC was coined, and the idea that these cells 
could be used as a biology therapy was formally proposed [1]. In close to 40 years of MSC 
study, thousands of scientific papers have been published describing the effects of MSC on target 
cells, biological processes, and disease states. Still, MSC therapy is not routinely used in human 
medicine, and although it is commonly used by equine practitioners to treat orthopedic injuries, 
there is minimal evidence that MSC therapy is effective. There is no one answer to the question: 
Why are MSC not yet widely used as a therapy? The paragraphs below outline a brief discussion 
of challenges faced when developing any cell-based therapy, followed by the suggestion that 
specific aspects of MSC biology make this cell type particularly difficult to introduce into the 
clinic.  
7.2.1. General challenges of developing a cell-based therapy 
 Advancing any therapy from a concept, through laboratory and clinical testing, and 
finally to patients, is a long, difficult and expensive process [2, 3, 4]. The development of cell-
based therapies is no exception, and arguably may be more difficult than other types, due to the 
inherent qualities of cells and the unpredictability and high cost of cell culture [5]. 
 7.2.1.1. Challenges with production and delivery of cell-based therapies 
 Depending on the type of cell-based therapy, delivery route to patients, and frequency of 
administration, following steps are commonly involved in preparing treatments: cell isolation 
and enrichment, characterization, expansion, encapsulation or seeding on supportive matrices, 
freezing, shipping, reviving, and administration to the patient [6]. Cells prepared for therapeutic 
purposes should be handled under sterile conditions and tested regularly throughout the 
preparation process to detect unwanted contaminants. In addition, and based on the fact that cells 
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are dynamic, living entities that can change in response to environmental stimuli, they should be 
tested regularly to ensure that their desired characteristics are maintained throughout the process 
and that they remain viable [3]. The balance between producing enough cell-based product to be 
effective and striving for the shortest production time possible to reduce both the risk of negative 
environmental impacts on the product and the cost of maintaining cells in culture, is difficult to 
manage. In addition to meeting the day-to-day demands of maintaining healthy cell cultures, 
researchers must comply with a slew of regulations, handed down by different governmental 
agencies to fulfill formal manufacturing requirements, [7]. 
 7.2.1.2. Challenges when validating cell-based therapies in vivo  
 A challenge in the development of a cell-based therapy in both human and veterinary 
medicine, is demonstrating convincing efficacy in large, randomized controlled studies. As many 
cell-based therapies rely on autologous products, cell-therapy trials often start in patients rather 
than healthy volunteers. When patients are involved, the traditional divisions between phases of 
human clinical trials; phase I (safety), phase II (efficacy), and phase III (confirmation of safety 
and efficacy) can be blurred, and cohort size may be limited [8]. In humans and veterinary 
species, the lack of clarity as to what is being evaluated during the course of a trial, and small 
numbers of participants, each weaken the power of study results. In addition, choosing an 
appropriate patient population for the initial trials is critical, but there is tension between 
enrolling patients with disease states that are advanced enough to warrant exposure to an 
experimental and potentially dangerous therapeutic, and those whose conditions are moderate 
enough that they will respond to therapy [9]. Finally, to critically evaluate both the safety and 
efficacy of cell-therapy trials, long-term follow up with trial subjects is ideal [5]. Long-term 
follow up is not only laborious, it can delay reliable conclusions by years to decades. These 
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hurdles of (i) difficulty in designing trials with clear read-outs, (ii) choosing an appropriate 
patient population, and (iii) need for long-term follow up, all have contributed to the lack of 
convincing evidence that many potential cell-based therapies are safe and effective in vivo.   
7.2.2. The knowledge gap preventing development of effective MSC-based therapies  
 As described briefly above, developing any cell-based therapy is a challenging process. 
MSC however, may be even more difficult to work with than other cell types, as extremely little 
is known about the origin of these cells, and how they function naturally in vivo. Indeed, this lack 
of knowledge about basic MSC biology contributes to the challenges faced when optimizing 
these cells for therapy. 
 MSC were first identified as adherent cells isolated from bone marrow cultures and were 
originally called colony-forming fibroblast [10]. In 1991 the term MSC was coined [1], and in 
that same year, MSC cells were identified as STRO-1-positive, glycophorin-A-negative cells in 
bone marrow, by antibody-based sorting [11]. STRO-1 is the name given to a mouse IgM that 
was discovered in a hybridoma screen, as an antibody that binds to stromal cells in the bone 
marrow, but for years its antigen remained undetermined. Glycophorin-A is a marker of 
erythroid precursors [11]. When STRO-1-positive, glycophorin-A-negative cells were separated 
from the remainder of the bone marrow components and cultured, it was determined that they 
were analogous to the colony-forming fibroblast that were isolated by adhesion years earlier. 
Although it is clear that these cells, named MSC, are present in the stromal compartment of the 
bone marrow, it is not known if, when, or how, they exit from the bone marrow, where they go if 
they do exit, how they may change as they develop, and what function they serve in vivo. STRO-
1 has not proven to be a marker specific for and inclusive of all MSC. Work using the STRO-1 
antibody showed that in adult tissues, this marker labels mature endothelial cells, as well as non-
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endothelial cells associated with the vasculature, some of which may be pericytes [12, 13, 14]. 
Additional studies suggest that STRO-1 does not react with cells called MSC that are isolated 
from tissues other than bone marrow, such as adipose tissue, umbilical cord, umbilical cord 
blood, peripheral blood [15, 16, 17, 18]. The antigen recognized by STRO-1 was only recently 
identified as heat shock cognate 70 (HSC70) [19]. HSC70 is a ubiquitously and constitutively 
expressed protein, but STRO-1 cell surface binding is limited to only a few cell types when 
measured by flow cytometry [20]. When lysate from a panel of cells with variable STRO-1 
surface binding was probed with STRO-1 for Western blot analysis, STRO-1 detected HSC70 in 
all lysates [19].  It has been proposed that cell surface expression of HSC70 coincides with 
specific stages of cellular development, but currently there is no convincing data to support this 
theory [19]. 
 Additional cell surface markers, such as the stage-specific embryonic antigen 4 (SSE-4), 
the low-affinity nerve growth factor receptor CD271, and the adhesion molecule CD146, have 
been proposed and examined as markers that might facilitate the isolation of MSC from tissues, 
or the selection of MSC with high stemness. But cells designated as MSC, isolated from various 
sources do not uniformly express these proteins either [21]. This raises the possibility that MSC 
isolated from sources other than bone marrow might not be the same MSC that are detected in 
bone marrow. However, cells isolated from other tissues are defined as MSC according to the 
minimal in vitro criteria put forth by the International Society of Cellular Therapy (ISCT) in 
2006: (i) MSC must be plastic-adherent when maintained under standard culture conditions, (ii) 
MSC must express the surface proteins CD105, CD73 and CD90, and lack the expression of 
CD45, CD34, CD14 or CD11b, CD79 or CD19 and HLA-DR, and (iii) MSC must have the 
potential to differentiate into osteoblasts, adipocytes and chondroblasts in vitro [22]. Clearly, 
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these minimal criteria encompass a heterogeneous population of cells termed MSC, that may 
express different surface markers as a result of being at various stages of differentiation or 
residing in different tissue environments. Culture conditions have proven to alter MSC surface 
protein expression as well, which may confound results obtained from in vitro studies [23, 24]. 
In the field of MSC biology, it is currently accepted that there is no single marker that is MSC 
specific [21], which results in the inability to track these cells and to answer questions about their 
basic biology. For example: Do all MSC originate in the bone marrow and then exit to populate 
various peripheral tissues as cells of hematopoietic origin do? The lack of a single marker also 
makes it challenging to follow MSC in vivo to sites of injury. Indeed, it has been suggested that 
these cells home to injured sites, based on the results of experiments using MSC labeled ex vivo, 
which were then introduced to animals with various pathologies [25, 26, 27, 28]. Seemingly, 
bone marrow transplant experiments could shed light on MSC origin and fate, as they have for 
the origin of hematopoietic cells, but studies in mice and data from human transplants 
overwhelmingly indicate that after bone marrow transplantation, donor MSC engraftment does 
not occur [29]. Bone marrow and peripheral blood stromal cells detected in human patients post-
transplant are recipient, not donor in origin, irrespective of the level of conditioning patients 
received prior to transplantation [30, 31, 32].  
 The lack of information about the basic biology of this heterogeneous population of cells 
named MSC has undoubtedly contributed to the lag in the field of MSC therapeutics. If more 
was known about how MSC interact with their in vivo environment, they could potentially be 
cultured in more optimal ways and researchers could focus on optimizing their innate potential. 
The naming of MSC and categorizing the diversity of cells that are MSC by ISCT definition may 
have also negatively impacted the field. Contradictory findings across laboratory experiments 
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and between clinical trials are common, and data are often not reproducible between groups. The 
seemingly inconsistent outcomes of MSC therapy cause researchers and funding agencies to lose 
interest in pursuing the development of MSC as a useful biologic treatment, which is unfortunate 
because many of the inconsistencies may be a result of “comparing apples to oranges”. There is 
great heterogeneity across MSC cultures isolated from different sources, even if they fit the 
definition of MSC proposed by the ISCT. Until more is known about the origin, development 
and function of MSC isolated from different tissues in vivo, it will be difficult to understand the 
“results” researchers and clinicians observe in vitro and in clinical applications.  
7.3. Final remarks 
 The work presented in this dissertation showed that in vitro, equine MSC-secreted factors 
act on target cell types found in the skin, in ways that suggest they may improve cutaneous 
wound healing in vivo. The next phase of this work, before attempting to move forward with the 
development of MSC therapies for horse or human skin wounds, might be to take a step back and 
invest in more tools to study the basic biology of these cells in vivo. When we know more about 
the origin, development and function of MSC, we may finally be successful in developing 
effective treatments using these cells.  
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